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Diabetic Nephropathy (DN), a major cause of end stage renal failure, is believed to 
result from hyperglycaemia-induced pathways in the kidney. We previously identified 
µ-crystalline (CRYM) and Molybdenum Cofactor Sulfurase C-terminal domain-
containing protein 2 (MOSC2) as two of several hyperglycaemia-induced renal genes 
in the Goto-Kakizaki (GK) rat, and showed that both were regulated by glucose in 
vitro in human mesangial cells (HMCs). In the current thesis, we investigated their 
expression in models of diabetes as well as in circulating cells from DN patients, in 
order to evaluate these genes as potential biomarkers and to explore their possible 
roles in the pathophysiology of DN. The expression of CRYM and MOSC were 
examined in tissues obtained from in vivo mouse models including a streptozotocin 
(STZ)-induced model of diabetes reversible through islet transplantation,  renal cells 
cultured in normal (5mM) and high (25mM) glucose, and blood samples from 
diabetic patients with and without nephropathy (n= 97)/ retinopathy (n= 36). mRNA 
levels were determined using qPCR relative to reference genes, and protein location/ 
abundance was determined using immunofluorescence. Functional analysis included 
N-hydroxylation assays.  
 
Both CRYM and MOSC2 mRNAs increased during hyperglycaemia in the diabetic 
kidneys of the STZ-induced mice and this increase was attenuated by treatment of 
diabetes (P<0.05). Immunohistochemistry revealed an abundant expression of both 
proteins in tubular cells, and very low expression in mesangial cells. The 
hyperglycaemia-induced increase in renal CRYM was specific as we could not 
demonstrate any change in cardiac CRYM, and similarly no change in expression was 
found under diabetic conditions in vitro in Molybdenum Cofactor Sulfurase C-
terminal domain-containing protein 1 (MOSC1), a homolog of MOSC2. Surprisingly, 
in high glucose (HG), CRYM and MOSC2 mRNA levels showed a slight decrease in 
cultured tubular cells, whereas they showed a significant increase in HMCs. 
Biochemical analysis of MOSC protein showed that hyperglycaemia increased the N-
reductive activity of MOSC2 protein. To evaluate CRYM and MOSC mRNA levels 
as potential biomarkers of DN, we examined their expression in the peripheral blood 
of diabetic patients. We could detect low levels of CRYM but there was no expression 
of MOSC2. However, the closely related homolog MOSC1 was expressed in the 
peripheral blood though its mRNA levels did not change in association with DN. 
CRYM mRNA levels were 7.4-fold increased in patients with type 2 nephropathy and 
this effect was strongest in patients with a well controlled nephropathy compared to 
those with proteinuria. However, we found that circulating CRYM mRNA was 
reduced in patients with retinopathy. Therefore it is currently unclear if circulating 
CRYM is associated with nephropathy and its low levels of expression suggest it may 
not be a useful biomarker. 
Our data suggest that diabetes leads to an increased expression of renal CRYM and 
MOSC2 mRNAs, and although there are high levels of both mRNAs in tubular cells, 
the up-regulation may be taking place in mesangial or other renal cells. Circulating 
CRYM mRNA levels showed changes in patients with nephropathy and retinopathy 
but MOSC1 remained unchanged. CRYM or MOSC1/2 are unlikely to be useful 
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Chapter 1. General introduction 
 
1.1. Diabetic mellitus 
 
Worldwide, approximately 347 million people have been diagnosed with diabetes 
mellitus (Danaei et al., 2011). Recent surveys have predicted that by 2030, diabetes 
mellitus will be the seventh leading cause of death in the world (WHO, 2011). 
Diabetes mellitus is a disease caused by an inappropriately high blood sugar 
(hyperglycaemia) resulting from insulin deficiency or insulin resistance. There are 
two factors which are central to the pathophysiology of diabetes: the pancreatic-β 
cells and the secretory insulin. In the standard definition, diabetic mellitus occurs as a 
result of excessive glucose in the blood of diabetic patients. The new definition of 
diabetes considers diabetic symptoms as well as three criteria: a random plasma sugar 
level greater than 11mmol/l (millimoles per litre); a fasting plasma sugar level greater 
than or equal to 7 mmol/l (or 6.1 mmol/l in whole blood); a plasma sugar level greater 
than 11 mmol/l two hours after drinking 75 grams of glucose dissolved in water in an 
oral glucose tolerance test (OGTT; Rubin and Jarvis, 2011). In 1679 the English 
physician, Thomas Willis was the first person who reported that diabetic urine 
contained sugar and Matthew Dobson demonstrated that the urine and blood of 
patients with diabetes contained sugar (Dobson, 1776). In 1921, Fredrick Banting 
(1891-1941) and Charles Best (1899-1978) found that insulin is in the pancreas islets 
(Pick up and Williams, 2003). 
In 1985, the World Health Organization categorized diabetes into two groups:  insulin 
dependent mellitus (IDDM), or type I and non-insulin dependent diabetes mellitus 
(NIDDM), or type II, based on clinical symptoms, lifestyle and the type of treatment 
applied. Type 1 diabetes mellitus (T1DM) cause a deficiency of insulin and is 
categorized by the loss of the insulin-producing β cells of the islets of langerhans in 
the pancreas. In 1997, the American Diabetes Association (ADA) characterised 
diabetes into four characterisations based on the etiology of the disease: type 1 
diabetes mellitus (T1DM); type 2 diabetes mellitus (T2DM); the secondary type of 
diabetes that can stem from genetic syndromes, surgery, drugs, malnutrition, 
infections and other illness; and gestational diabetes mellitus which appears during 





T1DM is characterised by the loss of insulin-producing β cells of the islets of 
Langerhans in the pancreas, caused by an autoimmune T-cell-mediated mechanism 
and which results in insufficient insulin production (Rother 2007). This type of 
diabetes is more common under 40 but it can appear at any age and is triggered by 
various factors such as viruses, diet or chemicals in genetically predisposed people 
(Burno et al., 2005). About 10-15% of diabetic people are affected with type 1 and 
they are treated by exogenous insulin injections to replace the missing hormone 
(Bruno et al., 2005). 
T2DM was formerly known as non-insulin-dependent or adult-onset (WHO, 1999), it 
is also known as obesity associated diabetes and is a metabolic disorder which is 
categorized by insulin resistance, relative insulin deficiency and hyperglycaemia 
(Kahn, 2000). This type of diabetes is very common and affects about 85-90% of 
diabetic people (Rizivi, 2004).  
T1DM and T2DM have some different phenotypic variations although they share 
common symptoms, such as hyperglycaemia, glucose intolerance, hyperlipidaemia as 
well as similar complications; however, their pathogenesis is different from each other 
(Brownlee 2001). Hyperglycaemia alone leads to changes in several systems in the 
body, such as altered glucose, fat and protein metabolism, which can make 
microenvironment alteration in various cells and tissues. These effects are long-term 
and can result in diabetic complications (Ryan et al., 2009). 
1.2. Complication of diabetes 
Diabetic complications are the major cause of morbidity and mortality in patients with 
diabetes mellitus. Diabetic patients have a much higher risk of complications that 
involve many different systems within the body. Diabetic complications can be 
classified into two groups, acute and chronic. Acute complications of diabetes include 
diabetic ketoacidosis, and non-ketotic. Chronic complications are related to vascular 
disease and they are classified as macrovascular disease (affecting arteries that supply 
the heart and brain) and microvascular disease (due to damage to the small blood 
vessels) (Weiss and Sumpio, 2006). Diabetes-specific microvascular disease can lead 
to one or more of the following complications: diabetic retinopathy, which is 
proposed to be the most common ischaemic disorder and presents as an ocular 




years (Chistiakov, 2011; Pardinato et al., 2005). Indeed, diabetic retinopathy is the 
result of damage to the blood vessels in the retina which can lead to blindness; 
diabetic nephropathy, caused by damage to the kidney, which can lead to chronic 
renal failure; and diabetic neuropathy, which is the result of high blood glucose levels 
and which can damage nerves throughout the body. Worldwide, Diabetes mellitus 
(DM) has been identified as the most common cause of renal failure (ADA, 2006).  
Chronic hyperglycaemia is linked to diabetes and can be the cause of structural and 
functional alterations in the retina, nerves, kidneys, and blood vessels (Table 1: 
Williams et al., 2002).  As described previously, many complications of  diabetes  are 
considered  to be due to persistently increased levels of blood glucose and are far less 
common and less severe in people who have well-controlled blood sugar levels 
(Nathan et al., 2006). Indeed, intensive control of hyperglycaemia reduces the 
progression of retinopathy, neuropathy and nephropathy in diabetic patients (Cefalu, 
2005; DCCT/EDIC, 2005; UKPDS, 1998; DCCT, 1993). 
1.3. Diabetic nephropathy 
Diabetic nephropathy (DN) is one of the most serious complications among diabetic 
patients (including T1DM & T2DM) and occurs in up to 40% of cases (ADA, 2004). 
Diabetic nephropathy is a non-immune disease and is the major cause of end stage 
renal disease; it is this progressive renal disease which develops within 10-30 years of 
the onset of diabetes in the western world (Schena and Gesualdo, 2005; ADA, 2004). 
It is also the leading cause of chronic kidney disease in patients and although both 
diabetic groups can lead to end stage renal disease, it is more common in patients with 
T2DM (Ritz and Tang, 2001). 
Diabetic nephropathy is closely associated with cardiovascular disease and blood 
vessel disease. High blood pressure is a common factor in diabetes which can involve 
diabetic nephropathy by damaging the kidneys. Indeed, heart disease, high blood 
pressure and cholesterol levels raise the risk of diabetic nephropathy, although 

























At the time of a diabetic diagnosis, major functional changes occur in patients with 
T1D and T2D. Theses functional changes include an increase in kidney size, 
reversible albuminuria and an increase in the glomerular hyperfiltration rate (GFR). 
At the early stages in the development of the onset of diabetes, renal biopsies are 
normal. Within 1½ to 2½ years, glomerular basement membrane (a filmentous 
network of collagen IV and laminin) thickening appears. Each kidney has a structure 
which is called the glomerulus; it has the capacity to filter and clean the blood. The 
blood is filtered by passing through the glomerular capillaries, which have intimate 
contact with tubules. When the filtrate passes into the tubules, most of the water and 
small solutes within the blood are reabsorbed. Meanwhile a small amount of water 
and solutes passes from the kidney into the ureter and finally forms urine (Rubin and 
Organ affected Disease  
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Jarvis, 2011; Border et al., 1966). The expanding membranes begin to reduce the 
space occupied by the capillaries within the glomeruli. Thus, this process prevents 
blood filtration. In addition to GBM thickening, there are other changes such as: 
nodular and diffuse forms of intracapillary glomerulosclerosis, the fibrin cap, the 
capsular drop lesion and mesangila matrix expansion (Greenberg, 1998).  
The estimated glomerular filtration rate (eGFR) and microalbuminuria are the first 
indicators for patients with DN. The eGFR is calculated on the basis of age and the 
creatinine level in the blood and is the most popular test used to check the kidney 
function. However, microalbuminuria is an alternative test which can reveal early 
signs of kidney damage when the eGFR is still normal. Less than 30 mg/24h albumin 
is detected in normal urine and about 20% of renal plasma is filtered at glumerulus 
over the duration of one day. Any filtered proteins are reabsorbed into peritubular 
capillaries (Gudehithlu et al., 2004). Patients with DN have increased urinary albumin 
excretion of 300 mg/24h. Under normal conditions, albumin accounts for 60% of 
protein in plasma and only tiny amounts of albumin are filtered at glumerulus. With 
the microalbuminuria test, those patients at risk of DN which have a urinary albumin 
excretion between 30 and 300 mg/24h can be identified. The presence of 
microalbuminuria in patients with DN is highly predictive of the development of DN 
over the next 10 to 15 years (Greenberg, 1998). Should it be undetected for more than 
15 years, the damage may become so severe that it can lead to kidney failure (Rubin 
and Jarvis, 2011). Figure 1 shows the normal management of albumin by the 
glomerulus. 
The progression of DN goes from relatively minor to end stage renal disease and 
includes five stages (Moregensen, 1989) namely hyperfiltration, microalbuminuria, 
proteinuria, advanced clinical nephropathy and end-stage renal failure (Rubin and 
Jarvis, 2011). At the first stage (hyperfiltration), a huge amount of glucose enters the 
kidneys and draws a large amount of water. Therefore, the blood flow through the 
glomeruli increases and the kidneys become enlarged. The second stage 
(microalbuminuria) usually occurs 10-30 years after diagnosis. During this stage, the 
























Figure 1.Normal renal management of albumin. 
a) Normal glomerulus and proximal tubule. The individual cells and constituents of  
the glomerulus and proximal tubules are shown. Albumin (represented by green spheres). 
b) Glomerular filtration barrier. c) Proximal tubule. The albumin that is physiologically 
filtered at the level of glomerulus into the urinary space is taken up by the megalin/cubulin 
receptor lining the brush border of proximal tubular cells. Albumin is internalized by 
vesicles, and upon lysozyme action, the resultant fragments are either reabsorbed or 





This damage provides the conditions for a small amount of albumin to leak into the 
urine. However, there is no diagnostic test, as the amount of urinary albumin is less 
than the estimated amount and therefore a number of patients continue at this stage for 
the remainder of their lives (silent stage). 
In the third stage, levels of creatinine and urea increase because of reduced ability of 
the glomeruli to filter. In this stage, patients show a decline in microalbuminuria and 
the GFR. In the fourth stage (advanced clinical nephropathy), there is a significant 
amount of albumin in the urine (AER; normal range =<30 mg/day), a gradual GFR 




reduction in GFR lead to extensive glomerular closure that marks end-stage renal that 
marks end-stage renal disease. During this stage, kidneys continue to supply residual 
function, even when dialysis has commenced (Morgensen, 1989). Table 2 represents 
the stages in the progression of DN. 
Table 2. Stages in the progression of diabetic nephropathy (DN) 
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The histological changes in the glomeruli of patients with DN are: first-mesangial 
expansion, which correlates with creatinine clearance and is induced directly by 
hyperglycaemia, perhaps via increased matrix production or glycosylation of matrix 
proteins; second-glomerular basement membrane (GBM) thickening; third-glomerular 
sclerosis as the result of intraglomerular hypertension.  The expanded mesangium is 
the cause of diffuse glomerulosclerosis, which ultimately leads to a decrease in the 
density of capillaries and in the glomerular filtration surface area.  Permeability of the 
filtration barrier falls and consequently GFR declines. Extracellular matrix (ECM) 
also builds up in the tubular BM and the interstitial compartment (Osterby, 1992; 
Vestra et al., 2000).  In the diabetic kidney, tubulointerstitial fibrosis and glomerular 
sclerosis occur. Indeed, tubulointerstitial fibrosis is described by an excess of ECM 
accumulation in the renal interstitium (Iwano et al., 2004). These hemodynamic 
alterations lead to DN progression as a result of shear stress on the endothelial and 




production (Raptis and Viberti, 2001). Figure 2 shows the histological changes in the 









  Figure 2. Characteristic glomerular changes of diabetic nephropathy (DN).  
              a) Normal glomerulus. Cells of the glomerular tuft (mesangial cells, endothelial cells, and 
 podocytes) and extracapillary glomerulus (parietal epithelial cells) are shown, along with 
 the GBM. (b) Diabetic kidney. In the diabetic kidney, characteristic glomerular changes 
 include thickening of GBM and mesangial expansion. Taken from Jefferson et al., 2008. 
 
 
1.4. Risk factors for DN 
1.4.1. Hyperglycaemia 
It is well established that most microvascular complications as a result of diabetes, 
such as diabetic nephropathy, are associated to the degree and length of exposure of 
hyperglycaemia. Indeed, hyperglycaemia is the main factor initiating the progression 
of nephropathy and other diabetic complications (Unnikrishnan et al., 2011). A 
number of clinical studies have highlighted the role and the value of early glycemic 
control in the prevention of the development of diabetic complications. The Diabetes 
Control and Complications Trial (DCCT) was the longest and largest prospective 
study to confirm the importance of optimising glycaemic control in T1DM (DCCT, 
1993). 
In this study, a total number of 1,441 subjects, aged 13 to 39, with T1DM were 




study was designed in two groups and both groups of patients were monitored for a 
mean period of 6.5 years. The first group (a primary-preventative cohort) was called 
the standard treatment group which included 726 subjects who were recruited within 
1-5 years after developing diabetes, had no diabetic nephropathy and had a urinary 
albumin excretion of <40 mg/day. The second group (a secondary-preventative 
cohort) was called the intensive treatment group which included 715 subjects who had 
been living for 1-15 years after developing diabetes and they had mild-to-moderate 
background diabetic retinopathy with a urinary albumin excretion of <200mg/day. 
In the standard treatment group, intensive therapy decreased the adjusted mean risk 
for the progression of retinopathy by 76% as compared with conventional therapy. In 
the intensive treatment group, intensive therapy slowed the development of 
retinopathy by 54% and decreased the progression of proliferative retinopathy (PDR) 
or nonproliferative retinopathy (NPDR) by 74%. In the combined groups, intensive 
therapy decreased the incidence of microalbuminuria (urinary albumin excretion of 
40 mg per 24 hours) by 39% and that of albuminuria (urinary albumin excretion of 
300 mg per 24 hours) by 54%, and it also reduced the occurrence of clinical 
neuropathy by 60%. This study concluded that intensive therapy efficiently delays and 
slows the development of diabetic complications in patients with T1DM (DCCT, 
1993). 
The DCCT demonstrated that improved glucose control in patients with T1DM had 
beneficial effects and decreased risks for the progression of microvascular 
complications. Following the DCCT study, the Epidemiology of Diabetes 
Interventions and Complications (EDIC) study began in January 1994. This study 
investigated the interactions between established and putative risk factors for long-
term microvascular complications and cardiovascular disease of patients with T1DM 
as well as prior treatments of diabetes and the level of glycemic control during the 
DCCT (EDIC, 1999). 
For the EDIC study, 28 out of 29 DCCT clinics contributed. The EDIC studies have 
shown that intensive blood glucose control reduced the risk of cardiovascular events 
by 42% and it also decreased the event of death as a result of cardiovascular causes, 




The conclusion of DCCT and its follow-up observational study (EDIC) showed that 
intensive therapy reduces the development and progression of all diabetic-specific 
complications. The long-term results of the DCCT/EDIC demonstrated that intensive 
therapy reduced the risk of kidney dysfunction by 50% (DCCT/EDIC, 2003). 
Furthermore, data reported by the DCCT/EDIC (2003) indicated that intensive 
therapy decreased the risk for albuminuria during the DCCT and throughout the first 
eight years of the EDIC study. In addition, a review of the DCCT/EDIC (2011) 
reported that the intensive therapy also reduced the risk for an impaired glomerular 
filtration rate by 50%. 
Based on the DCCT trial which indicated that strict control reduces complications in 
patients with T1DM, the results of the long-awaited UK prospective Diabetes Study 
(UKPDS) demonstrated that the risk of diabetic complications can be decreased 
significantly in patients with T2DM. The UKPDS trial recruited 5,102 patients with 
newly diagnosed T2DM and it ran for twenty years (1977 to 1991) in 23 clinical 
centres based in England, Northern Ireland and Scotland. 4,209 subjects were 
randomly allocated to receive either conventional therapy (dietary restriction) or 
intensive therapy (either sulfonylurea or insulin, or metformin in overweight patients) 
for the control of glucose. 
In this study, patients were monitored for a mean follow up time of 10 years to 
demonstrate whether the intensive pharmacological therapy to lower blood glucose 
levels can reduce the occurrence and progression of cardiovascular and microvascular 
complications. The second aim was designed to test the therapeutic advantages or 
disadvantages of the usage of numerous sulfonylurea drugs, the biguanide drug 
Metformin, or insulin. The UKPDS data revealed that diabetic complications such as 
nephropathy, retinopathy and neuropathy are benefitted by better blood glucose 
control in T2DM with intensive therapy and their overall rate was decreased by 25%. 
These results also established that hyperglycaemia is the major contributor to these 
complications. The study demonstrated that better blood pressure control (a mean of 
144/82 mmHg) in the majority of patients notably reduced the risk of death from 
long-term diabetic complications, stroke, heart failure and visual loss (UKPDS, 1998). 
Therefore, these results confirm previous conclusions that hyperglycaemia is the 




1993; UKPDS, 1998). However, this process is modified by both genetic and 
independent accelerating factors such as hypertension (Brownlee, 2001). 
1.4.2. Metabolic memory 
As described previously, hyperglycaemia is a main factor in the development of 
diabetic nephropathy. Despite strict glucose control,
 
vascular complications still 
develop in most diabetic patients. For instance, the UKPDS was unable to show a 
significant effect of tight glycaemic control in the prevention of cardiovascular 
disease, whereas a recent follow-up of the same study seems to confirm the usefulness 
of long-term glycaemia in patients with T2DM. Taken together, it was suggested that 
the control of hyperglycaemia is not enough to completely reduce complications 
(Ceriello et al., 2009). 
The first theory of metabolic memory was reported 20 years ago in the retina of 
diabetic dogs who were switched to good hyperglycaemia control after either 2 
months or 2.5 years of poor glycaemic control. The animals which were switched to 
good hyperglycaemia control after 2 months of poor glycaemic control had little sign 
of retinopathy. Conversely, the animals that were switched to good glucose control 
after 2.5 years of poor glucose control showed similar signs of retinopathy (Engerman 
and Kern, 1987). Following this study, Lorenzi‟s research group showed that in 
isolated endothelial cells and in the kidneys
 
of streptozotocin (STZ)-induced diabetic 
rats there was a memory of basement membrane (collagen IV, fibronectin)
 
mRNA 
induction one week after glucose
 
normalisation, after two weeks of high glucose 
condition (Roy et al., 1990). 
The metabolic memory phenomenon emerged clinically, to describe the fact that 
despite good glycemic control, T1DM patients in the DCCT-EDIC trial still had a 
higher occurrence of microvascular diabetic complications. The follow-up of the 
UKPDS results showed that patients with T2DM could also develop microvascular 
and cardiovascular complications during their intensive therapy. Therefore, these 
observations suggest that early metabolic control has continued beneficial 
consequences in both types of diabetes. The metabolic memory theory explains that 
an early glycaemic environment is memorised in the target organs such as the heart, 
kidney and extremities. This theory also mentions that good glycaemic control should 




(Cerielo et al., 2009). There are various factors including oxidative stress and age that 
are involved in this phenomenon, as well as hyperglycaemia (Sell, 1990). 
1.4.3. Hypertention and hyperlipidemia 
Aggressive control of blood pressure and cholesterol can reduce the progression of 
microvascular disease in patients with T1DM and T2DM (Grossman and Messerli, 
2008). The studies during the DCCT showed that hypertension and hyperlipidaemia 
can influence the progression of microvascular disease by altering glycaemia (DCCT, 
1993). Data from the follow-up of the UKPDS established that an increase of 38.7 
mg/dL in low density lipoprotein (LDL) cholesterol (1.00 mmol/L) was related to 
disease of the artery increasing by 57%, whereas an increase of 4mg/dL (0.10 
mmol/L) in high density lipoprotein (HDL) cholesterol was correlated with a 15% 
reduction in disease of the artery (KPDS, 1998). Furthermore, this study showed that 
high levels of LDL-C, low levels of HDL-C and hypertension are all risk factors for 
disease of the artery in T2DM patients as well as hyperglycaemia. 
Parallel to hyperlipidaemia, there was additional evidence that showed the effect of 
hypertension in microvascular disease. Ravid et al. (1993) revealed that patients with 
blood pressure show an annual decline in GFR, which is close to a normal average 
and the development of microalbuminuria is rare in this group. Conversely, diabetic 
patients who had hypertension (130/80-140/90 mm Hg) showed a larger decline in 
GFR and the microalbuminuria or macroalbuminuria had developed in 30% of these 
patients after 12-15 years. A year after this study, Tarnow et al. (1994) reported that 
there was an association between the progression of diabetic nephropathy with 
hypertension and the incidence of hyperglycaemia increased in those patients who 
developed diabetic complications. 
In the kidney, the process of high blood pressure to hypertension results in an increase 
in intraglomerular capillary pressure (Hosteller et al., 1982). The increase of 
intraglomerular blood pressure leads to the progression of glomerular sclerosis. This 
procedure is illustrated by an extracellular matrix accumulation within the glomerulus 
(Yasuda et al., 1996). Due to the elastic property of the glomeruli, this increase in 
pressure leads to changes in overall glomerular volume, which leads to a stretch and 
relaxation of cells, such as mesangial cells (Cortes et al., 1996). As a result, 




1.5. Glucose transport inside the cells 
Glucos is used as a primary source of energy and a metabolic intermediate inside the 
cells. Therefore, glucose acts as a precursor for the synthesis of triglycerides, 
glycoproteins and glycogen. Glucose is directly absorbed into the bloodstream and the 
kidneys reabsorb the filtered glucose back into the blood. Due to the nature of 
glucose, it does not readily disperse across the hydrophobic plasma membrane. Thus, 
it requires specific molecules to mediate the specific uptake of this sugar (Oslon and 
Pessin, 1996). 
Glucose transport inside the cells through specific glucose transporters is the first step 
of the glucose signalling pathway. Glucose can be transported into the cells through 
specific glucose transporters which belong to a family of proteins (Haneda et al., 
2003). Glucose transporters identified in glomeruli include GluT1, GluT2, GluT3, and 
GluT4. These transporter isoforms have been cloned and explored specifically for 
glucose transport: GluT1 is ubiquitously distributed and displays constitutive 
transport activity; GluT2 is present in various organs such as the liver, gut and 
pancreatic islets; GluT3 is present in the brain and the central nervous system; and 
GluT4 is present in insulin-responsive tissues, skeletal muscle, adipose tissue and the 
heart (Bell et al., 1993). 
High glucose activates various signalling pathways inside the cell (Heilig, 2013). 
Heilig et al. (1997) demonstrated that GluT1 synthesis and expression increased in 
mesangial cells, when exposed to high glucose. They also looked at the effects of 
elevated extracellular glucose on the regulation of a facilitative glucose transporter in 
rat mesangial cells. They found that GluT1 is the only transporter isoform which is 
detected and its mRNA and protein expression up-regulated in the presence of high 
glucose rather than normal glucose. Consequently, Glut1 easily facilitated the 
transport of excessive extracellular glucose from DM into the cells (Brousius and 
Heilig, 2005). 
 In the kidney, GluT1 plays an important role in this process by regulating glucose 
movement through the cells in which it acts as a primary gatekeeper for this process 
(Heillig et al., 2013). The studies indicated that GluT1 facilitated the transport of 
glucose, which activates Protein Kinase C (PKC) and Transforming growth factor 




Therefore, GluT1 activity could be a factor in the progression of fibrosis in DN. In 
support of this argument, overexpression of GluT1 in cultured mesangial cells in 
normal glucose results in elevation in glucose uptake and consumption, as well as 
excessive production of ECM proteins (Weigert et al., 2003). Additionally, in vivo 
studies showed that overexpression of GluT1 in transgenic mice lead to development 
of glomerulosclerosis and nephropathy, regardless of normoglycaemia (Heilig et al., 
1995). Thus, the GluT1 transporter seems to be a regulator of ECM production in both 
cultured mesangial cells and glomeruli cells. 
Studies have also been carried out to establish the correlation between polymorphisms 
of GluT1 with DN. Liu et al. (1999) found that GluT1 Xba1 (-) allele was associated 
with a higher occurrence of diabetic nephropathy. Another study in Poland showed 
that XbaI (+) genotype was more frequent in patients with DN when compared with 
patients without DN. They suggested an association between GluT1 polymorphism 
with DN (Grzeszczak, 2001). 
Understanding the mechanism of GluT1 is important since it appears that the 
expression of GluT1 gene leads to morphologic features of DN. A number of studies 
showed that GluT1 is regulated in the presence of high glucose in mesangial cells and 
its regulation activates various signalling pathways. Indeed, after glucose 
transportation through the cells, it is metabolized mainly by the glycolytic pathway. 
However, when present in excess, glucose is also metabolized by other pathways and 
activate numerous signalling pathways as indicated in Figure 3. It has been observed 
that there is an increase in glucose entry into the polyol pathway, the diacylglycerol 
(DAG) synthesis pathway, and the hexosamine pathway when mesangial cells are 
exposed to high glucose. For instance, chronic overexpression of GluT1 stimulates the 
polyol pathway activation (Henry et al., 1999) as well as PKCα and β1 activation 
(Henry et al., 1999; Weigert et al., 2003). Therefore, the metabolism of glucose 
through the polyol pathway can result in the synthesis of diacylglycerol and 
phosphaditic acid, which may lead to an increase of PKC levels and its activation in 

















Figure 3. Glucose-induced signalling pathways. 
Glucose is transported into the cells through GLUT-1 and metabolized mainly via the 
glycolytic pathway. Activation of the above pathways are capable of stimulating 
growth factors such as TGF-β1, which leads to structural and functional changes in 
kidneys and eventually to DN. DAG: diacylglycerol, AGE: advanced glycation end 




1.5.1. Metabolic factors 
It appears that DN results from the interaction between various factors namely: 
metabolic, hemodynamic, intracellular factors, growth factors and cytokines (Ritz et 
al., 2001). Metabolic factors are effectively glucose dependent pathways which are 
activated in diabetic renal tissues. These pathways include the polyol pathway, 
accumulation of advanced glycated end-products (AGEs), hexosamine flux and 
oxidative stress (Brownlee, 2001). Hyperglycaemia has been shown to alter the 




Berl, 2004). Figure 4 presents a schematic diagram of numerous factors which are 
involved in hyperglycaemia-induced tissue damage. 
 
                 
                        
              Figure 4. Glucose induced signalling pathways of diabetic microvascular damage. 
              AGEs: Advanced glycated end products, AngII: angiotensin II,  
              RAs: rennin angiotensin system, NO: nitric oxide, TGF-β: transforming growth factor  
              β, CTGF: connective tissue growth factor, VEGF: vascular endothelial growth factor,  
               DAG-PKC: diacylglycerol-protein kinase c, MAKP: MAP kinase, NF-κB: nuclear factor- 
              Kappa B (Modified from Schrijvers et al., 2004). 
 
● The polyol pathway 
The polyol pathway is one of the key pathways in the development of DN. Aldose 
reductase (AR) is the main enzyme in the polyol pathway which converts glucose to 
sorbitol. In converting glucose to sorbitol, the co-factor nicotinamide adenine 
dinucleotide phosphate (NADPH), and sorbitol dehydrogenase (SDH) with co-factor 
NAD+, is used to convert sorbitol to fructose (Figure 5; Djk and Berl, 2004). Under 
normal glucose conditions, only a small amount of glucose enters through the 
pathway as opposed to a diabetic state, with significant increase of 3% and upto 30% 




myoinositol. There is evidence that shows the cellular accumulation of sorbitol and 
the depletion of myoinositol are linked to the progression of DN (Greene et al., 1987). 
 
The polyol pathway is involved in the reduction of oxidative stress in different ways. 
Under hyperglycaemic condition, a depletion of NADPH co-factor to AR causes 
reduction of reduced glutathione (GSH). Therefore, the cells become susceptible to 
intracellular oxidative stress (Brownlee, 2005). Indeed, excessive activation of the 
polyol pathway results in an increase in intracellular and extracellular sorbitol 
concentration and is also a cause of increased ROS and decreased glutathione levels 
(Brownlee, 2001). In addition, fructose and its metabolites when glycosylated, have a 
powerful effect on AGE-induced oxidative stress (Chung et al., 2003). Each of these 
imbalances can damage cells (Brownlee, 2001). 
 
         
 
 
  Figure 5. The polyol pathway. 
  Aldose reductase (AR) reduce glucose to sorbitol with the aid of its co-factor NADPH. 
  This reaction oxidises NADPH to NADP+ and sorbitol dehydrogenase (SDH) can then  
              oxidise sorbitol to fructose (Modified from Djk and Berl, 2004). 
 
 
Several studies have reported the role of polyol pathway in the development of DN. 
Bank et al (1989) showed that that polyol pathway metabolism plays a role in 
glomerular hyperperfusion in IDDM of Streptozotocin-induced diabetic rats, by using 
aldose reductase inhibitors which is a specific inhibitor for the polyol pathway. 
Results showed that using the aldose reductase inhibitor sorbinil in STZ rats 
prevented the glomerular hyperfusion. In vivo studies have also shown the effect of 




inhibitors for 5 years and it was found that diabetes induced deficiencies in nerve 
conduction velocity were prevented (Engerman et al., 1994). An additional study in 
transgenic mice over-expressing human aldose reductase revealed that the mice 
developed pathological alterations such as thrombosis of renal vessels deposits in 
Bowman‟s capsules in the kidney (Yamaoka et al., 1995). 
 
● Advanced glycation end products (AGEs) Activation 
Advanced glycation end products (AGEs) are complex, heterogenous molecules that 
are formed non-enzymatically by the interaction of extracellular proteins and glucose 
(Yashpal et al., 2008; Ahmed, 2005). Various studies show evidence that AGEs 
accumulate in vivo in the renal cortex of diabetic rats (Mitsuhashi et al., 1993) and 
also increase in sclerosing glomeruli of patients with diabetes (Witztum et al., 1997). 
A further patient study indicated that increased AGEs are associated with the severity 
of DN (Tanji et al., 2000). Therefore, AGEs are important pathogenetic mediators in 
the development of DN and the accumulation of AGEs may lead to ESRD (Djk and 
Berl, 2004). AGEs appear to damage cells through receptor-dependent and receptor-
independent pathways. AGEs interact with receptors such as RAGE and RAGE 
regulates the uptake and clearance of AGE (Wendt et al., 2003).  It also appears that 
intracellular AGEs is the primary initiating feature in generating various signal events 
by activation PKC, MAP kinase and transcription factors. This would increase the 
activity of growth factors such as TGF-β and CTGF and thereby modify the 
regulation of expression of ECM proteins, which is a cause of renal hypertrophy and 
accumulation of extracellular matrix components (Jakus et al., 2004). In addition, it 
increases the synthesis of proteins which are involved in the regulation of gene 
transcription (Shinohara et al., 1998).  
 
Interestingly, AGEs have the capability to covalently bind with proteins and induce 
deleterious effects in various tissues. Indeed, AGE precursors have the ability to 
diffuse outside of the cell and alter circulating proteins within the blood, including 
albuminuria, or bind to cell-associated proteins that trigger abnormal cellular function 
(Vlassara and palace, 2002). Vittorio et al. (2007) revealed that urine and plasma 
AGEs increase in patients with DN compared to healthy subjects. In vitro studies by 
Chen et al (2001) showed that AGE-rich proteins and glycated albumin increase the 




glomerular and endothelial mesangial cells. Furthermore, it has been shown that 
AGEs can mediate their effect via AGE receptor (RAGE), resulting in formation of 
ROS (Tan et al., 2007). 
● Hexosamine pathway activity 
Under high glucose conditions, the excessive glucose is metabolized through 
glycolysis, going first to glucose-6 phosphate via hexokinase, which subsequently 
converts to fructose 6-phosphate and then continues through the rest of the glycolytic 
pathway. However, only some fructose-6-phosphate gets diverted in the signalling 
pathway by an enzyme called GFAT (glutamine: fructose-6 phosphate 
amidotransferase). Fructose-6 phosphate further converts to glucosamine-6 phosphate 
and finally to UPD-GlcNAc (uridine-5diphosphate-N-acetyglucosamine). 
Subsequently, the N-acetylglucosamine is added to serine and threonine residues of 
TGF-β (Brownlee, 2005). This procedure often results in changes in gene expression 
including the elevation of TGF-β levels, which is involved in the pathogenesis of DN 
(Du et al., 2000). 
Studies by Weigert et al. (2003) reported that the activation of the hexosamine 
biosynthetic pathway has been implicated in an elevated expression of TGF-β in 
mesangial cells, leading to mesangial matrix expansion and diabetic 
glumerulosclerosis.  Additionally, Singh and Crook (2000) showed that the activity of 
Protein kinase C through the hyperglycaemia-induced hexoamine pathway also 
contributed to the synthesis of ECM proteins in mesangial cells. Taken together, the 
activation of the hexosamine pathway via hyperglycaemia may produce various 
changes in both gene expression and protein function, which together leads to the 
pathogenesis of DN (Brownlee, 2001). 
1.5.2. Hemodynamic factors 
● The reactive oxygen species (ROS) pathway 
Reactive oxygen species (ROS) seem to have been an interesting topic in all areas of 
biology for many years. ROS are reduced forms of oxygen which are in a more 
reactive state when compared with molecular oxygen (Hancock et al., 2001). Normal 
metabolism of oxygen results in the formation of ROS, a natural byproduct which 
includes free radicals (Djk and Tomas et al., 2004). ROS are key signalling molecules 




dramatically increase the levels of ROS in the cells which causes damage to cell 
structure. This relative overload of oxidant and reduction of antioxidants is known as 
oxidative stress (Vittorio et al., 2007; Valko et al., 2006). Oxidative stress causes a 
harmful consequence on cells including severe damage to DNA, proteins, and lipids 
(Valko et al., 2006).  
It has been shown that hyperglycaemia induces vascular injury through complex 
overlapping pathways, including enzymatic and nonenzymatic processes such as 
ROS. Several in vivo and in vitro studies strongly suggest an important role of ROS in 
the initiation and progression of DN, by affecting the intracellular redox balance of 
the cell (Schafer and Buettner, 2001). Studies by Lee et al. (2003) showed that high 
glucose induces ROS in both mesangial and tubular epithelial cells. Lee et al. (2003) 
concluded that ROS activates signal transduction cascade and transcription factors 
resulting in an increase in the expression of genes involved in the expansion of 
glomerular and mesangial cells (Figure 6). Studies (Vittorio et al., 2007) also revealed 
that AGEs, together with hyperglycaemia and ROS, generate growth factors and 
cytokines which all result in renal hypertrophy and increased expression of 
extracellular matrix components. 
NADPH oxidase is the major enzymatic source for ROS generation in renal mesangial 
and tubular cells (Griendling et al., 2000; Shiose et al., 2001). A study by Guzik et al 
(2000) reported that hyperglycaemia independently correlated with NADPH oxidase-
derived ROS generation in diabetic patients. Generally, hyperglycaemia resulted in 
elevated ROS both via NADPH oxidase and through electron leakage from the 
mitochondrial electron transport chain (Lee et al., 2003). NADPH oxidase is one of 
the most important enzymes for controlled release of ROS. However, the exact 
function of ROS and their internal role as signals in the face of a barrage of 
antioxidants still require more research studies (Hancock et al., 2001). It has been 
suggested that modulation of ROS production in biochemical pathways may prove to 
















 Figure 6. ROS-regulated signalling in renal cells cultured under high glucose. 
Mitochondrial electron transfer chain and receptor-stimulated NADPH oxidases are  
important sources of intracellular ROS generation under high glucose conditions. High 
glucose-induced ROS activate signal transduction cascades and transcription factors, 
leading to up-regulation of expression of genes and proteins involved in ECM remodelling in   
the kidney. HG: high glucose, MCP-1: monocyte chemoattractant protein-1, RAGE: receptors 





Various in vivo and in vitro studies show the up-regulation of Ang II and Renin 
activity in DN. In vitro studies by Zhang et al. (1999) reported the up-regulation of 
angiotensinogen mRNA and protein in proximal tubular epithelial cells exposed to 
high glucose. Another study by Chouinard et al (2002) showed increased expression 
levels of AngII production in rat mesangial cells cultured in high glucose. In vivo 
studies have also confirmed the involvement of Ang II in DN. For instance, STZ-
induced diabetic rats showed higher levels of plasma Ang II than control and insulin 
treated rats (Zimplmann et al., 2000).   
Clinical studies were also performed in parallel with in vivo and in vitro studies and 
support previous findings. A clinical study in both hypertensive patients with DN by 
Lai et al. (1998), highlighted stronger signals of angiotensinogen, renin and ACE 




showed up-regulation of different components of the renin-angiotensin system (RAS) 
in the diabetic kidney. Furthermore, a number of studies suggested the activation of 
RAS in diabetes and they showed that DN has an increased sensitivity to AngII 
(Kennefic TM, 1996).  Zhang et al. (2006) showed that RAS plays a role in the 
pathogenesis of DN by regulating the PKC isoforms activity. These findings postulate 
the involvement of Ang II and the RAS system in the progression of DN. 
● Nitric oxide (NO) 
Nitric oxide (NO) is a signalling molecule which plays a role in the renal structure 
and function in diabetes. NO is derived from L-arginine (L-Arg) in macrophages and 
other cell types (Marletta, 1989). This reaction is catalyzed by several nitric oxide 
syntheses (NOS) isoenzymes. These NO isoforms include neuronal (nNOS), 
endothelial (eNOS) and inducible (iNOS), which have been identified in mammalian 
tissues (Komers et al., 2003) and all are expressed in the kidney. NO plays an 
important role in renal functions including the excretion of sodium, regulation and the 
maintenance of renal structural integrity (Kone et al., 1997). There are extensive 
studies which demonstrate that abnormalities of NO production modulates renal 
function. 
A number of in vitro studies showed that high glucose has an influence on NO 
bioavailability in cultured mesangial cells, which may involve the action of the 
prostanoid thromboxane A₂ and PKC activation (Trachtman et al., 1998; Noh et al., 
2002). In vivo studies by Choi et al. (1997) reported the elevation of renal cortical 
expression of all NOS isoforms in STZ diabetic rats. However, in medulla of the same 
samples there was no difference in their expression with respect to controls. Another 
study by Ishi (2001) indicated no change in NO synthase isoform protein levels in the 
renal cortex of the STZ rat. 
1.5.3. Intracellular factors 
● Protein kinase C activation 
Hyperglycaemia concentrations inside the cells lead to the activation of PKC through 
increased glucose metabolism (Brownlee, 2005). PKCs family includes at least 11 
isoforms of which some, such as Protein kinase-C, -β, -δ and –α, are activated by 
diacylglycerol (DAG ; Way et al., 2001; Idris et al., 2001)  and are also generated 




activation of PKC via intracellular hyperglycaemia results in various effects on gene 
expression in an abnormal way (Brownlee, 2005). PKC appears to be involved in the 
pathogenesis of DN (Li and Gobe, 2006). PKC activation contributes to the regulation 
of a number of vascular functions, such as cell proliferation and synthesis of 
extracellular matrix proteins and growth factors; it also leads to decreased NO 
production (Inoguchi, 2000). In renal glomeruli, in vitro studies have shown an 
evidence of hyperglycaemia-induced PKC activity in mesangial cells. 
Hyperglycaemia has been shown to be the cause of PKC activity, which in turn is 
linked to an increase in the expression of TGF-β as one of the main factors in 
regulation of ECM protein accumulation in DN (Kreisburg et al., 1994). PKC activity 
increased the expression of type IV collagen under high glucose which is the main 
component in capillary basement membrane thickening (Fumo et al., 1994). In 
addition to the effect of hyperglycaemia-induced PKC activity in mesangial cells, 
Koya et al. (1997) also reported the effect of hyperglycaemia in the activation of PKC 
in mesangial cells and they suggested that the activation of PKC, particularly the PKC 
(β) isoform can change gene expression and functions of glomerular cells which are 
involved in the progression of DN. 
 
Moreover, increased activation of PKC was also exhibited in the STZ diabetic rat 
during the early stages of diabetes (2 weeks) through to long term (24 weeks) diabetes 
(Carven et al., 1990). Changes in the subcellular distribution of PKC activity in the 
glomeruli of short term diabetic rats were also noted (Carven et al., 1990). The 
clinical study by Ceolloto et al. (1999) showed that the activity of the PKC membrane 
is increased with high concentration of plasma glucose in a patient with T2DM. It was 
also suggested that hyperglycaemia-induced changes in monocyte PKC activity might 
be associated with the progression of DN (Ceolloto et al., 1999). 
1.5.4. The role of growth factors 
● Transforming growth factor β (TGF-β) 
The AGEs, hexosamines, ROS and DAG/PKC described above are likely candidates 
that activate TGF-β signalling through hyperglycaemia (Leask, 2004). TGF-β is one 
effector molecule that has been reported as a major mediator of the pathologic 




synthesis of ECM proteins including type I collagen, type IV collagen, fibronectin and 
laminin (Sharma and Ziyadeh, 1997). 
TGF-β also reduces matrix degradation via the activation of protease inhibitors and 
inhibition of proteases (Ziyadeh, 1994). Several in vitro studies have demonstrated 
that hyperglycaemia stimulates hypertrophy of both mesangial and proximal tubular 
cells through the up-regulation of TGF-β expression (Ziyadeh, 1994; Han et al., 1999; 
Hoffman, 1998; Rocco, 1992). Furthermore, extensive studies in experimental models 
of diabetes indicated increased expression of TGF-β mRNA and protein in both 
glomerular and tubular cells compartments of diabetic rats and mice (Hill et al., 2000; 
Hong et al., 2001). Hill et al. (2000) reported that TGF-β protein was increased in 
tubules of the diabetic rat, whereas it was reduced in glomeruli. Immunohistochemical 
staining and in situ hybridisation studies detected an increase of TGF-β type II mRNA 
and protein in both glomerular and tubular cells in the db/db mice (Hong et al., 2001). 
An increase of glomerular TGF-β1 expression was also determined in a patient with 
T1DN (Yammoto et al., 1996). Therefore, all of these studies show the regulation of 
TGF-β in glucose-induced renal injury pathways. 
 
● Vascular endothelial growth factor (VEGF) 
Vascular endothelial growth factor (VEGF) is a secreted mitogen which is highly 
specific for endothelial cells. VEGF was first identified as a potent permeability factor 
in 1983 (Senger et al., 1983). VEGFR-1 (Flt-1) and VEGFR-2 (KDR/Flk-1) are two 
VEGF receptor tyrosine kinases which have their own biological and biochemical 
functions. VEGFR-2 meditates most of the endothelial cell responses, whereas 
VEGF-1 appears to be more elusive (Robinson and Stringer, 2001). Inside the cells, 
VEGF is involved in various functions including stimulating endothelial cell 
proliferation, increasing vascular permeability, mediating endothelium-dependent 
vasodilation, playing a cardinal role in physiological and pathological angiogenesis 
and modulating leukocyte kinetics (Neufeld et al., 1999).  
 
It has been suggested that VEGF and its receptors play a role in the development of 
DN in both in vitro and in vivo studies (Cooper, 1999; Hovind, 2000). Many growth 
factors and cytokines relevant to the pathogenesis of DN have also been reported to 
promote VEGF regulation. These include TGF-β and IGF-I (Neufeld et al., 1999). In 




et al. (1997) reported that VEGF expression is stimulated by hyperglycaemia in 
vascular smooth-muscle cells via the PKC pathway. It has also been shown that 
VEGF expression is induced via AGEs (Hirata, 1997) and Ang II (Puppili, 1999) in 
human mesangial cells; its secretion leading to proliferation (Thomas et al., 2000) and 
induction of collagen synthesis (Amemiya et al., 1999). 
In vivo, VEGF was found to be increased in the kidney of the STZ diabetic rats 
(Cooper et al., 1999). The up-regulation of VEGF expression was reported to occur at 
an early stage in diabetic rats (Cooper et al., 1999). This is evidenced by an increase 
in VEGF mRNA and protein expression at up to 32 weeks after onset of diabetes. 
However, some studies have shown a reduction in the STZ diabetic rats after only 1 
week following onset (Singh et al., 2004). 
Assessing circulating VEGF expression also provided evidence for the role of VEGF 
in DN. One large study of patients with T1DN showed that circulating VEGF levels 
in plasma were increased in nephropathy patients compared to normoalbuminuric 
patients. However, this difference was mostly owing to the elevated levels found in 
T1DN men, as there was no significant difference between the female patients 
(Hovind et al., 2000). Wasada et al (1998) also reported higher levels of plasma 
VEGF in patients with T2DM (Wasada et al., 1998). VEGF‟s urinary excretion has 
been examined in some patient studies with DN (Cha et al., 2000). In this study, 
VEGF‟s urinary excretion was elevated with the development of DN which was 
associated with serum creatinine, microalbuminuria and proteinuria levels (Cha et al., 
2000). The biopsy study found that VEGF levels were high in glomerular podocytes 
and distal tubular cells in patients with mild DN, whereas VEGF expression was low 
in tubules and especially the proximal segment in patients with advanced DN (Cha et 
al., 2000). Therefore, it is clear that VEGF and its receptors are vital for the 
progression of DN. 
 
● Connective tissue growth factor (CTGF) 
Connective tissue growth factor (CTGF) is a 38 kDa cysteine-rich secreted protein, 
which was originally isolated from conditioned media of human umbilical vein 
endothelial cells (Bork, 1993; Bradham, 1991). CTGF is a member of cysteine-rich 
growth factors (CCN family). This family of proteins is involved in various cellular 
effects such as mitogenesis, apoptosis, regulation of ECM physiology, osteogenesis, 




in humans, mice and rats which shows approximately 90% identity (Bork, 1993). It 
seems that CTGF transcription is mainly induced by TGF-β and is linked to the 
pathogenesis of fibrosis (Grotendorst et al., 1997). However, its physiological 
function remains unknown. 
Several lines of evidence show that hyperglycaemia induces CTGF mRNA and 
protein levels in humans and cultured rat mesangial cells (MC), and they also revealed 
that CTGF is involved in the progression of glomerulosclerosis and tubulointerstitial 
injury in the kidneys (Murphy, 1999; Riser, 2000). 
 
Several different factors including hyperglycaemia, AGEs, TGF-β and ROS are 
involved in the increased CTGF mRNA and protein levels in renal cells in DN 
(Murphy et al., 1999; Reiser et al., 2000; Wahab, 2001). Riser et al. (2000) indicated 
that hyperglycaemia increased the CTGF mRNA levels in mesangial cells and the 
addition of CTGF stimulates cultured mesangial cells to induce the expression of 
main components of ECM, such as fibronectin and collagen I. Another study by Liu et 
al. (2007) showed that in human vascular smooth muscle cells (VSMC) 
hyperglycaemia-induced CTGF expression and is associated with the accumulation of 
fibronectin and collagen I. Murphy et al. (1999) reported that in addition to 
hyperglycaemia, TGF-β1 stimulated CTGF expression in primary human mesangial 
cells, whereas the addition of an anti-TGF-β1 antibody inhibits the induction of CTGF 
in exposed mesangial cells. Moreover, Murphy et al (1999) revealed that PKC 
inhibitor inhibited the induction of CTGF, as well as TGF-β1 and concluded that 
hyperglycaemia-induced TGF-β1 and PKC pathways are involved in the expression of 
CTGF. 
 
To further determine CTGF function in the presence of hyperglycaemia, James et al. 
(2013) showed that hyperglycaemia increased the expression of ECM components 
such as collagen I, IV and XVIII as well as fibronectin and thrombospondin (TSP1) in 
cultured MEF from CTGF wild type mice. However, the activation of these 
components under hyperglycaemic conditions was attenuated in heterozygous mice. 




1.6. Hyperglycaemia-induced gene expression in DN 
High-throughput gene expression profiling is an important, integrative tool that 
provides global views into the regulatory pathways of DN (Liang et al., 2003). 
Several likely genes contributing to DN were identified by examining the changes in 
expression of a variety of mRNA transcripts throughout the course of diabetes. Gene 
expression profiling has been applied to demonstrate the regulated changes of genes 
inside a cell under different conditions. In DN, over 200 genes have been identified 
which are regulated differentially in mesangial cells grown in high glucose (Murphy 
et al., 1999). Furthermore, Clarkson et al. (2002) recognised 200 mesangial cell genes 
which are up or down regulated in the presence of high glucose. 
The results from various strategies may be analysed together to rationalize a 
collection of possible markers. For instance, caldesmon is a gene which is highly 
expressed in mesangial cells exposed to high glucose (Murphy et al., 1999) and is 
placed on chromosome 7q35in a region previously connected to vulnerability from 
DN in two independent genome-wide screens (Imperatore et al., 1998; Fogarty et al., 
1999). In addition to these results, a number of glucose regulated novel genes have 
been demonstrated (Wada et al., 2002). Gremlin (Dolan et al., 2003), serum 
glucocorticoid regulated kinase (Feng et al., 2005), beta-defensin-1 (Page and Malik, 
2003) and NSA2 (Shahni et al., 2011) are examples of glucose regulated genes in both 
in vivo rodent models of diabetes and in vitro studies. The isolation and recognition of 
glucose regulated genes could lead to recognition of potential therapies for DN. 
Therefore, it is interesting to consider the regulation of various genes in diabetic 
environments in an attempt to find a novel therapeutic target for DN. 
● Gremlin (IHG-2) 
Gremlin (IHG-2) was identified as a gene that is regulated by high glucose in human 
mesangial cells (Murphy et al., 1999). It is a 184 amino acid protein and a member of the 
cysteine knot superfamily. Gremlin influences various steps in growth, differentiation 
and development (Murphy, 2002). Gremlin expression has been detected in a number 
of kidney disease models in humans, but was almost undetectable in healthy kidneys 
(McMahon, 2000). It was also expressed in human mesangial cells cultured in high 
glucose, in those exposed to TGF-β in vitro (Murphy et al., 1999) and in kidneys 




reported that the mRNA expression of gremlin was increased in the renal cortex of 
STZ-induced diabetic rats and they were regulated in response to high extracellular 
glucose and mechanical strain. Studies in kidney biopsy specimens from patients with 
DN showed that gremlin levels were increased in DN patients compared to those with 
normal kidneys (Dolan et al., 2005). 
A high level of gremlin expression was observed in the tubular compartment of 
patients with advanced DN. Interestingly, gremlin was co-localised with TGF-β1 in 
proximal tubular cells, suggesting that TGF-β1 might be modulating gremlin 
expression in the tubulointerstitial compartment. Additionally, gremlin mRNA 
expression was associated directly with increased serum creatinine levels and renal 
fibrosis in patients with DN. Therefore, they suggest a role for gremlin in the 
pathogenesis of DN (Dolan et al., 2005). 
 
● NSA2 
CDK105 or NSA2 (Nop-seven-associated 2) was one of the candidate genes which 
was isolated by differential screening as it exhibited a strong hybridisation signal in 
kidneys of a GK rat diabetic for 40 weeks (Malik et al., 1997). Northern blot analysis 
using total RNA from GK rat kidneys at different ages (6-,16-,26- and 40- week-old) 
and aged-matched Wistar control kidneys showed up- regulation of CDK105 in GK 
rat kidneys diabetic for 40 weeks (Ziadi, 1997). CDK105 is a highly conserved gene 
in humans, mice and rats which encodes a 260 amino acid protein in humans (El 
Mahdi, 1995). The CDK 105 coding region shares 100% identity to the TGF-β 
inducible nuclear protein 1 (TINP1, AF077615) and 99% identity to hairy cell 
leukemia (HCL, AF372458). 
CDK105 is identical to NSA2 (Nop seven associated 2) and is also identified as 
TINP1 (TGF-β inducible nuclear protein 1) and hairy cell leukemia protein 1 (HCL-
G1). The NSA2 homologue in yeast is thought to be involved in ribosome biogenesis 
and it has been defined as a nuclear protein which includes numerous nuclear 
localisation signals (Laberton, 2006; Andersen, 2005). The human homologue NSA2 
was first recognised as one of the putative tumour suppressor genes involved in the 
pathogenesis of HCL1; it has been reported that it contributes to the regulation of cell 




Studies by Zhang et al. (2010) showed that NSA2 is regulated at higher levels in the 
kidneys, placenta, thymus and is also regulated at lower levels in most human tissues. 
Additional studies by Shahni et al. (2011) showed that renal NSA2 mRNA is 
increased in human mesangial cells exposed to high glucose. They also found that 
renal NSA2 is up-regulated in response to hyperglycaemia in the kidneys of both the 
GK rat and the streptozotocin-induced diabetic mice. Circulating NSA2 mRNA levels 
were increased in patients with albuminuria compared with nonalbuminuric patients 
and diabetic controls. These studies suggest that NSA2 may play a role in the 
pathogenesis of DN.  
1.7. Model systems to study Diabetic nephropathy 
1.7.1. In vitro: cultured kidney cells 
● Mesangial cells 
Mesangial cells are specialized cells which are located around intercapillary space in 
the kidney (Shigeta and Kikkawa, 1991). They play a key role in maintaining 
glomeruli structure and function (Wada, 2001). They also have a central role in the 
pathogenesis of glomerular injury (Wada, 2001) and are considered to be key 
mediators of glomerular inflammation and fibrosis (Wani et al., 2007). Therefore, 
human mesangial cells are a useful in vitro model for studying the early stages of DN. 
Progression of diabetic nephropathy is associated with glomerular hypertrophy, 
mesangial expansion and thickened glomerular basement membrane, which leads to 
glomerulosclerosis (Greenberg, 1998). The diabetic glomerulosclerosis is categorized 
by mesangial accumulation of extracellular matrix proteins such as laminin, collagen 
IV and fibronectin genes. Functional abnormalities such as glomerular 
hyperfilteration and hypertension, as well as alteration in metabolic pathways or the 
action of polypeptide growth factors may also contribute to diabetic glomerulopathy 
and renal failure in DN (Ziyadeh, 1998).   
A number of in vitro studies have suggested that high concentrations of glucose 
modify mesangial cell function and are a major stimulus for mesangial cell matrix 
production in diabetic nephropathy (Murphy, 1999). Studies by Wolf et al (1992) 
suggested a biphasic effect on proliferation when murine mesangial cells were 
exposed to elevated glucose levels. Exposure of mesangial cells to high glucose also 




suggesting an induced production or decreased degradation of type IV collagen as a 
result of high glucose (Shigeta and Kikkawa, 1991). Philip et al. (1999) reported that 
exposing glomerular mesangial cells to high glucose may alter cell proliferation and/ 
or ECM turnover. 
Activation of many pathways have been shown to regulate mesangial cell function 
leading to renal injury including: stimulation of TGF-β1 (Selliti et al., 2007); PKC 
activation (Portilla et al., 2000); increased formation of AGEs (Matsui et al., 2007), 
Ang II and RAS (Yano et al., 2007); oxygen free radicals (Lee et al., 2003) and up-
regulation of the thiol antioxidative pathway as an adaptational response of human 
mesangial cells to high glucose (Morrison et al., 2004). Moreover, there is evidence 
that high glucose activates an intrinsic pathway of proapoptotic signalling in cultured 
human mesangial cells. Additionally, an intrinsic pathway of apoptosis signalling is 
activated in db/db kidneys in vivo, which is correlated with apoptosis of glomerular 
cells (Mishra, 2005). 
The growth of human mesangial cells at high concentration of glucose has been used 
to determine glucose-regulated genes. Studies by Murphy (1999) have demonstrated 
that 15 novel genes are differentially induced when primary human mesangial cells 
are exposed in high glucose. Consistently, MOSC2 (CDK7) (Malik et al., 2007), 
CRYM (Al-kafaji and Malik, 2010) and NSA2 (Shahni et al., 2011) were included in 
this category as they are all up-regulated by high glucose in human mesangial cells. 
 
● Tubular cells 
Diabetic nephropathy is considered to be primarily a glomerular disease and there is 
less research about the pathogenesis of the tubulointerstitial changes in DN. 
Histological studies have widely shown that the deterioration of renal function in 
chronic kidney disease (CKD) is associated more with tubular and interstitial changes 
when compared with glomerular changes (Gilbert &Cooper, 1999). Indeed, the 
progression of renal disease is characterised by pathogenic mechanisms that lead to 
progressive interstitial fibrosis, peritubular capillary loss and destruction of 






Various in vitro studies have established that albumin and other urinary proteins such 
as immunoglobulin G can stimulate proximal tubular cells to produce chemokines and 
inflammatory molecules (Lai, 2007; Tang, 2001). In addition to inflammation, 
interstitial fibrosis is a major determinant of progressive renal disease. For instance, 
albumin stimulated proximal tubular epithelial cells (PTECs) to produce TGF-β 
which is the most effective cytokine for renal fibrogenesis (Liu, 2006). AGEs and 
RAGE pathways activate secondary messenger pathways such as PKC, and increase 
production of fibrogenic growth factors and inflammatory cytokines such as TGF-β 
and CTGF, which lead to interstitial fibrogenesis via tubular EMT induction (Tang 
and Lai, 2012). 
High glucose is the main component of diabetic milieu that can cause direct damage 
to tubular cells, alongside an accumulation of glycated proteins, increased intrarenal 
angiotensin II and oxidative stress (Singh, 2008; Tang and Lai, 2012). Studies by 
Phillip (1999) demonstrated that type IV collagen and fibronectin secretion was 
increased when human renal proximal tubular cells were exposed to high glucose. 
Ziyadeh et al. (1990) determined that growing mouse proximal epithelial cells in high 
glucose induces cellular hypertrophy and stimulates ECM production. They also 
found that type I collagen is stimulated by elevated glucose levels in PTECs. Studies 
have also demonstrated that high glucose caused an increase of TGF-β and VEGF in 
proximal tubular cells (Rocco, 1992). Furthermore, the polyol pathway is a potential 
mediator which meditates high glucose-induced collagen synthesis in proximal 
tubular cells (Blayer, 1994). 
1.7.2. In vivo: Rodent models 
● Streptozotocin C57BL/6 mice  
Streptozotocin-induced pancreatic injury is a widely accepted technique which is used 
to create rodent models of T1DM and expand renal injury with similarities to human 
DN. This model can be used to examine the molecular mechanisms and genetic 
susceptibility in the progression of DN (Tesch and Allen, 2007). Streptozotocin (STZ) 
is a D-glucopyranose derivative of N-methyl-N-nitrosourea (MNU) which is readily 
transported into pancreatic β-cells by Glut-2 and causes β-cell toxicity and results in 




β-cell O-GlcNAcase. This causes irreversible O-glycosylation of intracellular proteins 
and results in the apoptosis of β-cells (Lee et al., 2006). 
 
C57BL/6 mice are extensively used for studies of kidney disease which are typically 
made diabetic by an injection of STZ, as it results in the destruction of the pancreatic 
β-cells. In humans, diabetic nephropathy is clinically characterised by the 
development of microalbuminuria and a decline in renal function. These clinical 
parameters are observed in the rodent models, although the albuminuria level and 
renal dysfunction are less severe when compared with a patient with DN (Tesch and 
Allen, 2007). The STZ diabetic mice typically develop albuminuria and also have 
extreme hyperglycaemia and insulin deficiency which can be observed between 
weeks 1-2. Breyer et al. (2005) reported that there are associations between doses of 
STZ with microalbuminuria, as those mice receiving a high-dose of STZ developed 
more albuminuria in comparison with STZ mice receiving a low-dose. It is also 
possible the hemodynamic changes are involved in the progression of albuminuria at 
this early time point (Breyer et al., 2005). As time progresses (15-30 weeks of 
hyperglycaemia), the development of mesangial expansion and mesangial sclerosis 
are seen in the STZ diabetic mice. However, this severity is usually milder than 
patients with DN (Tesch & Allen, 2007). 
Although, the use of STZ is a robust technique for inducing diabetes in rodent models, 
the progression of DN in these animals is less compared to DN patients. There are 
also additional issues when using these rodent models. Firstly, STZ has a toxic effect 
on kidneys, especially the tubular epithelium and this may be a significant cofounder 
when DN is studied in STZ–treated mice. Secondly, one of the key features in humans 
is that diabetic complications develop gradually, occurring in patients 15 to 25 years 
after the onset of diabetes (Caramori et al., 2000). However, most of the DN studies in 
mice, such as the progression of albuminuria and histopathologic changes have 
focused on the earlier indication of DN due to cost and convenience; they have not 
openly used renal deficiency as an end point (Sharma et al., 2003). In our 
experiments, we are investigating the effect of hyperglycaemia on CRYM and 
MOSC1/MOSC2 genes in mouse kidneys as an indication of early change in diabetes 





● ß-phb2 KO mice 
Prohibitins are highly conserved proteins which assume a main role in the 
maintenance of mitochondrial function and architecture. Their dysfunction is 
correlated with various disorders such as cancer, obesity, aging and inflammation. 
However, their function in ß-cells of the pancreas is unclear. Ablation in a sequence 
of Phb2 in a mouse ß-cell caused mitochondrial dysfunction, impairment of insulin 
secretion, loss of ß-cells, progressive change of glucose homeostasis, and ultimately 
severe diabetes (Supale et al., 2013). ß-cell-specific Phb2 knockout mice were used to 
investigate the role of Phb2 in this endocrine cell type. These mice became diabetic at 
later age i.e. 11 weeks (>25 mM) and they suffered weight loss (Supale et al., 2013). 
In vivo studies by Supale et al (2013) demonstrated that the deletion of phb2 in these 
mice resulted in abnormalities of mitochondria, including a decrease in mtDNA copy 
number with changes in mitochondrial function and a reduction of complex IV levels. 
These events ultimately led to ß-cell loss and dysfunction which resulted in severe 
diabetes in this type of mouse. This model represents spontaneous diabetes 
progression, through a series of molecular events which appear after 3 weeks and does 
not require administration of chemicals such as STZ. Therefore, we used this 
spontaneous model of diabetes to examine the expression of our genes of interest in 
under hyperglycaemic conditions parallel to STZ models.  
1.8. Background of study 
In the Malik laboratory identified several candidate diabetes associated kidney cDNA 
clones in GK rat kidneys at progressive stages and they were isolated by differential 
screening (Page et al., 1997; Morris, 1997). Some of these clones showed 
transcriptional changes in GK rat kidneys during the progression of diabetes (Table 
3). Consequently, CDK108 (CRYM) and CDK7 (MOSC2) were selected as glucose 
regulated candidate genes and their expressions were further investigated during the 
course of diabetes through in vivo and in vitro studies 
1.8.1. CRYM 
CDK108 (CRYM) was one of several differentially expressed candidate genes from 
diabetic rat kidneys which displayed a strong hybridisation signal in 40-week-old 
diabetic kidneys of progressively hyperglycaemic GK rat compared to 6-week-old GK 




rat kidneys of 6, 16, 26 and 40 weeks old and aged-matched Wistar normoglycaemic 
kidneys showed CDK108 mRNA expression at higher levels in the kidneys of the GK 
rat at 40 weeks (Zaidi, 1997). The DNA sequence of rat CDK108 showed that it 
represents CRYM (µ-crystallin), an abundant protein normally detected in the eye 
(Zaidi, 1997). CRYM is also known as μ-crystallin or NADP-regulated thyroid 
hormone-binding protein (THBP) (Vie et al., 1997), and for the purposes of this study 
we will refer to this gene as CRYM. 
Northen blot analysis of human tissues showed that human CRYM mRNA is 
abundant in the kidney, heart, brain and skeletal muscle and neural tissue whereas 
there is less in the liver and lung (Kim et al., 1992). Studies have shown high 
expression of human CRYM in cochlear vestibular tissues in the inner ear (Abe et al., 
2003). In adult kangaroo, CRYM mRNA is most abundant in the lens, whereas it was 
expressed at lower levels in retina and brain (Kim et al., 1992). Among the mouse 
tissues, CRYM mRNA is most abundant in the skin, whereas its level is lower but 
detectable in the brain, eye, heart, kidney, liver and lung (Aoki et al., 2006). In the rat, 
the mRNA expression of CRYM has been detected in a number of tissues such as the 
kidney (Vie et al., 1996) and brain (Beslin et al., 1995). 
CRYM was originally identified as a major structural protein in the lenses of 
kangaroos (Chen et al., 1992). CRYM has been proposed to have enzymatic function 
due to its structural homology to bacterial enzymes including alanine dehydrogenase 
and ornitine cyclodeminase (Kim et al., 1992). Mutations in CRYM can be the cause 
of non-syndromic deafness (Abe et al., 2003; Oshima et al., 2006) and expression  
changes of CRYM mRNA has been shown in glioblastoma (Khalil, 2007), prostate 
cancer (Mousses et al., 2002), and breast cancer (Forti et al., 2002). Additionally, 
altered CRYM expression has been associated with diseases where oxidative stress 
plays a role such as cardiovascular disease (Yang et al., 2000) and muscular 
dystrophy (Reed et al., 2007; Fukada et al., 2007). Furthermore, CRYM has been 
proposed to be a cytosolic thyroid binding protein which is regulated by binding to 
NADPH (Vie et al., 1997; Suzuki et al., 2007). There is much evidence which show 
that patients with uncontrolled diabetes have disturbed thyroid metabolism (Patrisia, 




diabetes, and it has been suggested to be an independent risk marker for nephropathy 
events (Bando, 2002; Chen, 2007). 
In renal cells as described previously, hyperglycaemia elevates the cytosolic glucose 
concentrations, which leads to an abnormal activation of signalling pathways and 
biochemical dysfunction (Lee et al., 2003; Brownlee, 2001). For instance, 
hyperglycaemia results in an increase of ROS production as one of the hemodynamic 
factors which activates the pathways leading to the damage found in diabetic 
complications (Brownlee, 2001; Brownlee, 2005; Nishikawa, 2000). Much of this 
damage is considered to be a consequence of elevated production of ROS by either 
the mitochondrial respiratory chain or membrane bound NADPH oxidase, during 
hyperglycaemia leading to oxidative stress (Lee et al., 2003). The fact that the CRYM 
gene has the capability to bind to NADPH directly before being activated as a thyroid 
hormone binding protein is important in DN (Hashizume et al., 1989). NADPH is an 
essential component of the cellular antioxidation system and has been proposed as a 
central mediator of the fundamental biological processes containing energy 
metabolism and oxidative stress (Yan et al., 2006). 
 A study by Al-kafaji (2010) reported that CRYM mRNA levels increased in the 
diabetic kidneys and hearts of GK rats in response to hyperglycaemia when compared 
to normo-glycaemic age-matched Wistar rats. Al-kafaji and Malik (2010) reported a 
significant increase in CRYM mRNA and protein levels of renal mesangial cells 
exposed to high glucose, as well as increased intracellular ROS. Al-kafaji and Malik 
(2010) also showed that over expression of CRYM resulted in a decrease of glucose-
induced intracellular ROS in mesangial cells. It was concluded that CRYM is a 
glucose-regulated gene in vivo in diabetic models of rats and in vitro in renal human 
mesangial cells and thus, CRYM could play a role in the oxidative response of the cell 
in DN (Al-Kafaji and Malik, 2010).  
Taken together, we consider that there might be a link between CRYM expression and 
the mechanism of damage in DN. Thus, it is important to investigate the effect of high 
glucose on CRYM expression in different animal models in vivo and in vitro in 




1.8.2. MOSC2 (CDK7) 
MOSC2 (CDK7) was one of several differentially expressed genes from diabetic 
kidneys (Malik et al., 2007). Increased MOSC2 mRNA expression was found in a 40-
week-old GK rat kidney (Table 3; Page et al., 1997) and in human mesangial cells 
exposed to high glucose (Malik et al., 2007). The MOSC2 gene has been located on 
human chromosome 1q42 (near a diabetes susceptibility gene and linked to numerous 
diseases: e.g schizophrenia, prostate cancer, and diabetes). Sequence analysis of 
MOSC2 protein demonstrated that the MOSC2 contained Molybdenum cofactor 
Sulphurase C-terminal (MOSC) and MOSC_N, domain and a Cystine-Proline-
Argenine-Cystine (CPRC) motif, which is conserved in 15 diverse species (Malik et 
al., 2007). The CPRC region of MOSC2 may have a redox function, as the CPRC 
domain indicated a similarity to a redox protein structure (thioredoxin; Nordberg, 
2001). 
There is growing evidence that hyperglycaemia can induce ROS during the inhibition 
of thioredoxin function by interacting with thioredoxin protein (Schulze et al., 2004). 
Thioredoxin plays a central role in the redox regulation of the cell (Nordberg, 2001). 
A study by Ceriello et al. (2000) indicated that antioxidant genes have defective role 
in diabetic patients. Glyn-Jones et al. (2007) suggested that the protective effect of 
thioredoxin in experimental DN could be used as an antioxidant therapy for the 
treatment of DN (Glyn-Jones et al., 2007). In addition to this study, another study by 
Morrison et al. (2004) showed that altered thiol protein expression is linked to the 
progression of DN, and also the antioxidant response inside the cell has been shown 
to be defective in DN (Hodgkingson et al., 2003). Thiol groups also have the 
capability to modify protein functions in response to ROS. The high conservation of 
the CPRC domain in all MOSC2 homologue and its similarity to the catalytic 
thioredoxin domain (Schulze, 2004), are proposed to be a functional correlation 
between thioredoxin-like proteins and MOSC2 (Malik et al., 2007). 
According to these findings, MOSC2 may be involved in the cellular response to 
hyperglycaemia-induced oxidative stress and play a role in DN by the regulation of 
ROS levels in the mitochondria. Therefore, the functional characterization of MOSC2 
and its participation in renal cellular response to oxidative stress could provide a 




In 2010, the Havemayer group found that MOSC2 is a mitochondrial amidoxime 
reducing component-2 (MARC2). They also indicated that MOSC2 is the fourth 
molybdenum enzyme and it is part of a three component enzyme system which is 
located at the outer mitochondrial membrane. MOSC2 has the potential to reduce N-
hydroxylated compounds and is involved in the N-reductive pathway. As MOSC2 is 
involved in N-hydroxylation and plays an important role in the reductive 
biotransformation of N-hydroxy compounds, they suggested that MOSC2 could be 
used for drug therapy in diseases with rheumatic inflammation, pain and fever 
(Havmayer et al., 2010). Therefore, the functional study of MOSC2 (CDK7) can also 
provide a novel therapeutic target for DN in the future. 
Table 3. Differentially expressed clones from kidneys of the Goto-Kakizaki (GK) 
rat (Morris, 1997) 
 
Clone  Corresponding gene  Expression in DN  
CDK1 LDH, Lactase dehydrogenase  High  
CDK3 Epithelial sodium  channel, alpha 
subunit 
Low  
CDK4 Beta defensin High  
CDK6 Megalin High  
CDK7 Novel High  
CDK9 Phosphate inhibitor High  
CDK101 Novel Low  
CDK102 H-protein High  
CDK104 Novel High  
CDK105 Novel High  
CDK106 Zfnl, novel High  
CDK107 MOSC2 High  
CDK108 CRYM  High  
CDK111 GPX High  
CDK112 Novel High  
CDK113 Invariant chain-MHC Low  
CDK114 Rat thiazide sensitive sodium 
chloride channel-like 
High  






1.9. Aims and objectives 
In the current thesis we investigated CRYM and MOSC2/MOSC1 expression in 
models of diabetes as well as in circulating cells from DN patients, in order to 
evaluate these genes as potential biomarkers and to explore their possible roles in the 
pathophysiology of DN. The specific objectives are as follows: 
1) To investigate whether CRYM is a glucose regulated gene and if it is expressed 
abnormally in hyperglycaemia in two rodent models of diabetes: Streptozotocin 
C57BL/6 mice and ß-phb2 KO mice. The C57BL/6 mice can be made diabetic with 
STZ and where the diabetes can be reversed with islet transplantation to allow us to 
examine the effect of hyperglycaemia and corrected hyperglycaemia on renal and 
cardiac CRYM mRNA expression. We will also use ß-phb2 KO mice to test the effect 
of glucose on renal and cardiac CRYM expression in models of spontaneous diabetes 
progression. 
2) To investigate the location of CRYM protein in control and diabetic kidneys of 
Streptozotocin C57BL/6 mice and also examine the CRYM protein expression in 
renal tissues of control and diabetic Streptozotocin C57BL/6 mice. 
3) To further investigate glucose regulation of CRYM, we will use in vitro models of 
diabetic nephropathy. This in vitro study includes human renal tubular cells and 
human renal embryonic kidney cells. CRYM mRNA expression will be examined in 
human renal tubular cells in three different conditions, normal glucose, high glucose 
and normal glucose with mannitol. The cellular localisation of CRYM will be 
determined in normal glucose and high glucose of human renal tubular cells. 
4) To examine whether CRYM could be used as a possible diagnostic and therapeutic 
marker, CRYM mRNA expression will be measured and analysed in two different 
patient‟s studies: 1) the study of patients with only type 2 diabetes, with and without 
retinopathy, 2) the study in patients with type 2 diabetes, with and without 
nephropathy. 
5) To confirm and extend previous findings that MOSC2 is a glucose regulated gene 
by using in vivo mouse models of diabetes and in vitro models. MOSC2 mRNA and 




kidneys of ß-phb2 KO mice. The MOSC2 mRNA and protein expression also will be 
measured in human renal cells (mesangial cells, embryonic kidney cells and tubular 
cells). MOSC2 localisation will be demonstrated in control and diabetic kidneys of 
STZ mice. 
 
6) To determine if MOSC1 is regulated by glucose in vivo and in vitro models. Renal 
MOSC1 mRNA expression will be measured in STZ C57BL/6 mice and renal 
MOSC1 mRNA and protein expression will be examined in human renal cells. 
 
7) To investigate if MOSC N-reductive activity (associated to MOSC2 and MOSC1) 
is increased in the presence of hyperglycaemia in vivo and in vitro. 
 
8) To examine if MOSC2 and MOSC1 is a biomarker in the circulating blood of 
patients with type 2 diabetic nephropathy and compare their mRNA expression 
against patients without nephropathy. 
 
These experimental studies will provide further information as to whether CRYM and 
MOSC homologues (MOSC2/MOSC1) have a functional role in the progression of 




































Chapter 2. Materials and Methods 
 
2.1. Chemical and reagents 
The chemicals and reagents used in this study were of molecular biology grade unless 
otherwise stated. A list of the chemicals and reagents along with their suppliers are 
shown in appendix 1.   
2.2. Solutions and buffers 
The solutions and buffers were prepared according to the manufacturer‟s instructions 
or made up according to the laboratory manual (Sambrook et al., 1989) and were 
sterilized by autoclaving, except those supplied in kits. Through the entire thesis, the 
symbol „X‟ is used to describe the buffer working concentrations unless otherwise 
stated in the relevant chapters. Table 4a shows the buffers and reagents that were 
prepared according to the manufacturer‟s instructions.   
2.3. Cell culture 
2.3.1 Culturing of renal cells 
Three types of human renal cells were used; human mesangial cells (HMCs), human 
embryonic kidney cells (HEK293) and human tubular (HTC) cells. All renal cells 
(HMCs, HEK293, and HTC) grow as monolayers on negatively charged tissue culture 
plastic and were cultured in DMEM (Sigma, UK). The growth medium was made up 
as follows in 500ml of DMEM (Sigma, UK): 50ml of Foetal bovine serum (FBS), 1ml 
of 5µg/ml Insulin-Transferin-Selenium (Sigma, UK), 5ml of 2mM L-glutamine, 6ml 
of NaHCO3, 1ml of Amphotericin B, 10ml of 1M HEPES buffer. The cells were 
incubated in 5ml of the complete growth medium, in culture flasks, in a humidified 
atmosphere of 5% CO2 with 95% air at 37
ᵒ












Table 4a. Preparation of reagents and buffers 
 
Solution Chemical components 
0.5M EDTA pH 8.0/ 500ml Disodium ethylenediaminetetra-acetate.2H2O 186.1g (pH 8.0 
adjusted with NaOH)   
10X Tris-borate (TBE)/L Tris base 108g, boric acid 55g, 0.5M EDTA ( pH 8.0) 
10X Tris-acetate (TAE)/L Tris base 108g, glacial acetic acid 11.42g, 0.5 M EDTA ( pH 
8.0)  
1M Tris/ 500ml Tris-base 60.55g pH 7.0, 70ml HCl added 
10% (w/v) SDS/ 500ml Electrophoresis-grade SDS 50g, pH 7.2 with few drops of 
HCl 
DNA loading dye 0.25% (w/v) bromophenol blue, 0.25% (w/v) xylene cyanol 
FF, 30% (v/v) glycerol in water 
Ethidium bromide (10mg/ 
ml) 
Ethidium bromide 1g in 100ml ddH2O (stored in dark bottle 
at room temperature)  
Ampicillin 50 mg/ml Ampicillin 0.5g dissolved in 10ml ddH2O (filter sterilized 
using 0.2μM filter prior to storage at -20C) 
LB broth/L 10g NaCl, 10g tryptone, 5g yeast extract, ddH2O to final 
volume of 1 litre (pH 7.0) 
LB Agar/L 10g agar dissolved in 1 litre LB broth pH 7.0 (autoclave 
sterilized) 
LB/ Ampicillin agar/L 5ml of ampicillin (50 mg/ ml) was added to autoclaved litre 
of LB/Agar after cooling to 55C (25 ml/ mm-plate) 
 
2.3.2. Subculturing 
The cells were maintained in culture and the media was replaced every 72 hours. 
Upon reaching 70% confluence, the culture flasks were removed from the incubator, 
media was removed and the cells were washed twice with 5ml pre-warmed PBS. 
Then, 3ml of Trypsin-EDTA 0.25% (w/v) which  was warmed previously added to 
each flask and incubated for 3 mins at 37ºC to detach the cells from the flask. Cell 
detachment was observed under microscope. Trypsin actively digests the anchorage 
sites between the cells and the growing surface, and EDTA binds to Ca
2+
 that is 
required for Ca
2+




of media was then added to the flask to neutralize trypsin-EDTA solution. The 
mixture was transferred into a fresh falcon tube and centrifuged at 10,000xg for 3 
minutes. The supernatant was removed and the pellet was re-suspended with 10ml of 
fresh normal glucose (5mM) complete growth medium (Sigma, UK). The cell 
suspension was then transferred into culture flasks and incubated for 48 hours. Next, 
the media was changed and cells were seeded in triplicate with normal glucose 
(5mmol/L glucose), high glucose (25mmol/L glucose) and normal glucose with 
mannitol (5mmol/L glucose + 20mmol/L mannitol) for 3-4 days. 
2.3.3. Counting the cells 
The haemocytometer (Neubauer chamber) and the vital dye, trypan blue (Sigma, UK) 
was used to count the cells under study. The haemocytometer consisted of a thick 
glass microscope slide with two counting chambers. A cover-slip sits on top of it 
enclosing both chambers which are 0.1mm in depth (Figure 7). Reactivity of trypan 
blue is based on the fact that the chromophore is negatively charged and does not 
interact with the cell unless the membrane is damaged.  Therefore, all the cells which 
exclude the dye are viable. A volume of 0.1ml of cell suspension was placed in a 
screw cap test tube and 0.1ml of 0.4% (w/v) trypan blue stain was then added and 
mixed thoroughly. The mixture was allowed to stand for five minutes at room 
temperature. The haemocytometer was covered with a precision ground coverslip and 
a few drops of the stained cell suspension were placed at the edge of the coverslip. 
Under a microscope, the stained non-viable cells and viable cells that excluded the 
stain were observed.  The cells touching the right and upper lines in each chamber of 
the haemocytometer were counted and the average cell number was calculated using 
the following formula: 
 
Cell number per ml = average cell number per 0.1mm
3
 x dilution factor (e.g. 5 for 1 










Figure 7. Cell number estimation with Neubuer haemocytometer. 
The haemocytometer has a rectangular chamber etched with a grid of perpendicular 
lines and each grid consists of 9 primary squares, each of which measures 1mm
2
 with 
the plane of the grid rests 0.1mm below 2 ridges supporting a cover-slip. Since the 
area of the corner squares and the depth of the chamber are known, by counting the 
number of cells in this volume of fluid (0.1mm
3
) the total number of cells in the 




2.3.4. Freezing down and thawing of cells 
Cells which are in the logarithmic phase of growth and just approaching confluency 
(early passage 3 or 4) were harvested as previously described and re-suspended with 
freezing medium containing warmed DMEM 5% (v/v), 1ml DMSO 10% (v/v) and 
1ml FBS 85% (v/v). Cell suspension was dispensed in 1ml aliquots into sterile freezer 
Cryo-vials. The Cryo-vials were placed in a Nalgene Cryo freezing container filled 
with appropriate volume of isopropanol and placed at -80
o
C overnight (ideally, the 
temperature should decrease by 1
o
C per minute). Frozen vials were then stored in  
liquid nitrogen for permanent storage. Cells can be recovered from the frozen stage by 
rapid thawing in a 37˚C water bath and then transferring into a 25cm2 tissue culture 




2.4. Mouse kidney samples 
ß-Phb2 KO mice: The ß-Prohibitin2 knockout mice described in the work were set 
up and maintained by Prof Pierre Mieschler and his team according to local ethical 
rules (Department of Cell Physiology and Metabolism, Geneva). The ß-Phb2 KO 
mice were bred by crossing flox-Phb2-flox mice with rat-insulin promoter driven Cre 
mice so that Phb2 is specifically deleted in pancreatic beta cells. Therefore they were 
able to investigate its role in beta cells. The ß-Phb2 KO mice became diabetic (blood 
glucose >11.1mM) as glucose (2g/kg body weight) was administered intraperitoneally 
in 6h-fasted mice before the measurement of glucose levels on blood collected from 
the tail vein at indicated times using a glucometer (Accu-check, Roche Diagnostics, 
Rotkreuz, Switzerland) at the age of 5-6 weeks. The mice become diabetic at later age 
i.e. 11 weeks, when they have extensive polyurea and these mice die between the ages 
of 12-15 weeks. The kidneys and hearts from control and KO mice were collected at 
11 weeks of age; at this age KO mice had glycaemia ranging between 30-40 mM. 
Samples were snap frozen after collection. 
Streptozotocin mice: The mouse model described in the work has been set up and 
maintained by Dr Aileen King and her team (Diabetes Research Group, KCL). All 
animal procedures were conducted in accordance with the UK Home Office Animals 
(Scientific Procedures) Act 1986. Eight week old male C57/BL6 mice were made 
diabetic with an injection of 180mg/kg streptozotocin (STZ, Sigma-Aldrich). The 
blood glucose concentrations were determined using an Accu-Check glucose meter 
(Roche). Five days after STZ, the diabetic mice (>20mM) received a suboptimal islet 
graft of 150 islets transplanted under the left kidney isolated from the pancreases of 
C57/BL6 mice, as previously described (King et al., 2007). Four weeks after 
transplantation, the kidneys and hearts were obtained from the following: mice which 
had not been treated and thus remained diabetic throughout the study (blood glucose 
level> 20 mmol/L), treated mice (blood glucose level < 11 mmol/L for 4 weeks after 
transplantation) and 12 week-old non-transplanted, non diabetic control mice (glucose 
level < 11 mmol/L). The right kidneys and the hearts were removed and immediately 




2.5. Patient blood samples 
Diabetic nephropathy patient blood samples: Patients with diabetes (SEEDA/JJ 
study) were recruited with written informed consent from both Guy‟s and St Thomas‟ 
hospital clinics under ethical approval from the regional Research Ethics Committee 
(REC ref number 07/H0806/120). The study adhered to the Ethical Principles for 
Medical Research Involving Human Subjects, World Medical Association 
Declaration of Helsinki. The patients‟ blood samples were collected and preserved in 
RNA later solution (Ambion) to avoid degradation of the mRNA. 
Type 2 diabetes (T2D) was defined as an onset of diabetes after the age of 35, who 
were controlled by a healthy diet or oral hypoglycaemic treatment and/or insulin. 
Diabetic nephropathy (DN) has been classically defined by the presence of 
albuminuria in the absence of any other renal disease, though in the presence of 
retinopathy. For T2D, we defined a control group of patients from subjects with the 
onset of T2D who had suffered a long duration of diabetes (with ≥10 years) with 
normoalbuminuria, normal serum creatinine, normal blood pressure (130/80 mmHg) 
and taking no antihypertensive agents. 
Overweight patients were defined as those with a BMI of 25-30 kg/m
2
; obese patients 
were diagnosed as having a BMI ≥30 kg/m2 (using BMI measurements). 
Hypertension was identified as a blood pressure reading of ≥130/80 mmHg and mean 
blood pressure of ≥80 mmHg. The amount of glucose being carried by the red blood 
cells is indicated by HbA1c (glycated haemoglobin) and fructosamine measurements. 
A patient with ≥7.5 % HbA1C was considered diabetic. A random blood glucose level 
of ≥11.1 or a fasting blood glucose level of ≥7 mmol/l was considered to be indicative 
of diabetes. Cholesterol level of ≥4 mmol/l was considered to be above the normal 
range.  
In patients with diabetes, renal dysfunction was assessed by measuring albuminuria, 
serum creatinine (SCr), the albumin/creatinine (A/C) ratio and the glomerular 
filtration rate (eGFR). Diabetic nephropathy was classified when the Scr level was 
≥115 mmol/l, albuminuria was between 30-300mg/day (microalbuminuria), the A/C 







Diabetic retinopathy patient blood samples: Patient samples were obtained from 
the study 07/H0806/120 recruited by Dr Sobha Sivaprasad. Patients were recruited 
with written informed consent from King‟s College Hospital under NHS Research 
Ethics Committee approval (REC; ref numbers 07/H0806/120) and from Guy‟s and St 
Thomas‟ hospital clinics under ethical approval from the regional Research Ethics 
Committee (REC; ref number 07/H0806/120). The study adhered to the Ethical 
Principles for Medical Research Involving Human Subjects, and the World Medical 
Association Declaration of Helsinki. A random blood glucose level of ≥11.1 or a 
fasting blood glucose level of ≥7 mmol/l was considered to be indicative of diabetes. 
T2D was defined as onset after age 35, controlled by diet, or established oral 
hypoglycaemic treatment and/or insulin.  
● Grading of diabetic retinopathy 
The patients underwent 2-field digital photographs for each eye, one centreed on the 
optic disc and the other centreed on the macula after dilation of the pupils. 
Photographs were graded in a standardised manner, and DR severity was categorized 
according to the ETDRS (Early Treatment Diabetic Retinopathy Study) severity 
system. Consequently, the following categories were created, based on the more 
severely involved eye:  no DR (DR-0) defined as ETDRS <20, mild NPDR (DR-m) 
defined as ETDRS 35-43, severe NPDR and PDR (DR-s) defined as ETDRS 47 and 
above. 
2.6. Gene expression 
2.6.1. Total RNA extraction 
In living cells, RNA has four major types: messenger RNA (mRNA), transfer RNA 
(tRNA), ribosomal RNA (rRNA) and microRNA (miRNA). A high yield of total 
RNA of relatively high purity is essential to determine gene expression specifically by 
cDNA amplification using polymerase chain reaction (PCR). For the experiments 
described in this thesis, RNAs were extracted from mouse tissues, human cultured 
renal cells and patients‟ blood samples. All glassware and plastic ware were 
autoclaved before the RNA extraction. The work was carried out in a designated RNA 
area (DNA free) and the bench was cleaned with an RNase decontamination solution 
(RNaseZap, Ambion UK). The RNA extraction method used is based on the 




strong chaotropic denaturant which lyses cell membranes and rapidly inactivates 
cellular ribonucleases.    
● RNA Extraction from the tissue 
Total RNA was extracted from various mouse tissues using the QIAzol® Lysis 
Reagent (Ambion, UK) according to manufacturer guidelines.  Approximately 0.5-1g 
of tissue was ground in liquid nitrogen using a pre-chilled mortar and pestle, and was 
transferred to a 50ml Falcon tube.  The liquid nitrogen was allowed to evaporate and a 
denaturing solution (10ml) was added and the mixture shaken vigorously until the 
tissue dissolved.  Samples were sonicated on ice for 2-5 minutes using an MSE 
Soniprep 150 Ultrasonic disintegrator for 15 seconds to shear high molecular mass 
DNA and placed into the QIAzol Lysis Reagen tube.  RNA was separated from 
protein and DNA by adding 0.2ml chloroform per 1ml QIAzol Lysis Reagent, mixed 
vigorously and placed at 37C for 2-3 minutes. 
Samples were centrifuged for 15 minutes at 5,590xg at 4C and the aqueous phase 
was transferred to a fresh nuclease-free tube. Isopropanol (0.5ml per 1m QIAzol Lysis 
Reagent) was added to allow precipitation of RNA, followed by incubation at 37C 
for 10 minutes. The aqueous layer containing RNA was recovered by centrifugation at 
5,590xg for 10 minutes at 4C and carefully transferred to a fresh RNase-free tube 
(without transferring any material at or below the interface). RNA pellets were 
washed with 75% (v/v) chilled ethanol (1ml) and pellets were re-precipitated by 
centrifugation (5,590xg, 5 minutes, 4C) and left to air dry to remove the ethanol.  
RNA was re-suspended in 50μl RNase-free water and stored at - 80 C.      
● RNA extraction from cell culture  
For the extraction of RNA from cultured human renal cells, RNeasy mini kit 
(QIAGEN, UK) was used. Culture media was removed and the cells were washed 
twice with PBS. The PBS wash was removed and the cells were disrupted by adding 
300 μl of lysis/ binding solution (300μl per 1x106 cells) and mixed by vigorous 
pipetting. The lysate was transferred to a QIAshredder spin column and vigorously 
vortexed to completely homogenise the sample. 600 μl of ethanol 70% (v/v) was 
added to homogenised lysate and mixed thoroughly by gently pipetting and 700μl  of  
lysate/ ethanol mixture was applied to an RNeasy mini column (placed in a 2ml 




discarded and several washing steps were carried out using 700μl and 500μl of wash 
solution and then were added to the filter cartridge followed by centrifugation for 2 
minutes at 9,000xg. Pellets were left on the vacuum manifold for 10-30 seconds to 
remove the last traces of wash solutions. To elute the RNA, 50μl of elution solution 
(pre-heated at 95C) was applied to the centre of the filter, elute was recovered by 
centrifugation (1 minute, 9,0000xg) and the RNA samples were stored at -80C. 
● RNA extraction from patient blood samples 
 For DN patients (n= 99), we used a developed homemade method by using TRIzol ® 
LS Reagent (Ambion, UK). Total RNA was extracted from TRIzol® LS Reagent 
(Ambion, UK) according to manufacturer‟s guidelines. 500μl of patients‟ blood stored 
in RNAlater solution was used. The RNAlater solution was removed from blood after 
centrifugation. The blood cells were lysed in 1ml of TRIzol (pre-warmed to 56°C) and 
vigorously vortexed to completely homogenise the sample. The RNA was extracted 
with 200μl of 25:24:1 mixture of Phenol: Chloroform: Isoamylalcohol and the 
aqueous phase containing the RNA was recovered in a fresh 2 ml tube. 500μl of 100% 
chilled Isopropanol was added to the recovered aqueous and centrifuged for 10 
minutes at 7,000xg. The pellet was washed with 500μl of chilled 75% (v/v) ethanol 
and centrifuged for 5 minutes at 7,000xg. The 50μl of RNaese-free water was added 
to the pellet and then treated with DNase-1 enzyme. 
2.6.2. DNase-1 treatment of RNA 
No RNA isolation procedure can guarantee the complete removal of trace amounts of 
DNA below the limit of detection by RT-PCR. Therefore, a DNA inactivation kit 
based on DNase I treatment (Sigma, UK) was used to effectively remove trace DNA 
contamination from RNA.  8μl RNA was mixed gently with 1μl of 10X reaction 
buffer (Tris-HCl, pH 7.5) containing MgCl₂, 1μl of Amplification Grade DNase I and 
incubated at 37C for 15 minutes. 1μl of stop solution was then added to bind the 
calcium and magnesium ions and to inactivate the DNase I. Afterwards, the sample 
was heated at 70C for 10 minutes to denature the DNase I. The samples were 
incubated on ice for a few minutes and finally, the treated RNA samples were kept at 




2.6.3. Determination of RNA concentration 
The concentration of RNA was measured by using the ND1000 spectrophotometer 
(Nanodrop). This device has the capability to measure 260 and 280nm absorbance 
from samples in only 2μl of sample. A260nm is automatically converted to give an 
accurate estimation of RNA content in ng/μl. Furthermore, the ratio of A260nm/A280nm 
can be used for indicating quality of RNA. Generally speaking, a ratio of <1.6 
indicates contamination of samples with protein, phenol or other compounds which 
absorb at 280nm. Sample RNAs with A260nm/A280nm >1.6 were stored at -80˚C and 
used subsequently for cDNA synthesis (Section 2.3.2). 
2.6.4. cDNA synthesis 
DNA-free RNA (up to 9μl) was reverse transcribed to cDNA using a High Capacity 
RNA-to-cDNA kit (Applied Biosystems, UK). According to the protocol provided 
with the kit, cDNA synthesis was carried out as follows:  
 
Preparation of RNA: RT reaction mix: 
A reaction mix of 2X RT-buffer (10μl), 20X Enzyme mix (1μl) and RNA sample 
(10µg) was prepared in a final volume of 20μl nuclease–free H₂O. The RT reaction 
mix was transferred into 1.5ml tubes and were briefly centrifuged in 10,000x g for 30 
seconds to spin down the contents and then placed on ice until they were ready for 
reverse transcription reaction. The reaction mix was incubated at 37⁰C for 60 minutes. 
The mixture was then heated at 95⁰C for 5 minutes and then held at 4⁰C. The cDNA 
samples were stored at -20⁰C. 
  
2.7. Reverse-Transcriptase Polymerase chain reaction (RT-PCR) 
Polymerase chain reaction (PCR) is a widely used method, employed to accurately 
and rapidly amplify a specific DNA sequence of interest from nanogram amounts of 
DNA template (Saiki et al., 1988). In the experiments described in this thesis, RT-
PCR was performed with cDNAs from mouse tissues (kidney and heart), patient 
blood samples and human cultured renal cells (HMCs, HEK293, HTC). Specific sets 
of primers were designed and selected using the Roche Universal ProbeLibrary 





Corresponding annealing temperatures for various products were optimised by first 
running the reactions under temperature gradients at 3˚C from the predicted optimum 
annealing temperature. PCR reaction was performed in 0.2ml PCR tubes and the 
reaction mix was prepared by combining the following components which were 
provided by Promega, UK. A list of primers used in this thesis is shown in Table 5a 
and 5b. 
10X reaction reaction Tris-HCl (PH 8.3) buffer containing 500mM KCl; 15mM 
MgCl₂; 0.01% (w/v) gelatin (5µl), PCR Nucleotide Mix containing 10mM of sodium 
salts (pH 7.5),  dNTP (1μl), 50 ng/µl forward and reverse prime (1µl each), DNA 
template (1μl) and 5 u/µl  Taq DNA polymerase (0.3μl). DEPC water was added to 
make a final volume of 25μl. The reaction was spun in 17,900xg for 30 seconds to 
mix and PCR was carried out in a thermal cycler (Table 4b; Gene Amp System 2400, 
Applied Biosystems, UK). 
Table 4b. Thermocycler program 
Protocol Temprature Duration 
Initial denaturation 94⁰C 15 minutes 
Amplification Denaturation           94⁰C 
Annealing                62⁰C 
Extension                 72⁰C 
30 seconds 
30 seconds               x 30 
cycles 
1 minute + 30 seconds 
Incubation 72⁰C 7 minutes 
Cooling 4⁰C  
 
PCR amplification was carried out in the PCR thermal cycler (GeneAmp PCR 
Systems 2400, Applied Biosystem, UK) and took approximately 2.5 hours for 30 
cycles. 
Once the amplifications had been completed, 10μl of each PCR product was analysed 
by agarose gel electrophoresis using a 1% (w/v) agarose gel and 1X TBE buffer. The 
agarose was melted in a microwave oven (medium power, 5 minutes) and cooled to 
approximately 60C. Once cooled down, ethidium bromide (0.5 µg/ml) was added.  




was placed in a horizontal gel electrophoresis apparatus and covered with 1X TBE 
buffer.  A loading buffer (3µl) was added to each DNA sample (10µl), mixed and 
loaded into the well of the agarose gel.  Electrophoresis (50-100V, 1-2 hours) was 
carried out to allow sufficient separation of the DNA fragments.  Ethidium bromide 
stained agarose gels were then placed on a UV transilluminator and photographed. 
 
Table 5a. Human reference gene primers 





(5‟ to 3‟) 
Human CRYM  L02950 62bp hCRYM F₁ 
 
hCRYM R₁ 
gcc ctg aag gag tct gag g 
 
tct ccc agc tca gca aag  at 
Human MOSC1 NM_022746 78bp hMOSC1F₁ 
 
hMOSC1R₁ 
cca cag tgg acc cag aca c 
 
ggt cac act ggc gat aac tct 
Human MOSC2 NM_017898 187bp hMOSC2 F₁ 
 
hMOSC2 R₁ 
gac aca tgg tca ctg cc 
 
ttg cca cag tct ctg c 
Human β-actin NM-001101 64bp hβeta-actinF₁ 
 
hβeta-actin R₁ 
cca acc gcg aga aga tga 
 









gag aaa gcc tgt gcc aac c 
 
 
ctg gct cgg ctt taa cct t 
Human 
 Peptidylprolyl 
isomerase B (PPIB) 




ccc agt tct tca tca cga ca 
 
 














5b. Mouse reference gene primers 





(5‟ to 3‟) 
Mouse CRYM NM-016669 61 bp mCRYMF₁ 
mCRYMR₁ 
ggg gct caa tca atg ct 
 
gct cgt cat cca gtt ctc g 





gtt gtc atc cgg gat gtg g 
 
tcc aat gag aac ctc gtt cc 




gga tcc cat ggc tga cac 
 
gga aga tgg cca tga gga 
Mouse β-actin NM-007393 91bp mβ-actin F₁ 
mβ-actin R₁ 
att ggc aat gag cgg ttc 
 






NM-18735 65bp mPGK F₁ 
 
mPGK R₁ 




cac agc ctc ggc ata ttt ct 
Mouse PPIB 
   
 
NM-011149 144bp mPPIB F₁ 
 
mPPIB R₁ 





acc ttc cgt acc aca tcc at 
Mouse TBP 
TATA box binding 
protein 
NM-013684 90bp mTBP F₁ 
 
mTBP R₁ 
ggg aga atc atg gac gag 
aa 
 
gat ggg aat tcc agg gag 
tca 
Mouse Rn28s1 28S 
ribosomal RNA 
 
NM-016844 70 bp mRn28s1F₁ 
 
mRn28s1R₁ 
ata tcc gca gca ggt ctc c 
 







NM-008084 124bp mGAPDH F₁ 
 
mGAPDH R₁ 
cct cgt ccc gta gac aaa 
atg 
 
gcc atc aac gac ccc ttc a 
 
2.8. Purification of DNA from the gel band 
DNA was extracted using a Qiagen Gel Extraction Kit. The DNA fragment was 
excised from the agarose gel using a sterile scalpel with minimum exposure to UV 
light. A capture buffer (10µl/ 10mg of band weight) was added and vigorously mixed 
with the gel slice. The capture buffer is a chaotropic agent that denatures proteins, 
dissolves agarose and promotes the binding of double-standard DNA to a glass fibre 




incubating the samples at 60C for 5-10 minutes. DNA bound to the glass fibre matrix 
was recovered by passing the samples through a GFX column and the flow-through 
was discarded after brief centrifugation at 10,000xg for 30 seconds.  To remove the 
residual salts and contaminants, the matrix-bound DNA was washed with 500µl of 
washing buffer (previously mixed with 48ml absolute ethanol) and centrifuged at 
10,000xg for 30 seconds. The purified DNA was eluted in 40µl of sterile 
endonuclease-free water as required. 
The extracted DNAs were sequenced by DNA Sequencing Services at UCL. 
Sequence homology alignment and analysis were used to compare the homology 
between predicted sequences and actual sequences of products amplified by PCR. 
2.9. Real time quantitative PCR (qPCR) 
A quantitative real-time polymerase chain reaction (qPCR) is a sensitive and specific 
technique used to measure the level of the genes under study. In qPCR, the gene is 
amplified by means of a standard PCR reaction. Hence, the quantity of the amplicon 
was first quantified by Nanodrop, and the copy numbers were calculated on the basis 
of the molecular weight of each particular gene amplicon. Subsequently, serial 
dilutions of this amplicon have been tested by qPCR to produce a gene specific 
standard curve. The assay can be quickly and easily utilised to quantitate real-time 
levels of any gene product (Gentle et al., 2001). qPCR is broadly applied to accurately 
measure the gene activity by determining mRNA levels. It has the capacity to 
determine and quantify a very low amount of DNA and RNA, and clearly 
distinguished between samples including PCR products and non-template controls. 
The assays are easy to perform and they can merge reliable specificity with high 
sensitivity. Sensitive quantification of PCR product relies on detection of a 
fluorescent signal proportional to the amount of product by use of SYBR green 
binding dye, which binds only to double-stranded DNA. The amount of PCR product 
was directly measured in real time using the LightCycler ™ system that is able to 
carry out 30 PCR cycles in less than 20 minutes with real-time fluorimetric detection 
of PCR products. The system can perform continuous sampling with results displayed 
at once on the computer screen. To verify specificity, melting-curve analysis was 
applied where the temperature was raised slowly to the melting point of duplex DNA 




2.9.1. Standard preparation 
It is necessary that the dilution series from which the standard curve is produced be 
carefully prepared.  The units utilised to describe the dilution series are relative, not 
absolute values, are based on the dilution factor, and can be expressed either relatively 
as e.g. 1 fold, 10 fold, 100 fold, 1000 fold, etc or expressed as equivalent mass 
amounts e.g. 100 ng, 10 ng, 1 ng, etc. To prepare standards for a generation of 
standard curves, PCR products were purified applying a QIAquick Gel Extraction Kit 
(QIAGEN, UK). The amount of DNA present was determined by electrophoresis of 
the PCR products against a 100 bp DNA ladder (Promega, UK). The exact copy 
numbers of the purified PCR product were calculated using Avogadro‟s number. 
Dilution series including 10⁹, 10⁸,10⁷,10⁶,10⁵,10⁴,10³ and 10² copies/µl of the gene 
were quantified and prepared in the presence of carrier transfer ribonucleic acid 
(tRNA, 10 mg/ml; Sigma, UK). Subsequently, they were utilised as a calibration 
curve in every run with Roche light cycler. 
2.9.2. Quantification 
Serially diluted standards prepared for a target gene and a reference gene were utilised 
to establish standard curves by amplification in 10-fold dilutions of PCR product of 
each gene to be quantified. A qPCR was performed using the FastStart DNA Master
 
plus 
SYBR Green 1 Kit (Roche Molecular Biochemical, Germany). A qPCR was 
carried out in a total volume of 10µl containing 50 ng/µl forward and reverse primers 
(0.5µl each), Fast Start DNA Master SYBR Green 1
plus  
probe (2µl), DNA template (2 
µl) and nuclease free water (5µl). The reactions were performed in the Roche Light 
Cycler instrument using the following 4-cycle program protocol: pre-incubation at 
95°C for 10 minutes, amplification at 95°C for 10 seconds, annealing at 60°C (or 
optimum temperature) for 20 seconds, and 72°C for 10 seconds for 40 cycles, melting 
at 95°C for 0 seconds, 65°C for 30 seconds, and 95°C for 0 seconds and cooling at 
40°C for 30 seconds. The data were analysed using the Roche Molecular Biochemical 
Light Cycler software, version 3.5. The mean crossing point of each sample was 
compared with the standard curve of the target gene or the reference gene.  
Fluorescence detection was used immediately at the end of each annealing step and 




2.10. Protein extraction 
1) Preparation of cell lysates 
Cells were maintained as monolayers in 10 cm
2
 Petri dishes up to 75% confluency. 
The cells were harvested by trypsinisation, spun down and stored at -80°C. Frozen 
cell pellets were washed with PBS at room temperature and collected by low-speed 
centrifugation (13.975xg, 5 minutes). The pellets were lysed in 100µl lysis buffer 
(Table 6) supplemented with protease and phosphatase inhibitors to protect the 
proteins from being degraded and dephosphorylated, on ice for 10 minutes. The 
samples were sonicated on ice (20 seconds, 3 times) using an MSE soniprep 150 
Ultrasonic disintegrator and centrifuged at 11,000xg for 10 minutes at 4°C. The 
supernatant was the total cell lysate which was then transferred to a new micro-
centrifuge tube. The protein content of samples was quantified using 10μl of each cell 
lysate (section 2.11). The remaining protein extracts were kept at -20˚C in 2X 
NuPAGE
®
 sample buffer (contains lithium dodecyl sulfate, pH 8.4), which contains 
denaturing agents, prior to electrophoresis on polyacrylamide gels. 
 
2) Preparation of mouse tissues 
Kidneys from STZ mice were homogenised using liquid N₂ before being lysed in (30 
μl) of lysis buffer (Table 6), vigorously vortexed and kept on ice for 10 minutes. The 
samples were boiled at 90°C for 5 minutes and centrifuged at 6,000xg for 3 minutes. 






















Table 6. Preparation of lysis buffer (RIPA buffer)  
 
Reagent Amount for 100ml Final Conc. 
Tris-base 790mg 50mM 
NaCl 900mg 150mM 
NP-40 (10%) (v/v) 10ml 1% (v/v) 
Sodium-deoxycholate (10%) (v/v) 2.5ml 0.25% (v/v) 
EDTA (100 mM) 1ml 1mM 
 
790mg Tris-base and 900 mg NaCl were first dissolved in 75ml DI H2O, the pH was 
adjusted to 7.4 with concentrated HCl followed by an addition of NP-40, Na-
deoxycholate and EDTA. DI H2O was then added to make up the final volume to 
100ml. The RIPA buffer was stored at 2-8°C for further use. 
2.11. Determination of protein concentration 
To ensure equal loading for SDS-PAGE, the concentration of protein samples was 
measured by the BCA Protein Assay Kit (Pierce; distributed by Thermofisher 
Scientific, Cramlington, UK). This colourimetric method is based on bicinchoninic 




by protein in an alkaline 
medium and the formation of a purple-coloured reaction product by the subsequent 
chelation of the reduced Cu
+ 
with BCA. The amount of protein in the sample is 
directly proportional to the amount of purple coloured reaction complex. 
A stock solution of 2 mg/ml bovine serum albumin (BSA) was made by dissolving 
BSA (Sigma, UK) in the lysis buffer used and was diluted to provide final 
concentrations of 0.2, 0.4, 0.6, 0.8, 1.2 and 1.6 mg/ml. Lysates were further diluted 
1:4 in the lysis buffer. The working reagent was prepared for each sample by 
combining 50 parts reagent A (containing BCA in a 0.1M sodium hydroxide solution) 
with 1 part reagent B (containing 4 % cupric sulphate). 
10µl of standards and samples were added in triplicate to the wells of a 96 well plate, 
followed by the addition of 200µl of working reagent to each well. The plate was 
thoroughly mixed on a plate shaker for 30 seconds and incubated at 37
o




minutes. The plate was cooled to room temperature and the absorbance read at 570 
nm on a spectrophotometer (Macroplate Autoreader; Bio-Tek Instruments, Potton, 
UK). The absorbances of each standard point were plotted and a standard curve was 
used to detect the protein concentration of each unknown sample. 
2.12. Sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) 
SDS-PAGE is the most widely used method for separating proteins across an electric 
field based on their molecular weight. SDS is an anionic detergent that binds to a 
protein sample to linearise proteins and apply a negative charge. In the presence of an 
electric field, the negatively charged proteins migrate across the gel towards the 
positive electrode through a porous gel matrix of polyacrylamide. The amount of 
polyacrylamide determines the pore size, and each biomolecule will move according 
to their size. 
 The NuPAGE Bis-Tris electrophoresis system was utilised in the experiments 
described in this thesis. Equal amounts of total protein was loaded on to a 10% (w/v) 
Bis-Tris-HCl buffered (pH 6.4) polyacrylamide gel. The gel was set and divided in 
the Xcel Surelock mini cell apparatus, and the inner chamber containing sample 
proteins was filled with antioxidant-supplemented MOPS running buffer (Table 7). 
The outer chamber was filled with approximately 600ml of MOPS running buffer and 
the gel was subjected to electrophoresis at 200V for 50 minutes. A Rainbow
®
 
coloured protein molecular weight marker was included and analysed in parallel to the 
protein samples for demonstration of sample protein molecular weights. 
 
Table 7. Preparation of 3-(N-morpholino) propanesulfonic acid (MOPS)  
running buffer 
 
Reagent Amount for 500ml Final Conc. 
MOPS 104.6g 1M 
Tris Base 66.6g 1M 
SDS 10g 69.3Mm 
EDTA 3g 20.5mM 
 
The reagents listed above were dissolved in 400ml DI H2O and adjusted to a final 
volume of 500ml. The 20X MOPS running buffer was kept at 4˚C and diluted 1 in 20 




The MOPS running buffer was made up by adding 500μl of 15ml NuPAGE® 
Antioxidant to 200ml 1X MOPS running buffer.  
2.13. Western blotting 
After SDS-PAGE, the gel was carefully removed and the separated proteins were 
transferred to a suitable membrane such as polyvinylidene difluoride (PVDF) to allow 
access of specific antibodies for the immune-detection of proteins of interest. The 
transfer process is performed using a trans-blot sandwich which presses the 
polyacrylamide gel and PVDF membrane among layers of filter paper soaked in 
transfer buffer (Table 8). The transfer was carried out using the electroblotter system 
(BioRad, UK) to tranfer the proteins from the gel onto the PVDF membrane (Figure 
8). 
Table 8. Preparation of  1X Transfer buffer 
 
Reagent Volume 
DI H2O 849ml 
20X NuPAGE transfer buffer (Invitrogen) 50ml 
NuPAGE sample antioxidant 1ml 
Methanol 100ml 
 
After immunoblotting, the membrane was placed in the clean tray containing 10 ml of 
blocking buffer [(5% w/v skimmed milk powder dissolved in 10 mM TBS-T (Tris-
HCl PH 8.0, 0.15 M sodium chloride, 0.2% (v/v) Tween-20)], and incubated for 1 
hour at room temperature to block non-specific binding sites. Following the blocking 
process, the membrane was washed in TBS-T (3 times, 5 minutes) and incubated with 
an appropriate primary antibody (diluted in blocking buffer to increase specificity) 
overnight at 4°C. The membrane was subsequently washed in TBS-T (2 times, 10 
minutes) to remove any unbound primary antibodies. 
The membrane was then incubated for 1 hour in a horseradish peroxidase-conjugated 
secondary antibody (diluted in blocking buffer) at room temperature. After 5 washes 
with TBST (3 times, 5 minutes), immunoreactive proteins were identified with the 
chemilumimescence (ECL) detection system. Photographic film, which determines 




immunoreactive bands with those of the Rainbow
®












Figure 8. Diagrammatic representation of the polyacylamide gel/PVDF 
membrane blotting module assembles. 
To facilitate protein transfer, the pre-soaked PVDF membrane is placed on top of the 
gel and a trans-blot sandwich is assembled between pre-wetted blotting pads and two 
layers of filter paper thoroughly soaked in transfer buffer. The gel/membrane 
assembly is placed in the module so that the gel is closest to the cathode plate. When  
an electric current is applied, transfer of proteins from the gel to the PVDF membrane  




HTC were trypsinised, seeded into a 6-well tissue culture plate and fixed in ice cold 
methanol (1 minute, room temperature) once they reached ~70-80% confluency. After 
3 washes with ice cold PBS (5 minutes each), blocking process was carried out using 
5% (w/v) BSA in PBS (30 minutes at room temperature). Following blocking, the 
cells were treated with 2 ml primary antibody (diluted in 5% (w/v) BSA) overnight at 
4°C. A FITC-conjugated secondary antibody was applied after 3 washes of PBS (5 
minutes each). After incubation for 1 hour at room temperature (in a dark room), the 
cells were washed 3 times with PBS. For nuclear visualisation, 1µg/ml solution of 
DAPI (Sigma, UK) diluted in PBS was used and incubated for 10 minutes at room 
temperature. The cells were then washed with PBS (once, 5 minutes), covered with 





Immunohistochemistry is a different method from immunocytochemistry, which is 
used for detecting protein localisation in tissues. Tissues such as kidneys can be 
preserved by aldehyde fixation or rapidly frozen in liquid nitrogen. In the experiments 
described in this thesis, mouse kidneys were freshly removed and fixed in formalin 
overnight before being transferred into 70% (v/v) ethanol and stored at 4˚C. 
Embedding in paraffin wax was then carried out and slides of tissue sections (5μm) 
were prepared for immunostaining using antibodies against CRYM and MOSC2. 
To start immunohistochemistry, the paraffin wax was first melted on a heated plate 
before being removed in xylene solution. The sections were then treated with a series 
of 100%, 95% and 70% (v/v) ethanol washes (5 minutes each) for rehydration. Once 
the excess ethanol had been removed (3 washes in PBS, 5 minutes each), the sections 
were treated with 3% hydrogen peroxide for 15 minutes at room temperature to stop 
peroxidase activity as well as undiluted swine serum for 10 minutes with 3 washes 
using PBS (5 minutes) in between (Table 9). The sections were then incubated with 
primary antibody diluted in PBS/0.25% (v/v) Triton X-100/0.25% BSA overnight at 
4˚C. After removing residual primary antibody with 3 PBS washes, sections were 
exposed for 30 minutes to biotinylated link universal, a mixture of biotinylated anti-
rabbit, anti-mouse and anti-goat immunoglobulins that recognise and bind to the 
primary antibody. Sections were then washed 3 times with PBS and for 
immunofluorescent staining; FITC-conjugated secondary antibodies were made up in 
PBS/0.25% (v/v) Triton X-100/0.25% BSA where the sections were incubated for 2 
hours at 4˚C. Protein localisation was viewed under a fluorescent microscope (Eclipse 











Table 9. Preparation of 10X phosphate buffered saline (PBS) 
Reagent Amount for 1L (10X) Final Conc. of 1X PBS buffer 
NaCl 80g 136mM 
NaH2PO4  2g 1.7mM 
Na2PO4  11.6g 8mM 
KCl 2g 2.7mM 
Reagents listed above were dissolved in ~900ml DI H2O and the pH was adjusted to 
7.2 before being made to a final volume of 1L with DI H2O. 
The 10X PBS buffer was diluted 10-fold with DI H2O to make 1X working reagent.   
 
2.15. Semi-quantitative analysis using ImageJ 
ImageJ is a program that quantifies protein band intensity based on peak area. For 
analysing the protein expression, the densitometry of both target protein and reference 
protein was carried out using ImageJ (version 1.43: National Institutes of Health; 
www.rsb.info.nih.gov/ij). The amount of the target protein was expressed relative to 
the reference protein for each sample. 
2.16. N-reductive assay 
1) In vivo: 0.05mg homogenate proteins from kidneys and livers of mice were 
incubated in 100mM potassium-phosphate buffer pH 6.0 containing 3mM of the 
substrate benzamidoxime in a total volume of 150µl. After 3 minutes of pre-
incubation, a reaction was started with the addition of 1mM NADH (cofactor) and 
stopped after 20 minutes for the liver and 50 minutes for the kidney by adding 150µl 
ice cold methanol. Samples were shaken at room temperature for 5 minutes, 
centrifuged at 11,000xg rpm for 5 minutes and supernatant injected to HPLC to 
identify and quantify each component. 
2) In vitro: Human renal cells (HMCs, HEK293 and HTC) were seeded into a 6-well 
tissue culture plate. The media was then changed and cells were seeded in triplicate 
with normal glucose (5 mmol/L glucose), high glucose (25 mmol/L glucose) and 
normal glucose with mannitol (5 mmol/L+ 20 mmol/L mannitol) for four days. At day 
four of the experiment (reaching 100 % confluency), the medium was removed; cells 




pre-warmed incubation buffer at 37°C for 15 minutes. After removing the incubation 
buffer, 1ml pre-warmed substrate buffer was added to the cells and then incubated in 
at 37°C for 120 minutes. Next, the substrate buffer (6 mg benzamidoxime into 100 
ml) was transferred to a universal tube and stored at -20°C for HPLC. The cells were 
scratched from and re-suspended into 1ml ice cold PBS. The samples were 
centrifuged for 3 minutes at 10,000xg, PBS was removed and the cells were then 
stored at -80°C for protein content determination. 
Table 10. Preparation of incubation buffer  
 
Reagent Amount for 500ml Final Conc. 
HBSS buffer 50ml 1X  
HEPES 1.19g 10 mM 
NaHCo₃ 175mg 4,2 mM  
 
The reagents listed above were dissolved in DI H2O to make up the final volume to 
500ml; the PH was adjusted to 7.4 with concentrated KOH. 
2.17. Statistical analysis 
Data are expressed as mean ± standard deviations (SD). All statistical comparisons 
were made using SPSS 20 software and sigma plot 11. Descriptive statistics and 
multiple comparisons including Student‟s t tests, 1-way analysis of variance 
(ANOVA) and also post-hoc Tukey tests were performed. Differences between 
treatments were considered significant with p values <0.05 and highly significant with 
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Chapter 3. Is CRYM a glucose regulated gene in experimental 
models of diabetes in vivo and in human tubular cells in vitro? 
 
3.1. Abstract  
 
We previously found that the expression of CRYM, which is involved in the transport 
of intracellular thyroid hormone, is significantly up-regulated in response to high 
glucose in vivo and in vitro. The objective of this chapter was to investigate the 
expression of renal and cardiac CRYM in models of diabetes as well as in HTC to 
determine if its expression was altered in DN. Kidneys and hearts were obtained from 
(a) acute STZ-induced-diabetic, treated and control mice (n= 3) and (b) ß-Phb2 KO 
mice. In addition, HTC grown in NG (5 mM), HG (25 mM) and NG with mannitol 
(5mM glucose + 20 mM mannitol) were used. The cellular location of CRYM protein 
was examined in sections of mouse kidneys and in cultured HTC using 
immunofluorescence. 
Renal CRYM mRNA levels increased during hyperglycaemia in the STZ-induced 
diabetic mice and this increase was reverted by the treatment of diabetes (P<0.001). 
The hyperglycaemia-induced increase in renal CRYM was specific as we could not 
demonstrate any change in cardiac CRYM. We also could not demonstrate any 
change in renal and cardiac CRYM levels of KO mouse model (P>0.05). 
Immunohistochemistry revealed an abundant expression of CRYM protein in the 
cytosol of HTC, with less expression in HMCs. Surprisingly, CRYM mRNA levels 
showed a slight decrease in HTC under HG conditions. 
In summary, we show for the first time that renal CRYM is regulated by glucose and 
its expression is increased in STZ-induced diabetic mice. CRYM protein is highly 
abundant in HTC and expressed at low levels in the glomerulus. Unlike earlier finding 
in HMCs, CRYM mRNA levels decreased in cultured HTC in response to HG. These 
data support the view that CRYM is regulated by glucose and suggest that it may be 
playing a specific role in HTC. Further studies will be required to determine the 







CDK108 was one of 25 clones isolated by differential screening. The sequence of rat 
CDK108 presented a strong hybridisation signal in the kidneys of progressively 
hyperglycaemic GK rat at 40 weeks compared to GK rat kidneys at 6 weeks (Malik et 
al., 1997). Northern blot analysis of RNA from GK rat kidneys at age 6, 16, 26 and 40 
weeks old and aged-matched-Wistar control kidneys indicated a higher expression of 
CDK108 in the kidneys of the GK rat at 40 weeks (Zaidi, 1997). The DNA sequence 
of rat CDK108 showed that it represents µ-crystallin, an abundant protein normally 
found in the eye (Zaidi, 1997). 
 µ-crystallin has also been described as CRYM or NADP-regulated thyroid hormone 
binding protein (THBP) (Vie et al., 1997), and so for the purpose of this study we will 
refer to this gene as CRYM. The whole sequence of rat CRYM consists of 1227 bp 
with a polyA⁺ tail of 17 bp, located 13 nucleotides downstream of putative 
polyadenylation signal (AATAAA), as well as a 31 bp 5′ untranslated region and 245 
bp 3′ untranslated region (Ziadi, 1997). A putative coding region, which encodes a 
polypeptide of 314 amino acids, has a start codon (ATG) at position 32 and a putative 
stop codon (TGA) at position 790 bp in the second open reading frame (Zaidi, 1997). 
Previous studies showed that CRYM mRNA expression is altered in relation to 
progressive hyperglycaemia in the kidney of GK rat (Al-kafaji and Malik, 2010). This 
finding suggests a possible role for CRYM expression in early renal changes which 
contribute to DN. In order to further understand the possible role of CRYM in DN, we 
explored whether this gene was involved in the signalling pathways that lead to the 
damage in diabetic kidneys.  
CRYM was first identified as µ-crystallin, a major lens structural protein in Australian 
marsupials and the whole sequence of µ-crystallin was obtained from a Kangaroo lens 
cDNA (Chen et al., 1992). RNA analysis in kangaroo tissues displayed that CRYM 
was most abundant in kangaroo‟s lenses (Kim et al., 1992) and was also expressed at 
much lower levels in neural tissues, retina and brain (Kim et al., 1992). Northern blot 
analysis of human tissues showed that the human homologue CRYM mRNA is 
abundant in the kidney, heart, brain, skeletal muscle and neural tissue whereas there is 
less CRYM mRNA in the liver and lung (Kim et al., 1992). Vie et al. (1997) also 




that it was identical to nicodinamide-adenine dinucleotide phosphate (NADPH)-
regulated thyroid hormone binding protein (THBP) (Vie et al., 1997). The deduced 
314-amino acid protein had a predicted molecular mass of approximately 34 kDa. 
High expression of human CRYM was shown in cochlear vestibular tissues in the 
inner ear (Abe et al., 2003). Lower but significant concentrations of CRYM mRNA 
have been observed in various non-lens tissues in marsupials and humans (Wistow 
and Kim, 1991). 
Among the mouse tissues, CRYM mRNA is most abundant in the skin, whereas lower 
levels are detectable in the brain, eye, heart, kidney, liver and lung (Aoki et al., 2000). 
In the rat, mRNA expression of CRYM has been detected in a number of tissues such 
as kidney (Vie et al., 1997) and brain (Beslin et al., 1995). Also, CRYM mRNA 
expression has been observed in the spleen, stomach and urinary bladder (Vie et al., 
1997). 
 The CRYM gene is located at chromosome 16 P13.11-P12.3 in the human genome 
(Chen et al., 1992). More specifically, Yokoyama et al. (1992) demonstrated that the 
CRYM gene is localised on the short arm in the region 16p13.11-p12.3. 
● Involvement of CRYM in various diseases 
Hearing is one of the most important functions controlled by the thyroid hormone and 
CRYM is recognised as a candidate for hearing loss that is not related to other signs 
and symptoms (Abe et al., 2000). Abe et al. (2003) proposed that CRYM might be 
one of the genes responsible for non-syndromic deafness and demonstrated that 
mutant CRYM protein may affect clinical hearing ability. They suggest that T₃-
binding properties affect the fibrocytes of the cochlea. Therefore, mutant CRYM 
could abrogate the affinity of the thyroid hormone, a pivotal factor for the 
development of the auditory system, and might be involved in the potassium ions 
recycling system (Abe et al., 2003). 
Following the development of microarray techniques, numerous studies established 
specific regulation of CRYM expression. Malinowska et al. (2009) identified CRYM 
as one of the androgen-regulated genes and they reported elevated expression of 
CRYM in cancer tissue. They also demonstrated CRYM as a downregulated gene 
during tumour progression in prostate carcinoma (Malinowska et al., 2009). The 




(Chong et al., 2006), whereas the expression level was low in brain tumours (Khalil, 
2007). Although the putative role of CRYM in prostate cancer is unknown, it has been 
determined that changes in CRYM mRNA levels are induced following anticancer 
drug suppression of prostate cancer cells in vitro (Mousses et al., 2002). Furthermore, 
screening of a breast cancer cDNA library from SKBR3 human breast cancer cells 
demonstrated that 13 genes, one of which was CRYM, were identified mainly by the 
breast cancer patient sera (Forti et al., 2002). 
A recent article showed high CRYM RNA and protein expression levels in the muscle 
of patients with facioscapulohumeral muscular dystrophy (FSHD) (Klooster et al., 
2009; Reed et al., 2007). FSHD is a genetic disease of muscular dystrophy that is 
thought to be caused by the deletion of the megasatellite repeat on chromosome 4q35 
(Wijmenga et al., 1990). The disorder is linked to nonskeletal muscle manifestation 
including retinal and inner ear defects (Reed et al., 2007). High expression of CRYM 
may play a role in the pathogenesis of FSHD and it may also affect both hearing 
function and retinal development (Reed et al., 2007). 
● CRYM as a µ-crystallin 
 µ-Crystallins are water-soluble structural proteins of a heterogeneous family which 
were discovered in the cells of a vertebrate lens. The family contains the major groups 
such alpha (α), beta (β), gamma (γ), delta (λ), mu (µ) and numerous minor groups. 
These groups are classified according to their charge, size, vertebrate source and 
immunological properties. Crystallins are different from each other; some are 
abundant only in certain groups of associated species, whereas the remainder are 
common to most vertebrates (Lee et al., 1993). CRYM is one of the µ-Crystallin 
proteins and is a major structural protein of the lens (Chen et al., 1992). The μ-
Crystallin mRNA is most abundant in kangaroo lenses but is not abundant in human 
lenses (Vie et al., 1997). Hence, the non-lens expression of CRYM in humans and 
mice formulated the idea that the protein has a non-structural, probably enzymatic 
role in the retina and other tissues (Chen et al., 1992, Segovia et al., 1997). The 
complete predicted amino acid sequence of CRYM was similar to the ornithine 
cyclodeaminase (OCD) sequences (Kim et al., 1992; Witsow and Kim, 1991). The 
ornitine cyclodeaminase (OCD) is a bacterial enzyme which is encoded by tumour-
inducing Ti plasmids of Agrobacterium tumefaciens. This enzyme converts ornithine 




The superfamily relationship between CRYM and OCD suggests the possibility that 
mammalian CRYM has a non-structural, possibly enzymatic role (Kim et al., 1992). It 
has been reported that the (iodo) thyronine binding site of CRYM could be associated 
with the amino acid (ornithine, arginine, and lysine) binding sites of the 
cyclodeaminase enzymes (Segovia et al., 1997; Vie et al., 1997). The pyridine 
nucleotide binding site of CRYM could also be linked to that of OCD (Kim et al., 
1992) since enzyme activity is stimulated by NAD⁺ which acts as a catalyst, rather 
than a co-substrate. This suggests that the mammalian CRYM originated from an 
ancient family (Vie et al., 1997).  
● Human homologue of CRYM encodes NADP-regulated-thyroid hormone binding 
protein 
CRYM is also known as a cytosolic thyroid hormone binding protein which is 
regulated by nicotinamide adenine dinuclotide phosphate (NADP) (Vie et al., 1997). 
The cloned cDNA sequence and peptide sequencing data showed that THBP is the 
same as human CRYM (Kim et al., 1992).  A number of thyroid hormone-responsive 
tissues such as the kidney were known to contain a NADP-regulated-THBP 
responsible for most of the intracellular high-affinity thyroxine (T₄) and 
triiodothyronine (T₃) binding (Parker, 1993). The pivotal action of thyroid hormone 
occurs via the binding of T₃ to its nuclear receptors in the target tissues. These 
receptors are part of a superfamily of ligand-dependent transcription factors that 
contain the receptors for steroid hormones, retinoids and vitamin D (Guiochon-Mantel 
and Milgrom, 1993; Lazar, 1993). Many studies demonstrated that the binding of T₃ 
to cytosolic proteins in different types of cells and tissues are regulated. This indicates 
that these proteins could play a role in the control of intracellular T₃ homeostasis 
(Donovan et al., 1995). 
Hashizume (1989) reported for the first time that T₃ binding was activated by 
NADPH and NADP⁺ in rat kidney cytosol. Analysis of cytosolic T₃-binding from rat 
(Beslin et al., 1995) and human kidneys (Vie et al., 1997) demonstrated that binding is 
activated in the presence of NADPH, whereas NADP⁺ inhibits the activation by 
NADPH (Hashizume et al., 1989; Vie et al., 1997). Accordingly, there is a similarity 
between cytosolic binding sites for T₃ and T₄ with thyroid hormone nuclear receptors 




al., 1997). For this reason, they are responsible for most of the high affinity T₃ and T₄ 
binding in rat astrocytes and human kidney tissue (Vie et al., 1997).  Binding of T₃ to 
cytosolic CRYM indicates that CRYM is involved in the regulation of intracellular T₃ 
homeostasis (Vie et al., 1997). 
The relationship between the function of human THBP and the major lens protein in 
kangaroos is not clear. In fact, most of the crystallins which are expressed in lenses do 
not just act as structural proteins and their synthesis is not limited to the lens (Wistow 
and Piatigorsky, 1988). For instance, several multifunctional species-specific 
crystallins are NAD(P)H-binding proteins, which defend against oxidation in the lens 
and/ or help to filter UV radiation (Wistow, 1993). Notably, THBP has a high affinity 
for NADPH, which is known to regulate cellular redox (Beslin et al, 1995; Vie et al, 
1996). 
The crystal structure of human CRYM suggests it might have redundant functions as 
it binds not only to T₃, but also to NADPH (Cheng et al., 2007; Hashizume et al., 
1989). However, the physiological importance of this coupling is still not clear. Since 
NADPH inhibits T3 binding, oxidative stress might be another agent for control of T₃ 
binding to CRYM in cytoplasm (Kobayashi et al., 1991). According to these findings, 
it has been established that CRYM plays an essential physiological role in regulated 
thyroid-hormone-associated gene expression and transporting and reserving T₃ in the 
nuclei in vitro, and also has a clinical effect on hearing ability. However, the main 
role of CRYM remains to be elucidated in vivo (Suzuki et al., 2007). 
● CRYM as a candidate gene for DN 
Previous studies by Al-Kafaji (2010) showed that CRYM is a glucose-regulated gene 
in DN and it was the first report on the regulation of CRYM in hyperglycaemia (Al-
Kafaji and Malik, 2010). These studies displayed that CRYM mRNA is abundantly 
expressed in the GK rat and it is significantly increased by diabetes in the kidney and 
heart among other tissues. For instance, CRYM mRNA is highly expressed in the 
kidneys (326±50 vs 147±54, p<0.05) and hearts (326±277 vs 191±63, p<0.05) of GK 
rats compared to non-diabetic controls. These results suggested that rat CRYM 
mRNA is elevated in diabetic kidneys and supported a link between hyperglycaemia 
with rat CRYM mRNA expression (Figure 9a). Also, these studies demonstrated that 




To investigate the direct effect of glucose on CRYM, they analysed CRYM mRNA 
expression in cultured HMCs and a human mesangial cell line (HMCL) (Al-Kafaji 
and Malik, 2010). CRYM mRNA levels were increased in HMCs and were directly 
regulated by glucose (Figure 9b). For example, CRYM mRNA was significantly 
increased in HMCs (P<0.005) (Al-Kafaji and Malik, 2010). The glucose regulation of 
CRYM and elevated mRNA/ protein expression in HMCs suggested an important role 
for CRYM in hyperglycaemia-induced molecular pathways that lead to DN (Al-Kafaji 
and Malik, 2010). 
ROS have been identified as signalling molecules in HMCs grown under HG 
(Hancock et al., 2001) and therefore studying ROS in HG condition is important. Al-
Kafaji and Malik (2010) examined whether the increase in CRYM in HG was 
occurring in parallel with increased intracellular ROS. They found that ROS levels 
significantly increased in cells grown in HG and data demonstrated that CRYM 
mRNA levels were enhanced together with increased intracellular ROS in HMCLs 
grown in HG. This was the first report to show elevated CRYM mRNA levels in renal 
cells exposed to HG in association with increased intracellular ROS (Al-Kafaji and 


















Figure 9a. Elevated rat CRYM mRNA expression in a diabetic kidney. 
 This data taken from Al-Kafaji (2008) shows that CRYM mRNA expression was elevated in 







Figure 9b. The effect of high glucose on the expression of human CRYM mRNA 
            in primary cultures of mesangial cells (HMCs) and in the human mesangial cell 
            line (HMCL). 
This data taken from Al-Kafaji (2008) shows that CRYM mRNA expression was  





















































































The simultaneous increase in CRYM expression and in intracellular ROS suggests 
that CRYM may be involved in ROS induced pathways in the cell (Al-Kafaji and 
Malik, 2010). To examine the effect of CRYM on intracellular ROS, CRYM was 
over-expressed as a fusion protein in HMCs. The expression of CRYM as a fusion 
protein in transfected HMCs resulted in a decrease of glucose-induced intracellular 
ROS (Al-Kafaji and Malik, 2010). These observations suggested that CRYM levels 
might be increased to counteract oxidative stress caused by increased production of 
ROS resulting from hyperglycaemia (Al-Kafaji and Malik, 2010). Hence, ROS and 
oxidative stress play an important role in DN. CRYM expression is linked to 
increased intracellular ROS in response to glucose. The elevation of CRYM is 
accompanied by reduced glucose-induced ROS (Al-Kafaji and Malik, 2010). These 
results lead us to the hypothesis that CRYM may be acting as an antioxidant involved 
in reduction of intracellular ROS and to follow up on previous studies and further 
investigate CRYM mRNA/ protein expression in mouse and mammalian cells. 
Aims and Objectives 
1) To investigate whether CRYM is a glucose regulated gene in a mouse model of 
diabetes and is abnormally expressed in hyperglycaemia, we will use in vivo models 
of diabetes. Kidney and heart tissues from two experimental models (ß-Phb2 KO and 
C57/BL6 mice) will be used. CRYM mRNA levels will be quantified using real-time 
qPCR; protein expression and localisation will be determined using 
immunofluorescence.  
2) To further investigate glucose regulation of CRYM, we will use in vitro models of 
DN namely HTC. HTC will be grown in NG, HG and NGM (n=3) for 3 days and 
CRYM mRNA expression will be determined using qPCR. Protein expression will be 








3.3.1. Experimental models of diabetes used in this study 
 
The in vivo diabetic mouse models and the in vitro renal cell model used in this study 
are shown in Table 11a. These were: a) ß-Phb2 KO mouse, b) STZ- induced mouse 
and c) HTC. 
 
a) ß-Phb2 KO mouse: The diabetic and control kidneys and hearts from male and 
female mice (University of Geneva Medical Centre, Switzerland) used in this study 
were bred by crossing flox-Phb2-flox mice with rat-insulin promoter driven Cre mice 
so that Phb2 is specifically deleted in pancreatic beta cells (Section 2.4). ß-Phb2 KO 
mice become diabetic at the age of 5-6 weeks and they were markedly diabetic at a 
later age i.e. 11 weeks when they have extensive polyurea (Table 11a). Kidney and 
heart tissues were collected at 11 weeks; by this time KOs had glycaemia ranging 
between 30-40mM. Indeed, ablation of ph2 in mouse ß-cell sequentially resulted in 
impairment of insulin secretion, a loss of ß cells and severe diabetes (Supale et al., 
2013). These mice represent a spontaneous model of diabetes development through a 
series of molecular events which do not require the administration of toxic diets or 
chemicals.  
b) STZ-induced mouse: Eight week old C57Bl/6 mice were rendered diabetic by 
using STZ; the mice were then treated by islet transplantation (Section 2.4.). Tissues 
from this mouse model were provided by Dr Aileen King, King‟s College London. 
The untreated diabetic mice had blood glucose levels of >20 mmol/L and the treated 
mice had blood glucose levels of <11.1 mmol/L for a period of 4 weeks. In addition, 
non-diabetic, non-transplanted mice were used as controls (blood glucose <11.1 
mmol/L). The right kidneys and the hearts were used to determine CRYM mRNA 








Table 11a: Mouse models of diabetes used in this study 
































Kidneys and hearts were taken from control (n= 4) and KO (n= 6) of a ß-Phb2 KO 
mouse model at 11 weeks and from an acute STZ-induced mouse model in which we 
obtained control (n= 3), diabetic (n= 3) and cured (n= 3) samples at 8 weeks. 
 
C) Human renal tubular cells (HTC): HTCs (ATCC®, UK) were cultured in NG, 
HG and NGM for 3 days of experiments as described previously (Section 2.3). NGM 
was included to rule out the osmolarity effect. Samples were then stored in -80°C and 
used for mRNA and protein studies (Table 11b). 
Table 11b. In vitro renal cells models used in this study 












5 mM glucose+20mM mannitol 
Human renal tubular cells grown in normal glucose (NG, 5mM), high glucose (HG, 
25mM) and normal glucose with mannitol (NGM, 5 mmol/L+ 20 mmol/L mannitol) 
for 3 days. 
3.3.2. Gene expression assay for mouse and human CRYM 
The aim of this part of the work was to set up a quantification assay for mouse and 
human CRYM to detect the mRNA levels of CRYM in vivo and in vitro. 
1) Primer design and amplification of mouse and human CRYM 
Oligonucleotide primers designed for both mouse and human CRYM based on the 
mRNA sequence of the gene (Accession number NM_016669 and L02950) were used 
to quantify the 61 bp and 62 bp fragments of mouse and human CRYM cDNAs 
respectively (Table 12a). The primers were designed using Roche Applied Science 
software and synthesised at Sigma-Aldrich (Figure 10a and 10b). The protein 





Table 12a. Oligonucleotide primers used in PCR and RT-PCR 
 
Gene name Accession 
number 
Product size Sequence 
mCRYM F₁: Forward 
primer 
 
mCRYM R₁: Reverse 
primer 
 
NM_016669 61 bp ggg gct caa tca atg ct 
 
 
gct cgt cat cca gtt ctc g 
hCRYM F₁: Forward 
primer 
 
hCRYM R₁: Reverse 
primer 
 
L02950 62 bp gcc  ctg aag gag tct gag g 
 
 
tct ccc agc tca gca aag  at 
The sequences shown in Table12a are 5‟ to 3‟ with F primers representing the sense 
strand and R primers representing the anti-sense strand of the CRYM F1 and CRYM 
R1 primers. 
        1 atttagggct cagctcctgg aacgtggagt gtgtttcagc ccgggttcga aggcaggcgg 
       61 cgagatgaag cgggcgccag cgttcctgag cgcagaggag gtgcaggatc accttcgcag 
      121 ctccagcctt ctcatcccac ccctggaggc cgcactggcc aacttctcca aaggtcccga 
      181 cggaggggtc atgcagccag tgcgcaccgt ggtgcctgta gccaagcacc gaggcttcct 
      241 gggagtcatg cctgcctaca gtgctgctga ggatgcgctc accaccaagt tagtcacctt 
      301 ctatgagggc cacagcaaca cagcggtccc ctcccatcag gcatcggtgc ttctctttga 
      361 tcccagcaat ggctccctgc tggcggtcat ggatggaaat gtcataactg caaagagaac 
      421 agcagcggtg tctgccattg ccacaaagct gttgaagccc ccaggcagtg atgtgctgtg 
      481 catccttgga gcgggggtcc aggcgtacag tcactatgag atcttcacag agcagttctc 
      541 cttcaaggag gtgagaatgt ggaaccgcac cagggaaaat gctgagaagt ttgcaagcac 
      601 agtgcaagga gatgttcggg tctgttcatc agtgcaggag gctgtgacag gtgctgatgt 
      661 catcatcaca gtcaccatgg caacagagcc cattttattt ggtgaatggg taaagccggg 
      721 ggctcacatc aatgctgttg gagccagcag gcctgactgg cgagaactgg atgacgagct 
      781 catgaggcaa gcggtgctgt atgtggactc ccgggaggct gccctgaagg agtcaggaga 
      841 cgttctgttg tcaggggctg acatctttgc tgagcttgga gaagtgattt caggagcgaa 
      901 gcctgcacac tgtgagaaga ccacagtgtt caaatctttg gggatggcag tggaagacct 
      961 ggttgcagcc aaattagtat atgattcttg gtcatctggc aagtgagttg aaggaaccgt 
     1021 gcctgagttg gccatcacag ctcaacactg tttcacaagt gtcaaaatca aaggaggtcc 
     1081 agtccccagt gaatggtagt gattgtcatt cataagtact gacaccccta ttcatgtttg 
     1141 tggttggata gctaaaccag gtaaccattt cttctgttaa ggggtgatgg ccacattatc 
     1201 tacccttgat cttactagtc ttgtatctct ctgaaataaa tcatttccac ttcttc 
 
Figure 10a. Nucleotide sequence of mouse CRYM mRNA, accession number NM- 
016669.  
The forward primer (CRYM F₁) is represented in blue and reverse primer (CRYM R₁) in 
green. The putative initiation codon is at position 65 and is in red. The stop codon is also 







        1 agactgaggt tagaaggcac aggtggcgag atgagccggg taccagcgtt cctgagcgcg 
       61 gccgaggtgg aggaacacct ccgcagctcc agcctcctca tcccgcctct agagacggcc 
      121 ctggccaact tctccagcgg tcccgaagga ggggtcatgc agcccgtgcg caccgtggtg 
      181 ccggtgacca agcacagggg ctacctgggg gtcatgcccg cctacagtgc tgcagaggat 
      241 gcactgacca ccaagttggt caccttctac gaggaccgcg gcatcacctc ggtcgtccct 
      301 tcccaccagg ctactgtgct actctttgag cccagcaatg gcaccctgct ggcggtcatg 
      361 gatggaaatg tcataactgc aaagagaaca gctgcagttt ctgccattgc caccaagttt 
      421 ctgaaacctc ccagcagtga agtgctgtgc atccttgggg ctggggtcca ggcctacagc 
      481 cattatgaga tcttcacaga gcagttctcc tttaaggagg tgaggatatg gaaccgcacc 
      541 aaagaaaatg cagagaagtt tgcagacaca gtgcaaggag aggtacgggt ctgttcttcg 
      601 gtccaggagg ctgtggcagg tgcagatgtg atcatcacag tcaccctggc aacagagccc 
      661 attttgtttg gtgaatgggt gaagccaggg gctcacatca atgctgttgg agccagcaga 
      721 cctgactgga gagaactgga tgatgagctc atgaaagaag ctgtgctgta cgtggattcc 
      781 caggaggctgccctgaagga gtctggagat gtcctgctgt caggggccga gatctttgct 
      841 gagctgggag aagtgattaa gggagtgaaa ccagcccact gtgagaagac cacggtgttc 
      901 aagtctttgg gaatggcagt ggaagacaca gttgcagcca aactcatcta tgattcctgg 
      961 tcatctggta aataaaacaa aggaacttga tgttgagatg gatgcttgag gaatattgct 
     1021 gctggttctc ataatttcta gagtaaatga gggagtccag tccccagtga actctccttt 
     1081 tgtgcttatc atgttttacc ttaaatgctg agatcctcat ttatgtttgt agttggaaag 
     1141 caaagctagg tagccatttc ttctgttcta ccaagttata atagcattca tttcccttta 
     1201 tatttccctg aaataaagca cattccaatt gtgcagtg 
 
 
Figure 10b. Nucleotide sequence of human CRYM mRNA, accession number L02950. 
The forward primer (CRYM F₁) is represented in blue and reverse primer 
(CRYM R₁) in green.The putative initiation codon is at position 31 and in red. The 




Figure 10a and 10b show the position of the primers. Primers for mouse CRYM F₁ 
and CRYM R₁ were used to amplify a fragment of mouse kidney cDNA ( Figure 10c) 
and human CRYM F₁ and CRYM R₁ primers were used to to determine the CRYM 
mRNA transcript in HTC (Figure 10b). PCR was carried to confirm the product sizes 
of mouse and human CRYM genes using an annealing temperature of 60⁰C and 3 mM 
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  Figure 10c. Purification of mouse and human CRYM. 
 
A): mCRYM, B): hCRYM. Approximately 30 µl of each PCR product was loaded on  
an agarose gel (1%, 1X TBE) and the DNA of each PCR product was excised from the gel 
band and purified. 10 µl of purified products was then gel electrophoresed along with a 




2) RNA isolation and cDNA synthesis from mouse tissues and human renal 
tubular cells 
To determine the regulation of mouse and human CRYM mRNA expression in vivo 
and in vitro models total RNA was isolated from the kidneys and hearts of ß-Phb2 
KO and STZ mice and from HTC in each condition (Section 2.6.1). RNA 
concentration was determined by measuring the absorbance of RNA at A₂₆₀ using 
nanodrop (Table 12b). For each condition, cDNAs were synthesised (Section 2.6.4.) 
and CRYM primers were used to detect CRYM mRNA expression in the kidney and 
hearts of mouse models in vivo and also in HTC in vitro. qPCR was carried out to 








mCRYM (61 bp) 100 bp 100 bp    




Table 12b. Concentration of RNA isolated from samples  
Models Samples Condition RNA 
Concentration 
(ng/µl) 




















































































































































   
RNA was extracted from kidneys and hearts of ß-Phb2 KO and STZ-induced mice in 
vivo and human tubular cells in vitro. Concentration of RNA in each condition was 
detected by measuring the absorbance at A₂₆₀ using nanodrop. 
3) Identification of most stable control gene for quantitative gene expression 
measurements in vivo and in vitro 
a) In vivo: To evaluate the most stable and reliable reference gene in vivo, 
endogenous gene expression stability was measured using geNorm and NormFinder 
Programs (Vandesompele et al., 2002). Both geNorm and NormFinder are popular 
algorithms for identifying the optimal normalisation gene for a set of candidate 
reference genes by ranking them for normalisation according to their expression 
stability (Vandesompele et al., 2002; Andersen et al., 2004). In this experiment, we 
used the prepared cDNA samples from 6 samples of control, diabetic and treated 
C57/BL6 mice for kidney tissues. Then, we assessed mRNA expression of six 




binding protein (TBP), 28S ribomosal RNA (Rn28s1), phosphoglycerate kinase 
(PGK), peptidylprolyl isomerise B (PPIB), and glyceraldehyde-3-phosphate 
dehydrogenase (GAPDH). A list of primers used in this part is shown in Section 2.7 
(Table 5b). 
 
All candidate reference genes were quantified and the normalisation factor (NF) was 
calculated based on the mean expression value of the best endogenous controls. Both 
software programs pick the most stable genes in terms of improved reduction of 
technical variation and more accurate appreciation of biological changes 
(Vandesompele et al., 2002; Andersen et al., 2004). The findings showed that all 
candidate reference genes in this experimental study are stable and they are similar to 
each other. geNorm identified mouse β-actin (M= 0.072) as the gene with least 
stability, as they have the highest M-value and more variation compared to other 
genes. GAPDH (M= 0.047) is the most stable gene in mouse kidney tissues 
(Appendix 3). Normfinder also identified mouse GAPDH (M = 0.01) as the most 
stable gene with the least overall variation and mouse β-actin was determined to be 
the least stable expressed gene (M= 0.042). Both geNorm and Normfinder determined 
GAPDH as the most stably expressed gene and we therefore used mouse GAPDH for 
our in vivo experiments to normalise the quantification of mouse CRYM most 
accurately. 
 
b) In vitro: Gene expression was quantified by normalisation to 3 different 
endogenous reference genes: β-actin, PGK and PPIB (Section 2.7, Table 5a). In this 
experimental study, HTC (n= 4) and HMCs (n= 4), cultured in NG and HG 
respectively, were quantified relative to reference genes using real-time qPCR. 
geNorm and NormFinder software were used to normalise these expression patterns, 
independent of mRNA expression levels. Both programs picked two genes with the 
lowest M-value which were most stable, as well as the gene with the highest M-value 
which was the least stable reference gene. For both HTC and HMCs samples, PGK 
(M= 0.779) was selected as the most stable gene and PPIB (M= 1.049) was calculated 






4)  Purification and generation of standard curves  
To accurately measure the copy numbers of mouse CRYM and human CRYM in vivo 
and in vitro, standards were prepared from purified PCR products to use with qPCR. 
(section 2.8). The amount of amplicon in each purified PCR product was measured 
using nanodrop and the number of copies was calculated based on the molecular 
weight of each individual gene. The amount of DNA was calculated for each gene in 
10 µl PCR products as presented in Table 12c. 
 
Table 12c. Concentration and amount of DNA in the purified PCR products 












 copies per µl) of the PCR product containing the target cDNA. The first tube for 
CRYM contained 0.15× 10¯⁹ copies of the gene, and was applied in 10-fold serial 
dilutions by adding 10 µl of 0.15× 10¯⁹ to 85 µl of DEPC-treated water and 5 µl of 
tRNA (10 μg/ml; Sigma, UK). This process was repeated to make up 0.15x102 
concentrations. Amplification of the 10-fold dilution series was performed in qPCR 
by using the LightCycler 480 and QuantiFast DNA Master SYBR Green kit 
(QIAGEN, UK). The successful generation of standards for both target genes and 
reference genes are shown in Appendices 4 and 5. 
 
5) Quantification of renal and cardiac CRYM copy numbers in ßeta-Prohibitin 2 
knockout and streptozotocin-induced diabetic mice in vivo 
To measure copy numbers of CRYM mRNA in control and diabetic kidneys and 
hearts of both a ß-Phb2 KO mouse and an acute STZ-induced mouse, previously 
described in section 3.3.1., total RNA was extracted from each sample (Table 12b). 
From this, cDNA was synthesised and CRYM mRNA copy numbers relative to the 
reference gene (GAPDH) were determined.  




Amount of DNA 
(g/µl) 
Cpoies of gene 
per µl (g/µl) 
mCRYM 61 22.1 22.1× 10¯⁹ 0.5x10¹¹ 
mGAPDH 125 35 35× 10¯⁹ 3.3x10¹¹ 
hCRYM 62 10.6 10.6× 10¯⁹ 0.5×1011 




The quantification of each sample was achieved by comparing the fluorescence of a 
PCR product of unknown concentration with the fluorescence of several dilutions of 
both mouse and human CRYM external standards (measuring Ct for each reaction and 
using the standard curve to determine starting copy number). Fluorescence values 
were calculated in the log-linear phase of amplification to produce a fluorescence 
curve which increases with each cycle as the product accumulates. To examine 
specificity, melting-curve analysis was performed. The result shows a fluorescence 
curve profile that was obtained during a slow denaturation of PCR products. Melting 
peaks have been generated by differentiation of melting curves, and defining the 
melting temperature of amplified product. Samples were normalised with respect to 
mRNA expression of the reference gene (GAPDH). The concentration of the nucleic 
acids used as standards for target genes and reference genes were known and prepared 
for absolute quantification. All qPCR experiments were performed in triplicate; 
cDNAs were used for each experimental condition. Statistical analysis of the data 
using student‟s t test provided the mean, standard deviation and the p values. 
● Renal and cardiac mRNA levels of CRYM in the ßeta-Prohibitin2 knockout 
mouse 
Renal and cardiac CRYM copy numbers relative to mouse GAPDH mRNA copy 
numbers were detected using qPCR in ß-Phb2 KO mice as shown in Table 13a. The 
results showed that there was no difference in diabetic renal CRYM mRNA levels 
compared to their control (0.0133 ± 0.00516 vs. 0.0200 ± 0.0200, P>0.05; Table 13b).  
We could not also demonstrate any change in cardiac CRYM mRNA levels in 
presence of hyperglycaemia. Statistical analysis of the data using student‟s t test 
showed a non-significant difference in diabetic hearts compared to control hearts 












Table 13a. Relative CRYM and GAPDH mRNA expression values of ß-Phb2 KO 
kidney and heart tissues 



































































































































































CRYM mRNA copy numbers relative to GAPDH copy numbers were determined 
using qPCR in control and diabetic mouse kidneys and hearts of a ß-Phb2 KO mouse. 
For each condition, samples were used to prepare cDNA. Renal and cardiac CRYM 
mRNA levels were quantified from each sample in triplicate. Data are shown as 
relative expression values. 
 
Table 13b. Relative copy numbers of CRYM mRNA in ß-Phb2 KO mice kidneys 
and hearts tissues 
Tissue Condition N 
Mean values ± SD of mouse 
CRYM copy numbers 
Kidney 
Control 4 0.0200 ± 0.0200 
KO 6 0.0133 ± 0.00516 
Heart 
Control 4 0.00 ±  0.00 
KO 5 0.0060 ± 0.0054 
CRYM mRNA copy numbers relative to GAPDH copy numbers were detected in 










Figure 11a. Effect of high glucose on renal CRYM mRNA levels of ß-phb2 KO mice. 
 
Kidneys from diabetic (n= 6) and control (n= 4) of ß-Phb2 KO mice were used to examine the 
effect of hyperglycaemia on CRYM mRNA levels in the kidneys. A) Levels of expression of 
renal CRYM mRNA were quantified by qPCR and quantification being carried out and the 
results were expressed as levels of renal CRYM relative to GAPDH. B) The data were log 
transformed and showed a non-significant difference in renal CRYM levels when compared 
to their control, P>0.05.  
 
            
 
            Figure 11b. Effect of high glucose on cardiac mRNA levels of ß-Phb2 KO mice. 
 
Hearts were collected from diabetic (n= 5) and control (n= 4) of ß-Phb2 KO mice. Cardiac 
CRYM copy numbers were detected using qPCR. The mean values and standard deviation of 
different experiments are shown. A) Values shown are copy numbers of cardiac CRYM 
mRNA relative to GAPDH. B) The data were log transformed and found not to change in 





As shown in Figures 11a and 11b, no difference was seen in diabetic conditions. This 
is the first study to examine the expression of renal and cardiac CRYM mRNA levels 
in a ß-Phb2 KO mouse model and we could not demonstrate any change of renal and 
cardiac CRYM mRNA levels in diabetic conditions. 
 
● Renal and cardiac mRNA levels of CRYM in streptozotocin-induced diabetic mice 
As described previously, renal and cardiac CRYM copy numbers were measured in 
control, diabetic and treated kidneys of mice relative to GAPDH, as shown in Table 
14a. The data were log transformed as the actual CRYM copy number values were 
skewed and not normally distributed. Student's t test was used to obtain the mean, 
standard deviation and p values. The results showed that renal CRYM levels were 
increased by hyperglycaemia in the kidneys of STZ mice and this increase was 
attenuated by the treatment of diabetes (0.76 ± 0.33 vs. -2.17 ± 0.22, P<0.001; Table 
14b). 
The hyperglycaemia-induced increase in renal CRYM was specific as we could not 
demonstrate any change in cardiac CRYM (P>0.05; Table 14b); the results showed a 
non-significant difference between control and diabetic hearts (Figure 12b). The mean 
values of cardiac CRYM mRNA in control and treated kidneys were close to each 














Table 14a. Relative CRYM and GAPDH mRNA expression values of STZ mouse 











CRYM copy numbers relative to GAPDH copy numbers were determined using 
qPCR in control, diabetic and treated kidneys and hearts of STZ-induced diabetic 
mice. For each condition, samples were used to prepare cDNA and renal and cardiac 
CRYM mRNA levels were quantified from each sample in triplicate. Data are shown 
as relative expression values. 
Table 14b. Relative copy numbers of CRYM mRNA in STZ mouse kidney and 
heart tissues 
Tissue Condition N 
Mean values ±SD of 
mouse CRYM copy 
numbers 
Mean values ±SD of 
CRYM log 
Kidney 
Control 3 0.006 ± 0.005 -2.17 ± 0.22 
Diabetic 3 7.24 ± 5.98 0.76 ± 0.33** 
Treated 3 0.596 ± 0.914 -0.91 ± 1.57 
Heart 
Control 2 0.005 ± 0.0007 -2.3 ± 0.06 
Diabetic 3 0.009 ± 0.008 -2.1 ± 0.39 
Treated 2 0.028 ± 0.027 -1.6 ± 0.50 
CRYM mRNA copy numbers relative to GAPDH copy numbers were detected in 
kidneys and hearts of STZ-induced diabetic mice. Values are shown as mean ± SD. 




















































































































































Figure 12a. The effect of high glucose on renal CRYM mRNA levels of STZ mice. 
 
Kidneys were collected from control, diabetic and treated STZ-induced diabetic mice. Renal 
CRYM copy numbers were detected using qPCR. A) The mean values and standard 
deviation of different experiments are shown. Values shown are copy numbers of renal 
CRYM mRNA relative to GAPDH. B) Student‟s t test of the log-transformed values showed 
a significant increase of CRYM levels in diabetic kidneys. **P<0.001 
 
 
Figure 12b. Effect of high glucose on cardiac CRYM mRNA levels of STZ mice. 
Hearts were collected from control, diabetic and treated STZ-induced diabetic mice. Cardiac 
CRYM copy numbers were detected using qPCR. A) The mean values and standard deviation 
of different experiments are shown. Values shown are copy numbers of cardiac CRYM 
mRNA relative to GAPDH. B) The data were log-transformed and showed a non-significant 








Figure 12a showed that diabetes leads to increased expression of renal CRYM 
mRNAs, which can be corrected in kidneys through treatment of diabetes. This 
increase in renal CRYM mRNAs of STZ mice supports previous finding, which 
showed that renal CRYM mRNA is up-regulated in the kidneys of a GK rat (Al-
Kafaji and Malik, 2010). However, there are no changes in cardiac CRYM mRNAs of 
STZ-induced diabetic mice (Figure 12b). 
3.3.3. CRYM protein expression is up–regulated in diabetic kidneys of 
streptozotocin-induced diabetic mice 
 
In this part of the study, the expression and the localisation of CRYM protein was 
determined in control and diabetic kidney sections of STZ-induced diabetic mice 
using immunoflourescence. Mouse kidney sections of STZ mice which were 
previously used for mRNA study were incubated with the CRYM antibody overnight 
and anti goat FITC conjugated secondary antibodies for 2 hours; nuclei were stained 
blue with DAPI (Section, 2.14.1). Sections were examined under a fluorescence 
microscope (Eclipse TE 2000-U, Nikon). 
The fluorescence probe was determined by a green emission indicating the location of 
CRYM protein in the kidney and it revealed that CRYM protein was located 
predominantly in the glomerulus and tubules of the kidney; it also showed that 
CRYM was more abundant in the tubules. CRYM protein was expressed at relatively 
higher levels in hyperglycaemia compared to control, suggesting increased protein 
expression of CRYM protein in diabetic kidney (Table 15). Besides the higher levels 
of CRYM protein, the tubules were bigger (hypertrophy) and distorted compared to 
control sections (Figure 13a).  
To confirm the accuracy of CRYM protein expression, public domain image analysis 
software (ImageJ v3.91 http://rsb.info.nih.gov/ij) was applied to measure the 
fluorescence intensity in control and diabetic sections. Furthermore, it showed that the 
increase in FITC green fluorescence was not due to over-exposure of the images. Four 
images were selected for each condition and ImageJ analysis was used to calculate the 
optimal signal to noise ratio. The average of each condition was found and the data 
showed a 1.4-fold increase in the fluorescence intensity of the CRYM protein in the 




support previous results illustrating renal CRYM mRNA to be significantly increased 
in STZ diabetic mice. 
Table 15. Statistical analysis of CRYM protein fluorescence intensity in STZ 
kidneys  
Tissue Condition N Mean values ± SD of mouse 
CRYM protein 
Kidney Control 4 45.76 ± 29.42 
Diabetic 4   65.73 ± 29.58* 
Fluorescence intensity of FITC was obtained in control and diabetic mice kidneys of 
STZ-induced diabetic mice using ImageJ analysis. The data are shown as mean ± SD. 
*P<0.05 
 
Control                                                              Diabetic 
 
 
Figure 13a. Increased protein levels of CRYM are associated with diabetic mouse 
kidney. 
Kidney sections of cortex from diabetic and control STZ- induced diabetic mice were labelled 
with the CRYM primary antibody and FITC conjugated secondary antibody. Green represents 










                 Figure 13b. Increase in fluorescence intensity in diabetic mice compared to  
                 controls. 
                 CRYM protein was increased in diabetic kidneys of STZ mice. *P<0.05 
 
 
• CRYM protein is more abundant in tubular cells compared to glomerular cells of 
streptozotocin-induced diabetic mice 
The fluorescent probe detected by the green emission determined that CRYM protein 
was located abundantly in tubules and less in the glomerulus of control and diabetic 




















































                        A)                     Control                              B)                        Diabetic 
        
        
    Figure 13c. CRYM protein is highly abundant in tubular and less present in         
    glomerular cells from control and diabetic kidneys of mice. 
 
                 Localisation and expression of mouse CRYM protein was assessed by CRYM primary 
                 antibody and FITC-conjugated secondary antibody; nuclei were stained with DAPI. 
                 These sections in the cortex of control and diabetic STZ mice showed kidney tubules 
                 and glomeruli. White boxes are showing less green staining in glomeruli and indicated 
                 higher expression of CRYM in the tubules as there is more green staining there. Scale 




A higher magnification was used to further investigate the location of CRYM protein 
in mouse kidney sections. The CRYM protein was presented with green staining and 
the nuclei were labelled as blue. CRYM protein was found to be located in the 









   A) Control                                                  B) Diabetic 
 
 
 Figure 13d. CRYM protein expression in the cytoplasm in control  and diabetic  
  kidneys of mice. 
  Mouse kidney sections were labelled with CRYM primary antibody and FITC conjugated  
  secondary antibody, and nuclei were stained with DAPI. A) These cortical sections of 
               control and diabetic STZ-induced diabetic mice showed kidney tubules. One glomerulus and 
               one tubule of each condition has been magnified and shows the cytoplasmic localisation of  
               CRYM protein in the control and diabetic kidney. B) A higher magnification of a section in 
               both the control and diabetic kidneys further confirmed cytoplasmic localisation of CRYM 
              protein and more expression of CRYM in tubular cells, T: tubule and G: glomerulus. 




3.3.4. Is renal CRYM mRNA regulated by glucose in cultured human tubular 
cells? 
Our previous results showed that renal CRYM mRNA is up-regulated by glucose in 
the diabetic kidneys of STZ-induced diabetic mice. Immunohistochemistry study 
revealed an abundant expression of CRYM protein in renal tubular cells of the STZ 
mice. These results suggested that diabetes leads to an increased expression of renal 
CRYM which can be corrected in the kidneys by the treatment of diabetes, and 
although there are high levels of CRYM protein in renal tubular cells, the up-
regulation may be taking place in mesangial or other renal cells. Previously, Al-Kafaji 
(2010) reported the up-regulation of renal CRYM mRNA by glucose in HMCs and 
HMCL. 
Therefore, in this part we examined renal CRYM mRNA levels in HTC to see if they 
could be induced by high glucose. As described previously, HTC were cultured until 
highly confluent and cells were exposed to NG, HG and NGM for 3 days. NGM was 







measuring the absorbance of RNA at A₂₆₀ using nanodrop (Table 12b; Section 3.3.1). 
cDNA was synthesised from RNA (Section 2.6.4.). For each condition, cDNAs were 
synthesised and CRYM primers were used to detect the CRYM mRNA expression in 
HTC. qPCR was carried out to measure copy numbers of renal CRYM mRNA 
relative to a reference gene.  
● Quantification of renal CRYM copy numbers in human cultured renal tubular 
cells  
In HTC, renal CRYM mRNA copy numbers were measured relative to PGK using 
qPCR (Table 16a). Surprisingly, in HG, renal CRYM mRNA levels showed a slight 
decrease in HTC (Figure 14) whereas they had previously shown a significant 
increase in HMCs and HMCL (Al-Kafaji and Malik, 2010). Statistical analysis of the 
data using student‟s t test showed a significant decrease in cells exposed to HG when 
compared to NG (0.03 ± 0.05 vs. 0.5 ± 0.26, P<0.05; Table 16b). We also found no 
significant difference between NG and NGM (p>0.05), thereby showing the absence 
of osmolarity effect. 
 
Table 16a. Renal CRYM mRNA expression values relative to PGK in human 
renal tubular cells cultured in different conditions  
Renal CRYM mRNA copy numbers relative to PGK mRNA copy numbers were 
detected using qPCR in human tubular cells, cultured in normal glucose (NG), high 
glucose (HG) and normal glucose with mannitol (NGM) for both experiments. For 
individual conditions, three separate samples were used to prepare cDNA and human 
CRYM was quantified for each sample in triplicate. Data are shown as relative 



























































































Table 16b. Relative copy numbers of CRYM mRNA in human cultured renal 
tubular cells  
Cells Condition N Mean values ± SD of human 
CRYM copy numbers 
HTC NG 3 0.50 ± 0.26 
 HG 3 0.03 ± 0.05* 
 Mannitol 3 0.30 ± 0.36 
Renal CRYM mRNA copy numbers relative to PGK mRNA copy numbers were 
detected in in human tubular cell lines grown in normal glucose (NG), high glucose 
(HG) and in normal glucose plus mannitol (NGM). Copy numbers are shown as mean 






Figure 14. Effect of high glucose on renal CRYM mRNA levels in human 
             tubular cells.  
After being synchronised, tubular cells were incubated in normal glucose (5 mM), 
high glucose (25 mM) and normal glucose with mannitol (5 mM glucose + 20 mM 
mannitol) for 3 days. Renal CRYM copy numbers were detected using qPCR (n= 3). 
A) The mean values of three different experiments are shown. Values shown are copy 
numbers of renal CRYM mRNA relative to PGK. B) The data showed a decrease in 
CRYM mRNA level in cells exposed to HG. *P<0.05 
 
            
 
1)  Cellular localisation of CRYM protein in human embryonic kidney 293 
(HEK293) cells 
The aim of this part of the study was to test the specificity of the human CRYM 
antibody in human HEK293 cells before investigating the CRYM protein expression 




maintained in DMEM media until they reached confluence and were then growth 
arrested for 24 hours. The quiescent cells were seeded on 6-well pellet at a density of 
10,000 cells/well in DMEM media containing NG, HG and NGM and were incubated 
for 3 days. However, we only used HEK293 cells grown in NG to test the CRYM 
antibody for the first time. 
The specificity of the purified antibody was assessed by immunostaining. Two 
different concentrations of the primary antibody were used (1:30, 1:50 dilutions). The 
HEK293 cells were incubated with a goat polyclonal IgG primary antibody made 
against CRYM and FITC-conjugated donkey anti-goat IgG secondary antibody at 
1:30 and 1:50 dilutions for 2 hours. Immunostaining was carried out to detect the 
location of CRYM protein in HEK293 cells. The results showed successful detection 
of CRYM protein in HEK293 cells at different concentrations of the primary antibody 
and suggested that a 1:30 dilution would be the best working concentration for future 
immunostaining (Figure 15). 
 
● Cellular localisation of CRYM protein in human renal tubular cells 
Previously, we found a moderate decrease in renal CRYM mRNAs in HTC in the 
presence of HG. The aim of this section was to determine the localisation and 
expression of CRYM protein in NG and HG conditions. Part of the cell pellets used 
for mRNA study was saved for the protein study. In this study, we used only cells 
grown in NG and HG.  
 
Quiescent cells were subjected to immunofluorescence analysis. The cells were 
prepared as described above for the detection of CRYM protein in HEK293 cells. 
Localisation and expression of CRYM protein was assessed by confocal microscopy 
following staining of cells with a goat polyclonal IgG primary antibody against 
CRYM and FITC-conjugated donkey anti-goat IgG secondary antibody for 
fluorescence labelling. Cells were mounted with PBS and nuclei were counterstained 
with DAPI (blue). Figure 16a and 16b illustrates confocal microscope images of HTC 
expressing CRYM protein after exposure to NG and HG respectively for 3 days. 
CRYM protein was distributed throughout the cytoplasm in cells both in NG and in 
HG. The fluorescent probe detected through the green emission indicated that CRYM 




nuclei, which were counterstained with DAPI. These results were in line with 
previous studies demonstrating CRYM protein to be located in the cytoplasm of 
HMCs (Al-Kafaji and malik, 2010) and HEK293 cells under NG. In addition to 
CRYM protein localisation, no difference in the expression level of CRYM protein 
was found in both NG and HG conditions (Figure 16a and 16b). 
 
                           FITC                                    DAPI                            FITC+DAPI 
                       
                       
                        Figure 15. Detection of CRYM protein expression in normal glucose of human 
                       embryonic kidney 293 cells. 
                       
         Human embryonic kidney 293 cells were cultured in normal (5 mM) glucose. Cells were 
         incubated with goat polyclonal IgG primary antibody and FITC-conjugated secondary 
        antibody (1:30 dilution) and they were stained with DAPI. The reactivity was visualised 
       for FITC to detect the location of the protein. Arrows show that CRYM protein is 
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Figure 16a. Detection of CRYM protein expression in normal glucose  of human 
tubular cells. 
Human tubular Cells were cultured in normal (5 mM) glucose. Cells were incubated 
with goat polyclonal IgG primary antibody and FITC-conjugated secondary antibody 
and they were mounted using DAPI. The reactivity was visualised for FITC to detect 
















Figure 16b. Detection of CRYM protein expression in high glucose of human 
tubular cells. 
Human tubular Cells were cultured in high (20 mM) glucose. Cells were incubated with 
goat polyclonal IgG primary antibody and FITC-conjugated secondary antibody and they 
were  stained with DAPI. The reactivity was visualised for FITC to detect the location of 







We report that CRYM, also known as thyroid hormone binding protein and µ-
crystallin is involved in the cell‟s glucose response in diabetes. In this part of the 
study we looked at CRYM expression in vivo and in vitro. The main focus of this 
study was to investigate whether renal CRYM mRNA and protein were regulated by 
the presence of HG in the in vivo and in vitro models and also to detect the location of 
CRYM protein in HTCs. In the first part of this study, we analysed renal and cardiac 
mRNA expression in ß-Phb2 KO and STZ mice and also CRYM protein expression 
were measured in the kidneys of diabetic induced STZ mice compared to healthy 
controls. Secondly, CRYM copy numbers as well as were measured and the location 
of CRYM was examined in HTC. 
Our study is the first to show that renal CRYM mRNA is regulated during the 
development of hyperglycaemia in the kidneys of STZ-induced diabetic mice. We 
found that renal CRYM mRNAs increased in response to hyperglycaemia in the 
kidneys of STZ-induced diabetic mice and this increase was attenuated by the 
treatment of diabetes (P<0.05). Renal CRYM mRNA expression was significantly 
increased in diabetic kidneys compared to control kidneys. The increase in renal 
CRYM in whole kidneys was specific as we could not demonstrate any change in 
cardiac CRYM. We also examined renal and cardiac CRYM mRNA levels in ß-Phb2 
KO mice to see if they followed the same pattern of expression, however we could not 
find any change in renal and cardiac CRYM mRNAs in the presence of 
hyperglycaemia. The differential expression of CRYM in ß-Phb2 KO and STZ-
induced diabetic mice might be as a result of the difference between these biological 
models. Therefore, it is possible that the biological difference of these two models 
could be affecting renal and cardiac CRYM expression. 
Following these results, immunofluorescence staining was carried out to determine 
the expression and location of CRYM protein in control and diabetic kidneys of the 
STZ mice. CRYM protein was widely expressed in diabetic kidneys, mostly in the 
tubules and it was expressed at lower levels in the glomerulus. By analysing the 
fluorescent intensity, it was found that CRYM protein expression was significantly 




Further analysis of protein localisation showed that CRYM protein was localised in 
the cytoplasm of the HTC in the control and diabetic sections of the kidney.  
We also examined renal CRYM mRNA levels in HTC to see if they could be induced 
by HG. However, we found a moderate decrease of renal CRYM mRNA levels in 
HTC in the presence of HG. In contrast, renal CRYM showed up-regulation by 
glucose in cultured HMCs in previous studies by Al-Kafaji (2010). We also showed 
that renal CRYM protein is predominantly found in HTC and its expression is not 
increased in HG condition. 
It was previously shown that renal CRYM is differentially regulated by glucose and 
strongly hybridised to a cDNA probe prepared from poly (A)+ RNA isolated from the 
kidneys of a GK rat compared to the normoglycaemic kidneys of a wistar rat at 6 
weeks (Malik et al., 1997). The detection of renal CRYM mRNA transcript in the 
kidneys of a GK rat but not in the normoglycaemic kidneys of a Wistar rat suggested 
the up-regulation of renal CRYM mRNA levels in diabetic kidneys (Zaidi, 1997). A 
study by Al-kafaji (2010) which reported a gradual elevation in CRYM mRNAs from 
the kidneys of GK rats from 6 weeks to 40 weeks is consistent with these results and 
therefore our data supports the notion that renal CRYM is up-regulated by glucose in 
diabetic kidneys and suggests glucose regulation of renal CRYM mRNA expression 
in a mouse model. 
The location of CRYM has not been demonstrated in the kidney previously. The 
CRYM gene is located at human chromosome 16p13.11-p12.3 which contains several 
genes (Chen et al., 1992). These genes encode proteins that have both specific and 
unique renal localisation and function and some encode for proteins whose functions 
are still unknown, but whose alteration causes renal diseases (Stiburkova et al., 2000; 
Kamatani et al., 2000; Pirulli et al., 2001). Our observation of up-regulation in renal 
CRYM mRNAs occurring in the diabetic kidneys of STZ mice, rats and in HTC raises 
the idea that CRYM may be involved in the pathogenesis of DN. 
In HG, ROS produces and increases glucose signalling in renal cells and it is also 
involved in excessive ECM deposition in DN (Ha and Lee, 2005; Lee et al., 2003). 
The increase of CRYM is parallel with increased ROS in HMCs in response to HG, 




high glucose-induced ROS formation and increases the hypothesis that CRYM may 
serve as an endogenous antioxidant.  
Immunofluorescence showed that mouse CRYM protein expression is mostly 
localised in the tubules and less in the glomerulus. Consistent with this observation, 
human CRYM protein was also found to be more abundant in the renal tubules of a 
human kidney compared to the glomeruli (Suzuki et al., 2007). Therefore, they 
suggested that CRYM expression is cell–type specific. 
We have also shown that CRYM protein localises into the cytoplasm in control and 
diabetic mice. This is consistent with the previous study by Al-Kafaji (2010) that 
showed CRYM protein was expressed in the cytoplasm. Interestingly, CRYM was 
identified as a cytosolic T₃-binding protein in rat cytosol by Suzuki (2007).  
A study by Suzuki et al., (2007) demonstrated that CRYM has the capability to 
modulate the activity of T₃. Indeed, CRYM binds to T₃ and NADPH and holds T₃ in 
cytoplasm, which increases the concentration of T₃ (Hashizume et al., 1989; Vie et al., 
1996). However, NADP inhibits T₃ binding and it is possible that for oxidative 
metabolism is another factor for control of T₃ binding to CRYM in cytoplasm 
(Kobayashi et al., 1991). It was reported that mutations in the CRYM gene have been 
linked to non-syndromic deafness in patients and this suggested that mutant CRYM 
could abrogate the affinity of thyroid hormone (Abe et al., 2003; Oshima et al., 2006). 
It is also notable that diabetic patients commonly suffer from thyroid dysfunction such 
as hyperthyroidism (Patricia, 2000). This finding supports the hypothesis that CRYM 
could have a possible role in thyroid hormone function.  
The glomerulus mainly consists of endothelial cells, podocytes and mesangial cells 
and the mesangial cells have a contribution in ECM production and accumulation 
(Greenberg, 1998). The previous study by Al-Kafaji (2010) showed that CRYM 
protein was elevated in HMCs (Al-Kafaji and Malik, 2010). Therefore, over-
expression of CRYM in these cells in diabetic mice might play an important role in 
diabetes-induced GBM thickening and ECM production. There are other factors such 





 Hyperglycaemia is known to be a key factor in pathological changes in DN (Kanwar 
et al., 2011). HTC involved in DN and their central role in injury to DN has been 
extensively studied (Qi et al., 2007). Therefore, HTC are an ideal model in which to 
unravel the cellular mechanism such as proliferation, contributing to the 
tubulointerstitial changes in DN and leading to the progression of renal failure in DN 
(Qi et al., 2007). Furthermore, other abnormalities in diabetes may contribute to the 
cause of pathological alterations of HTC. Hyperglycaemia is believed to be the main 
factor and induces renal injury through various complex and overlapping biochemical 
pathways that are involved in several key molecules, for example; TGF-β1, AGE 
products, protein kinase C, the polyol pathway, the hexoamine pathway and oxygen 
free radicals (Sheetz and King, 2002).  
In this study, we showed that CRYM is down-regulated by glucose in HTC. Human 
CRYM mRNA levels were reduced following exposure of cells to HG compared to 
NG. Unexpectedly, we found that when HTC were exposed to HG, its effect on 
CRYM was less; in fact, CRYM mRNA expression was decreased in HTC. Within 3 
days of exposing HTC to HG, tubular expression of human CRYM mRNA was 
reduced. Hence, the low regulation of human CRYM mRNA in response to high 
glucose observed was unexpected in our tubular cell model, as we previously found 
that human CRYM was increased in association with hyperglycaemia in the primary 
and transformed mesangial cell line. These changes suggest that this effect might be 
specific for certain cell types such as mesangial cells, rather than having a non-
specific cellular response. In response to this finding, we suggested that expression of 
CRYM  might be cell–type specific. 
CRYM protein expression in HTC was also examined by confocal microscopy and we 
found no changes in CRYM protein expression for HTC cultured in either NG or HG. 
In addition, cellular localisation of CRYM within HTC showed cytoplasmic 
localisation of CRYM protein in both NG and HG conditions. Therefore, this suggests 
that CRYM may be a cytosolic protein.  
As mentioned previously, CRYM is known to be involved in ROS (Al-Kafaji and 
Malik, 2010) and its altered expression in diabetes may play a role in oxidative stress 




Therefore, further studies are required to discover the potential role of CRYM in 
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Chapter 4. Circulating CRYM mRNA levels in peripheral blood of 
patients with diabetic retinopathy and nephropathy 
 
4.1. Abstract  
As we had shown that CRYM is regulated by glucose, the aim of this chapter was to 
determine if we can detect CRYM in peripheral blood and to see if its expression is 
associated with DN and DR.  
Two cross sectional studies were carried out to compare the expression of circulating 
CRYM mRNA in T2DM patients with and without retinopathy (n= 36), as well as 
with and without nephropathy (n= 99). Circulating CRYM mRNA expression was 
quantified using qPCR relative to the reference genes. Resulting data were analysed 
using student‟s t  test  and P<0.05 was considered significant. 
For the first time we demonstrated that low levels of CRYM mRNA can be detected 
in peripheral blood of patients with diabetes. We found that circulating CRYM 
mRNA levels were reduced by 2.9-fold in DR patients (P<0.05) compared to diabetic 
controls without retinopathy. Patients with retinopathy had a longer duration of 
diabetes and higher HbA1c and ACR in comparison to controls. 
In contrast, circulating CRYM mRNA levels were 7.4-fold higher in patients with 
nephropathy when compared with a large group of patients without nephropathy. 
Patients with nephropathy had a long duration of diabetes, and they also had higher 
ACR in comparison to patients without nephropathy.  
In summary, for the first time we were able to show that circulating CRYM mRNA is 
regulated in blood of patients with DR and DN. Circulating CRYM mRNA levels 
were decreased in patients with DR. However, they were increased in patients with 
DN. Therefore, it is currently unclear if this finding is indicative of different 









Patients with T1DM and T2DM have a much higher risk of complications involving 
many different systems within the body. DN and DR are major complications of 
diabetes which can result in end stage renal failure and blindness respectively 
(Brownlee, 2001). Currently, the presence of microalbuminuria is monitored in 
patients with DM (Cruickshanks et al., 1993). Microalbuminuria is defined as 
persistent albumin excretion rate of between 30 and 300mg/24 hours. 
Microalbuminuria is used as a marker for vascular damage (Stehouwer et al., 1992) 
and an indicator for nephropathy (Bojestig et al., 1996) and retinopathy of patients 
with diabetes (Cruickshanks et al., 1993). However, it is not indicative in the early 
stages and is usually detected once the microvasculature has been damaged 
(Mogensen et al., 1995) and is therefore not a predictive marker for diabetic 
complications. 
 Angiotensin-converting enzyme (ACE) inhibitors are current therapies for the 
treatment of DN which efficiently slow the development of DN (Lewis et al., 1993; 
Parving et al., 2001). Only 30% to 40% of patients with diabetes will develop disease. 
However, in all newly diagnosed diabetic patients the treatment is not desirable as 
these drugs have long-term side effects (Parving et al., 2001). Therefore, there is great 
demand for the identification of early markers and predictors, which will help to 
identify those patients with a higher risk of developing renal disease and this may 
prove beneficial for early treatments. 
Microvascular diseases are the result of several factors such as hyperglycaemia, 
glycated proteins and oxidative stress which activate metabolic pathways and PKC 
isoforms (Brownle, 2001). These factors can generate various growth factors in the 
kidney and they could be a potential marker for diabetic complications. TGF-β1, 
CTGF and podocytes-derived VEGF are some of the markers which have been 
proposed for the detection of the progression of microvascular diseases (Ziyadeh et 
al., 2008).  
TGF-β1 is believed to be an important profibrotic factor in the development of DN 
and it plays a role in GBM thickening which is the main characteristic of DN (Sharma 
and Ziyadeh, 1997; Ziyadeh, 2008). The increased activation of TGF-β1 is one of the 




extracellular matrix which may be an important contributor in DN (Loeffler and Wolf, 
2013; Wada et al., 2002; Zhu et al., 2007). There are many studies that show an 
association between circulating and renal TGF-β1 activity in the progression of DN. 
Sharma et al. (1997) found an increase of renal TGF-β1 in patients with diabetes and 
the urinary levels of TGF-β1 were significantly increased in those patients. TGF-β1 
mRNA levels and TGF-β1 receptor have also been shown to increase in db/db mice 
(Ziyadeh et al., 1999). Therefore, it can be used as a predictive marker for DN. 
However, further studies are required to define its role as a marker of DN progression 
(Jermus et al., 2008). 
CTGF is a member of CCN matricellular proteins which is induced by TGF-β1. 
CTGF is downstream of TGF-β1 and it is involved in renal fibrosis. It also has 
capability to bind to a number of growth factors for modifying its function (Mason, 
2009). Therefore, CTGF is a potential biomarker for DN. CTGF may act to meditate 
the actions of mesenchymal cells and also act as an effector of TGF-β1 (Grotendorst, 
1997; Mason 2009). Indeed, it can stimulate TGF-β1 signalling by binding directly to 
the growth factor, and stimulating its interaction with the TGF-β1 receptor (Mason 
2009). A number of findings showed the up-regulation of CTGF in DN. For example, 
Riser et al. (2003) showed that glomerular expression of CTGF is greatly up-regulated 
early in experimental and human diabetes. Urinary levels of CTGF were also elevated 
in STZ-diabetic animals (STZ-rats after 30 weeks) and they were increased in patients 
with DN compared to healthy controls (Riser et al., 2003).  
Similar to these results, Wahab (2005) showed that the glomerular CTGF mRNA and 
protein were increased at early stages of DN and continued to increase as DN 
progressed. They also concluded that both CTGF and CTGF-independent pathways 
mediate increased synthesis of fibronectin in hyperglycaemia. High levels of CTGF 
plasma has been demonstrated in patients with renal disease and was established to be 
a self-regulating predictor of kidney failure and mortality in T1DM patients with 
nephropathy (Nguyen et al., 2008). CTGF mRNA expression and protein levels were 
also more expressed in the podocytes and mesangial cells of murine models of DN 
(Roestenberg et al., 2004). Protein levels of CTGF also increased in proximal tubular 
epithelial cells in rodent models of type 1 diabetic nephropathy in STZ-rats (after 30 




Nevertheless, CTGF regulation in DN is likely to be a key factor in the progression of 
glomerulosclerosis by affecting matrix synthesis (Wahab 2005).     
While a number of studies indicated that the TGF-β1 pathway is a key mediator of 
mesangial matrix accumulation, there is doubt over the function of TGF-β1 as the 
main mediator of DN with albuminuria (Ziyadeh, 2008). Growing evidence suggests 
that VEGF has a pivotal role in microvascular complications of diabetes and perhaps 
it directly contributes to the proteinuria of diabetes rather than the extracellular matrix 
build up (Wolf et al., 2005). VEGF is a potent angiogenic and vasculogenesis factor, 
which is implicated in both DR and DN and also participates in the progression of 
albuminuria (Caldwell, 2003). In DR, VEGF is involved in the neovascularisation of 
PDR and plays a pivotal role in the retinal microvascular disease. Therefore, it has 
been proposed as an exciting target for therapeutic intervention in DR (Caldwell, 
2003).   
VEGF is involved in the progression of DN due to the reduction of hyperfilteration 
albuminuria and glomerular hypertrophy by neutralisation (Hovind et al., 2000; 
Flyvbjerg, 1998). Consistently, there was evidence which demonstrated that VEGF is 
up-regulated in the diabetic kidneys of diabetic animal models and also contributes to 
the progression of albuminuria (Chen et al., 2008). In patients with diabetes, VEGF is 
increased in both their urine and plasma. This phenomenon has been discussed in a 
study by Hovind (2000), who showed that plasma levels of VEGF were significantly 
increased in DN patients compared to patients with normalbuminuria. With regards to 
this, they suggest that VEGF is increased early in the course of DN in men with 
T1DM. A marked decrease in albuminuria of diabetic animals has been established 
through inhibition of VEGF activity by neutralising antibodies or small molecule 
inhibitors of VEGF receptor kinase in animal studies (Virese et al., 2001; Sung et al., 
2006). 
Taken together, it is noticeable that TGF-β1, CTGF and VEGF could be potential 
markers for diabetic complications and future therapeutic strategies might be based on 
their activity. For instance, anti-TGF-β1 treatments could counter the matrix 
accumulation. Therefore, strategies could reduce albuminuria by normalising over-
activity of CTGF and VEGF signalling (Ziyadeh et al., 2008).  However, it is very 




activity for these signalling pathways and they should not be much lower than normal. 
This is because a basal activity for each is necessary to make the optimal homeostasis 
of all types of glomerular cells (Lindenmeyer et al., 2007). It is vital for anti-TGF-β1 
strategies to be aware of the possible external inhibitions of the inflammatory 
properties of TGF-β1 (Ziadeh, 2008). One way to overcome this issue is to recognise 
other molecules as potential therapeutic markers in the TGF-β1 signalling pathway 
instead of inhibiting the whole signalling pathway. 
NSA2 is also a new marker for diabetic complications which was recently reported by 
Shahni et al. (2011). NSA2 is a putative cell cycle regulator in mammalian cells 
which became elevated in the kidney of a GK rat, a spontaneous model of T2DM. 
Shahni et al. (2011) showed for the first time that renal and circulating NSA2 levels 
are increased in the presence of HG in the experimental models of diabetes. In DN 
patients with albuminuria, NSA2 is elevated in their peripheral blood. They concluded 
that the circulating NSA2 mRNA levels were related to renal impairment within the 
patient population independent of other risk markers and it may also play a role in the 
pathology of DN.  
In the previous chapter we demonstrated that renal CRYM mRNA and protein levels 
were increased in STZ-induced diabetic mice. Previous studies have shown that 
CRYM is increased in cultured mesangial cells in response to glucose and the diabetic 
GK rats (Al-kafaji and Malik, 2010). Therefore, CRYM shows an increase in 
experiments like other putative biomarkers mentioned above such as NSA2, TGF-β1, 
CTGF and VEGF, all of which are increased in DN; for example, in circulating urine 











Aims and objectives of this chapter 
The main objective of this chapter was to evaluate circulating CRYM mRNA as a 
biomarker of DN and DR. The specific aims were as follows: 
1)  To detect CRYM mRNA in human blood  
2) To quantify the mRNA levels of circulating CRYM mRNA relative to the 
reference gene from T2D patient samples with retinopathy 
            3) To determine the best reference gene for quantification of human blood mRNAs 
4) To verify the circulating CRYM mRNA levels in type 2 DN patients  
Two sets of patient samples were used, which had been collected separately for this 
study: 
Diabetic retinopathy patient samples (DR): This set comprised of 36 patients from 
the study 07/H0806/120 recruited by Dr Sobha Sivaprasad (Section 2.5), of which 5 
patients had no retinopathy and were used as controls (T2D with > 10 years duration 
of diabetes) and 31 patients had progressive retinopathy (T2D with NPDR and PDR 
respectively; Section 2.5).  
Diabetic nephropathy patient samples (DN): Comprised of 99 patients with T2D, 
of which 30 patients had no nephropathy and 69 patients had DN. These samples were 
collected from SEEDA/JJ study (undertaken by Dr Malik and Professor Gnudi) and 
has been previously described (Section 2.5). 
4.3. Results 
4.3.1. Detection of CRYM mRNA in human blood 
There are no previous reports of CRYM expression in human blood; cDNA was 
synthesised from RNA (Section 2.6.4) to determine whether CRYM is expressed in 
the blood of DN patients, RNA was isolated from whole blood (Section 2.6.1), cDNA 
was synthesised and human CRYM primers (Section 3.3.2) were used to amplify the 
CRYM gene (Figure 17). The expressed 62 bp CRYM PCR product could be detected 
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   Figure 17. mRNA expression of  human CRYM in whole blood.  
   Total RNA (1µg) was extracted from whole blood of patients with and without  
   diabetic nephropathy. The RNAs were reverse transcribed to cDNA and amplified 
   by qPCR with hCRYM F1 and hCRYM R1 primers. M: 100 bp ladder, lane 1-6:  




4.3.2. Circulating CRYM mRNA levels in type 2 diabetic retinopathy patients 
CRYM mRNA levels were investigated in T2D patients with and without retinopathy. 
Samples were selected from the study 07/H0806/120, recruited by Dr Sobha 
Sivaprasad (Section 2.5). All the DR samples had been collected in PAXGENE tubes 
and RNA had been prepared by Dr Asif Butt, St Thomas‟ Hospital. cDNA 
corresponding to the set had also been previously prepared by Dr Shahni (KCL). The 
control samples from a separate SEEDA/JJ study were selected and converted to 
cDNA by Dr Shahni. This was used to determine circulating CRYM mRNA levels 
relative to GAPDH by measuring CRYM copy numbers and CT values using qPCR. 
● Absolute quantification of CRYM mRNA in the circulating blood of diabetic 
retinopathy patients, using qPCR standards 
CRYM copy numbers were quantified with each sample being carried out in triplicate 
using qPCR (Appendix 6). For each replicate sample, the values of both CRYM and 







CRYM copy numbers showed a huge variation in each replicate in both DR and the 
control group. We found that CRYM mRNA levels were low in the blood samples 
and CRYM copy numbers ranged from non-detectable to several thousands (Table 
17a). As shown in table 17a, CRYM copy numbers ranged from high (93650) to non-
detectable (0) showing variability in their expression. 
GAPDH mRNA levels were expressed more consistently in comparison to CRYM 
mRNA levels and their expression was much higher than CRYM mRNA levels (Table 
17a). However, there was a major difference in the DR group when compared to 
control, as there was less RNA in the control samples. Table 17a shows that the range 
of GAPDH copy numbers was between 500-10,000 in the control group, whereas the 
range in the DR group was more than 10,000. 
Table 17a. Range of CRYM and GAPDH copy numbers in all patients with and 
without retinopathy 
Name Range Control DR 



















We also examined the frequency distribution of both CRYM and GAPDH copy 
numbers from the entire data. The frequency distributions of both CRYM and 
GAPDH copy numbers were found to be positively skewed, due to the high variation 
of both CRYM and GAPDH copy numbers. Figure 18a showed that mean and 
standard deviation for both CRYM and GAPDH values were slightly higher as there 











Figure 18a. Frequency distribution of CRYM and GAPDH values in patients 
with and without retinopathy. 
Skewed distribution was obtained for both CRYM and GAPDH values. The mass 
distribution was concentrated on one side of the figures. The frequency distribution of 
both CRYM and GAPDH values showed a positive skew. 
 
We also measured CRYM copy numbers relative to GAPDH and the data were 
analysed using SPSS 20 with results being expressed as mean ± standard deviation 
(Table 17b). A student‟s t test analysis was performed with DR as the grouping 
variable and CRYM copy numbers as test variables to test for significant differences 
between groups with no DR (n= 5) and DR (n= 31). Error bars were then generated to 
represent the trend of the mean CRYM ratio in the respective types of diabetes. The 
ratio of most samples was very low due to low expression of CRYM mRNA levels. 
As described previously, our data were positively skewed. Therefore, our data were 
log transformed to achieve a symmetric distribution (Figure 18b). An analysis of log 
CRYM mRNA copy numbers in DR patients versus those without retinopathy for the 
whole data set showed a significant decrease (P<0.001; Table 17b) in CRYM copy 







Table 17b. Relative copy numbers and log copy numbers of CRYM in all 
patients with and without retinopathy 
Patient data 
set 




Log CRYM copy 
number relative 
to GAPDH±SD 




0.12 ± 0.13 
0.001 ± 0.002 
-1.16 ± 0.53 
-3.40 ± 1.04** 
Circulating CRYM mRNA copy numbers relative to GAPDH mRNA copy numbers 
were detected in all type 2 diabetic patients and log values were calculated. No DR: 
No diabetic retinopathy, used as control, DR: Diabetic retinopathy. **P<0.001 
 
 
Figure 18b. CRYM mRNA copy numbers in circulating blood from patients  
with diabetic retinopathy. 
A) Comparison of diabetic patients without retinopathy (No DR, n= 5) to those with 
retinopathy (DR, n= 31; -3.40 ± 1.04 vs. -1.16 ± 0.53) is illustrated as a boxplot 
(SPSS 20). B) A student‟s t test of the transformed values showed a highly 
significant difference in CRYM mRNA copy numbers of patients with and        
without retinopathy. **P<0.001 
.  
● Relative quantification of CRYM mRNA in circulating blood of DR patients, 
using the comparative CT method, i.e., 2
-δδC
T method 
In this part, we used CTvalues for relative quantification as well as absolute 
quantification. Relative quantification is the second most widely used method for 
processing qPCR data, where the PCR signal of the desirable gene in the experimental 
group is compared to that of a calibrator group such as the control group (Livak & 




difference in gene regulation among various groups. Conversely, absolute 
quantification is appropriate for resolving the exact number of gene copies present in 
a group. Thus, the comparative CT  method was used in this experimental study. 
For this purpose, the average threshold cycle number (CT) of the triplicates obtained 
for every sample and the CT of target gene (CRYM) to control gene (GAPDH) was 
measured. Next, the Delta Delta CT method was used with respect to the calibrator 
group (patients with only T2D, with a mean age of 50 ± 15 years and with > 10 years 
duration of diabetes). The fold difference in CRYM values was then worked out to 
determine the difference in CRYM ratio at different states, using the following 






The fold difference in CRYM ratio (mean ± SD) at different stages of DR for each 
sample was then determined (Appendix 7). The DR risk factors of the respective data 
were examined for significant differences with DR status. The data were analysed 
statistically using SPSS 20 to assess the significance of the differences noted in mean 
fold change of CRYM values with severity of DR and was log-transformed to achieve 
a normal distribution. 
A student‟s t test analysis was performed with DR as the grouping variable and 
CRYM fold difference as a test variable. The student‟s t test analysis showed a 
significant difference of CRYM log values between DR groups when compared with 
controls (-1.71 ± 1.77 vs. 1 ± 0.81, P<0.001, Table 17c). Patients with DR showed a 
0.5-fold decrease in the mean fold difference in the circulating CRYM mRNA values 
when compared with controls. The data showed the same trend in the fold-difference 
of CRYM ratio which was observed previously with CRYM copy numbers (Figure 
18c). 
 
δCT = Average CT CRYM - Average CT GAPDH 
δδCT = δCT of specific retinopathy stage -  Average δCT of calibrators 







Table 17c. Fold difference in CRYM ratio with respect to calibrators, at varying 
stages of diabetic retinopathy for the complete data set  
Patient data 
set 










24 ± 29.63 
1.17 ± 2.57 
1 ± 0.81 
-1.71 ± 1.77** 
CRYM mRNA CT values relative to GAPDH CT values were calculated in all type 2 
diabetic patients and log values were calculated. No DR: No diabetic retinopathy, 
used as control, DR: Diabetic retinopathy. **P<0.001 
 
                                                                                        
Figure 18c. CRYM mRNA CT values in the circulating blood from patients with 
diabetic retinopathy. 
A) Comparison of diabetic patients without retinopathy (no DR, n= 7) to those with 
retinopathy (DR, n= 41; -1.71 ± 1.77 vs. 1 ± 0.81) is illustrated as a box plot 
(SPSS 20). B) A student‟s t test of the transformed values showed a highly 




● Overall trend in the circulating blood CRYM mRNA regulation in DR 
Circulating CRYM mRNA expression was decreased in patients with DR compared 
to patients with no DR in both absolute (Figure 18b) and relative (Figure 18c) 
quantification. The relative quantification data support the absolute quantification data 
and they both demonstrated the same trend as each displayed a down-regulation of 
CRYM mRNA expression in patients with DR compared to controls.   
GAPDH mRNA levels were not constant as they exhibited an altered expression in 




strategies used to store blood and extracted RNA. However, it could also be because 
GAPDH is not a suitable reference gene for RNA normalisation from blood samples. 
4.3.3. Determination of the most stable reference gene for blood RNA 
To evaluate the most stable and reliable reference gene for our DN data, endogenous 
gene expression stability was measured using the geNorm and NormFinder Programs 
(Vandesompele et al., 2002). Both geNorm and NormFinder are the most popular 
algorithms for identifying the optimal normalisation gene for a set of candidate 
reference genes, by ranking them for normalisation according to their expression 
stability.  
Gene expression was quantified by normalisation for three different widely used 
endogenous control genes: β-Actin, PGK and PPIB (Table 5a, section 2.7). The 
expression patterns for these three reference genes were determined in 6 whole blood 
samples from T2DM patients with and without DN using qPCR (Table 18). They 
represented RNAs from each of the two quantitative methods. geNorm and 
NormFinder software were used to normalise the expression patterns, independent of 
mRNA expression levels. As shown in table 18, normalising the data to β-actin 
introduces large and variable errors into the analysis. Both programs picked two genes 
with the lowest M value which was the most stable, and conversely the gene with the 
highest M value was the least stable control gene. For whole blood samples, PGK 
(M= 0.54) were selected as the most stable genes and β-Actin (M= 0.818) was 
calculated as the least stable gene. In the following study, we have used PGKvalues as 












Table 18. Quantification of reference gene values in circulating blood of type 2 













PPIB, PGK and β-actin copy numbers were determined using qPCR. For each group, 
pre-used cDNAs was used and the average of each reference gene was quantified 
from each sample. T2DN: type 2 diabetic nephropathy, T2D: type 2 diabetes. 
4.3.4. Quantification of CRYM mRNA in circulating blood of patients, with and 
without nephropathy 
In this part of the study, CRYM mRNA levels in the circulating blood of type 2 
diabetic patients with and without nephropathy were compared. To determine 
circulating CRYM mRNA levels, selected samples from the SEEDA/JJ study (Section 
2.5) were used to measure CRYM mRNA copy numbers relative to PGK. A qPCR 
was carried out to measure the circulating CRYM copy numbers and the values were 
normalised by using the PGK. All samples were run in triplicate (Appendix 8). 
CRYM mRNA levels expressed were low in the circulating blood of patients. As 
shown in table 19a, CRYM copy numbers ranged from the highest (106) to the lowest 
(0) in whole data. PGK values also showed a constant expression in all the samples 
and their range was from 10 to 68. Thus, normalising PGK improved the data as PGK 
values showed more stability in their expression than we had found for GAPDH 




Samples  Group  PPIB PPIB Ave PGK PGK  Ave actin actin  Ave  
18  T2DN  6.85  9.55  8.20  80.30  68.90  74.60  2x 10³  8x10³  5x10³  
51  T2DN  14.50  17.50  16.00  73.20  68.90  71.05  5x10³  7x10²  2x10³  
282  T2DN  15.00  25.30  20.15  95.00  70.80  82.90  0  0  0  
172  T2D  17.10  38.40  27.75  84.00  73.60  78.80  0  0  0  
131  T2D  24.50  14.10  19.30  96.20  94.30  95.25  0  0  0  




Table 19a. Range of CRYM and GAPDH copy numbers in all patients with and 
without retinopathy 
Name Range Control DN-NA DN-A 

























We also examined the frequency distribution of both CRYM and PGK copy numbers 
from the entire data. The frequency distributions of both CRYM and PGK copy 
numbers were found to be positively skewed, as the tail was longer on one side 
(Figure 19a). This was because of high expression of CRYM and PGK in a few 
samples. Therefore, this affected the data distribution. CRYM values showed a mean 
of 13.2 and a standard deviation of 21.5 while PGK values had a mean of 6.5 and a 
standard deviation of 11.9. As figure 19a shows, the standard deviation for PGK 


















Figure 19a. Frequency distribution of CRYM and PGK values in patients with 
and without retinopathy. 
Skewed distribution was obtained for both CRYM and PGK values. The mass of 
distribution was concentrated on one side of the figures. The frequency distribution  
of both CRYM and PGK values showed a positive skew. 
 
 
A comparison of patients with no DN (n= 30) and patients with DN (n= 69) showed a 
significant 7.4-fold (P<0.001) increase in patients with DN (57.51 ± 98.17) compared 
to patients with no DN (7.76 ± 24.95; Table 19b). As the patient data were not 
normally distributed, the data were log transformed to achieve a symmetrical 
distribution (Figure 19b). 
Table 19b. Relative copy numbers and log copy numbers of CRYM mRNA in 
patients with type 2 diabetes nephropathy and without nephropathy 
Patient 
data set 






Log CRYM Copy 








7.76 ± 24.95 
57.51 ± 98.17** 
-0.17 ± 0.97 
1.29 ± 0.71** 
Circulating CRYM mRNA copy numbers relative to PGK copy numbers were 






                                                                                       
 Figure 19b.  CRYM mRNA copy in the circulating blood of patients with and 
 without diabetic nephropathy.  
A) Comparison of diabetic patients without nephropathy (control no neph, n= 30) to 
those with nephropathy (neph, n= 69; 57.51 ± 98.17 vs. 7.76 ± 24.9 and P<0.001) is 
illustrated as a boxplot (SPSSS 20). CRYM distribution is skewed and is increased in 
neph versus control no neph. B) The data were log transformed. A student‟s t test of 
the transformed values showed a highly significant difference. **P<0.001 
 
 
For further analysis, our patients with a history of albuminuria in this study were 
divided into groups: (1) Control: Patients with type 2 diabetes with > 10 years 
duration of diabetes, respectively, without history of albuminuria, with normal renal 
function, normal blood pressure (<130/80 mmHg) and taking no antihypertensive 
agents.  (2) Normoallbuminuria: ACR < 2.5 mg/mmol for men (albumin extraction 
rate AER <25 mg/day) and ACR < 3.5 mg/mmol for women (AER < 35 mg/day). (3) 
Albuminuria: ACR > 2.5 mg/mmol for men (AER >25 mg/day) and > 3.5 mg/mmol 
for women (AER > 35 mg/day). GFR was evaluated using the Modification of Diet in 
Renal Disease (MDRD) formula. 
In order to see if CRYM could be a potential predictive or diagnostic marker, the 
circulating CRYM mRNA copy numbers were analysed in DN patients with 
normalbuminuria (DN-NA) and DN patients with microalbuminuria or proteinuria 
(NA-A). The data showed that patients with DN-NA had a significant 11.7-fold 
higher CRYM mRNA expression in their blood compared to diabetic controls (Table 




Table 19c. Relative copy numbers and log copy numbers of CRYM mRNA in 
patients with nephropathy 
Patient 
data set 
Condition Number of 
patients 
CRYM copy 
number relative to 
PGK±SD 
Log CRYM Copy 












7.67 ± 24.55 
90.32 ± 133.68* 
31.79 ± 44.22* 
-0.14 ± 0.97 
1.48 ± 0.76** 
1.13 ± 0.63** 
Circulating CRYM mRNA copy numbers relative to PGK mRNA copy numbers were 
determined in patients with nephropathy and log values were calculated. DN-NA: 
nephropathy patients without microalbuminuria and DN-A: nephropathy patients with 
microalbuminuria. *P<0.05 and **P<0.001. 
 
                  
             Figure 19c. CRYM mRNA copy number in the circulating blood of diabetic 
              patients with and without nephropathy according to their blood function. 
A) Comparison of nephropathy patients with microalbuminuria or proteinuria (DN-A, 
n= 38) and nephropathy patients who had reverted to normallbuminuria (DN-NA, n= 
31) with diabetic controls (n= 30). The data are illustrated as a boxplot (SPSS 20). 
Circulating CRYM mRNA copy numbers were increased in patients with 
normalbuminuria (DN-NA) compared to control (90.32 ± 133.68 vs. 7.67 ± 24.55). B) 
The data were log transformed. A student‟s t test of the transformed values showed a 








● Overall trend in circulating blood CRYM mRNA regulation 
Circulating CRYM mRNA regulation showed a 7.4-fold increase in patients with 
nephropathy compared to patients without nephropathy (57.51 ± 98.17 vs. 7.76 ± 
24.95, P <0.001; Table 19b). In these patients, circulating CRYM mRNA levels was 
2.8-fold higher in those receiving medication who had reverted to microalbuminuria 
(DN-NA, n= 31) compared with those receiving medication with microalbuminuria 
(DN-A, n= 38; 90.32 ± 133.68 vs. 31.79 ± 44.22, P<0.05; Table 19c).   
In summary, the results showed that circulating CRYM mRNA levels were up-
regulated in T2DN-NA even after adjusting for predictor variables. These data 
suggest that there might be an association between circulating CRYM mRNA levels 
and DN as they significantly increase in DN patients. However, CRYM mRNA levels 
were reduced in DN-A patients and this reduction suggested a further biological role 
for CRYM in the progression of kidney failure. Thus, this result suggests the need for 
future studies to determine the function of CRYM in the circulating blood of patients 
with kidney failure. 
1) The association of clinical parameters in diabetic retinopathy and diabetic 
nephropathy patients  
Parallel to the demonstration of circulating CRYM mRNA in each set, clinical 
parameters were investigated for each set separately: 
● Diabetic retinopathy (DR set)  
Clinical parameters were also investigated in patients with type 2 diabetes with > 10 
years duration of diabetes and without retinopathy as controls (No DR, n= 5), type 2 
diabetes with severe retinopathy (DR, n= 31). The clinical parameters of the 
respective data were examined for significant differences with DR status. Student‟s t 
test analysis was performed with DR as the grouping variable and age, gender, 
diabetes duration, BMI, HbA1c, Systolic blood pressure, Diastolic blood pressure and 
cholesterol as test variables using SPSS 20. 
DR patients had a significant association with duration of diabetes; they had a lengthy 
duration of diabetes compared to control groups (17.10 ± 9.37 vs. 12.17 ± 3.86, 
P<0.05, Table 20) and they had a significant correlation with HbA1c (8.6 ± 1.67, 




(51.89 ± 50.26, P<0.001) and lower eGFR compared to controls (57.71 ± 23.42, 
P<0.05). It is noteworthy that the DR groups had 52% more ACR compared to No DR 
group (Table 20). 
Table 20. Baseline characteristic of diabetic patients with and without 
retinopathy 










Diabetes duration (years) 
 





32.55 ± 2.92 32.35 ± 7.68 
HbA1c (%) 
 
6.45 ± 2.11 
 




0.97 ± 0.54 
 
51.89 ± 50.26** 
eGFR (ml min–1 1.73 m–2) 
 
79.83 ± 25.41 57.71 ± 23.42* 




133.57 ± 17.67 
 
71.43 ± 11.25 
161.66 ± 135.57 
 
99.32 ± 145.07 
 
Cholesterol (mmol/L) 4.2 ± 4.8 5.8 ± 4.9 
BMI: body mass index, HbA1c: Haemoglobin A1c, ACR: albumin/creatinine ratio, 














● Diabetic nephropathy (DN set) 
As previously described, DN set was only composed of T2D (n= 30) and T2DN (n= 
69). For the control group, there were 17 women and 13 men with an average age of 
56 ± 12 years and slightly overweight (BMI of 29 ± 8 kg/m2, Table 21). Despite 
diabetes, their blood glucose was controlled and they had good blood pressure control 
(126 ± 20 mmHg). They also had normal renal function as their ACR, eGFR and 
albuminuria were all within a normal range. In the patient group with DN, there were 
34 women and 35 men with an average age of 63 ± 11 years (an average of 10 years 
older than the controls). Their blood glucose was high as their HbA1c was higher than 
the normal average (22 ± 32%) and their blood pressure was higher than the normal 
average (132 ± 24 mmHg). Their ACR was significantly higher when compared with 
the normal group (15.92 ± 41.92 vs. 1.36 ± 1.62, P<0.001) and they suffered from 
kidney disease as their ACR and albuminuria were higher than the normal range and 
eGFR was lower than controls (Table 21). 
Clinical parameters were also examined separately in DN patients with a history of 
albuminuria. Patients with T2DN-NA (n= 31) and T2DN-A (n= 38) were older than 
controls (n=30). There were less male in the T2DN-NA group and more female in the 
T2DN-A group (Table 21). The T2DN-A group had higher blood pressure compared 
to the T2DN-NA group and their BMI and HbA1c were nearly identical. Both groups 
had nephropathy as they had higher ACR and lower eGFR compared to the control 
group. However, the most important difference between DN-NA and DN -A was the 
difference in their ACR as they had 24% more ACR compared to the DN-NA group 
(Table 21). This implies that the T2DN-A group is progressing more speedily towards 
end stage renal disease, compared to the T2DN-NA group, despite both groups taking 
medication. 
A student‟s t test analysis was performed with DN as the grouping variable and age, 
gender, BMI, HbA1c, SBP and DBP and duration of diabetes as test variables using 
SPSS 20. Compared with diabetic controls, patients with DN showed a significant 
increase with their age, duration of diabetes and their ACR (P <0.05; Table 21). There 



















56.45 ± 12.33* 63.03 ± 11.72* 57.76 ± 11.03 66.79 ± 12** 
Gender (F:M) 
 
17:13 34:35 15:16 19:19 
Diabetesduration (years) 
 
14.66±27.41** 34.39±46.77** 35.16 ± 49.69* 32.89±44.57* 
BMI (kg/m2) 
 
29.93 ±8.46 29.55 ± 10.74 30.21± 10.96 29.08±10.54 
HbA1c (%) 
 
13.38±22.24 22.18 ± 32.11 22.65 ± 31.65 21.35±32.59 
ACR (mg/mmol) 
 
1.36±1.62** 15.92±41.92** 12.52 ± 30.51 
 
36.73±55.27* 
eGFR(ml min–1 1.73  
m–2) 
 
102.38±25.56 64.41 ± 16.5 67.16 ± 18.17 62.61±32.26 




132.56± 24.84 128.83±23.96 135.86±25.41 
Diastolic Bp (mmHg) 
 
77.2± 9.38  73.17± 14.55 73.86 ± 15.8 73.02±13.67 
     
BMI: body mass index, HbA1c: Haemoglobin A1c, ACR: albumin/creatinine ratio, 










In this chapter, we demonstrated for the first time that CRYM mRNA can be detected 
in the circulating cells of patients with DN. We also found that circulating CRYM 
mRNA levels were decreased in patients with DR. However, CRYM mRNA levels 
showed an increase in patients with DN.  
Circulating CRYM mRNA levels were measured in patients with type 2 DR (n= 31) 
and compared with patients with no DR (n= 5). CRYM copy numbers showed a large 
variation in their expression and CRYM copy numbers ranged from non-detectable to 
several thousand. GAPDH values were also not detected at constant levels. This 
difference in GAPDH levels in both the control and the DR groups is likely to be due 
to different RNA samples, as the samples for the control and the DR groups were 
collected by separate students and stored differently. 
Statistical analysis showed that circulating CRYM mRNAs were significantly 
decreased in patients who had severe retinopathy, compared with patients with no DR. 
Both absolute and relative quantification methods showed the same trend. The 
student‟s t test analysis revealed a significant relation between DR and ACR. There 
was also a significant correlation in patients with DR with other risk factors such as 
the duration of diabetes, HbA1c and eGFR.  
In the DN set, we found that circulating CRYM mRNA levels were significantly 
elevated in patients with T2DN (n= 69) compared to diabetic controls without DN (n= 
30). CRYM copy numbers were more consistent in DN data when compared to 
CRYM levels in DR data. However, their expression was still very low in circulating 
cells.  
Circulating CRYM mRNA levels were increased 7.4-fold in patients with T2DN and 
this effect was strongest in patients with well controlled nephropathy compared to 
those with proteinuria. This finding was contrary to our previous findings in the DR 
set. However, we used a different reference gene for the DN set, and samples were 
stored in different ways. 
In the DN set, there were some correlations between the patients with DN risk factors. 
All patients with T2D, T2DN-NA and T2DN-A had a significant correlation with the 




correlation with age and ACR. The increase of circulating CRYM mRNA levels in 
patients with DN in this study is interesting however as we do not have CRYM values 
for healthy controls, it is difficult to make a conclusion.   
As circulating CRYM mRNA levels increased in patients with DN and their mRNA 
expression pattern is similar to NSA2, it raises the theory that CRYM might be acting 
as a putative biomarker. However, we cannot confirm these results as circulating 
CRYM mRNA levels were expressed at low levels in whole blood. Furthermore, 
differences in how patient samples were stored may have affected the data. Thus, 
these results are an initial finding and they require further confirmation.  
An early determination of diabetic complications is not very applicable or useful. For 
instance, to detect DN in patients with diabetes requires urinary albumin extraction 
and declining GFR. However, these methods usually identify renal dysfunction only 
after a long duration of clinical silence when kidney damage has already begun 
(Glassock, 2010). Hence, it is necessary to discover new biomarkers that have 
predictive power. Emerging candidate biomarkers of renal and retinal dysfunctions 
contained markers of oxidative stress, inflammation, glomerular damage and 
endothial dysfunction. 
There are some promising new biomarkers which all show an increase in patients with 
DN. One such example is a cysteine protease inhibitor which is known as cystain C. 
Cystain C is elevated in the serum and urine of patients with DN (Pucci et al., 2007; 
Oddoze et al., 2011). Jeon (2011) has reported that patients with macroalbuminuria 
have higher levels of cystain C in their serum and urine along with an increasing 
degree of albuminuria. They also showed a significant correlation with GFR, ACR, 
and sex (Jeon et al., 2011). A renal liver-type fatty acid-binding protein (L-FABP), 
was another biomarker which was detected as increased in patients with type 2 
diabetes compared to healthy controls and this increase was associated with HbA1c, 
eGFR and cholesterol (Kamijo-Ikemori, 2011). 
It was surprising, in the context of our investigation, that circulating CRYM mRNA 
levels showed a different trend in the DR set compared to the DN set. This converse 
trend might be as a result of using different reference genes for DR and DN sets as 
they were expressed at different levels. PGK was determined as the most stable and 




showed that the expression of PGK levels is more consistent when compared with 
GAPDH and their standard deviation was lower than GAPDH. However, PGK was 
expressed at lower levels in circulating cells and their expression was close to CRYM 
expression. 
It would have been ideal to repeat our DR experiments with PGK to see if the same 
trend was followed or not. However, it was not possible to repeat the experiments 
with PGK owing to a lack of samples. Therefore, it is unclear if this observation is 
indicative of different pathophysiological processes in DR and DN, or is because of 
an experimental alteration. 
This was the first study of an examination of circulating CRYM mRNA levels in the 
whole blood of patients with diabetes. Owing to restrictions regarding Ethics  
Approval for this research, we could not determine levels of circulating CRYM 
mRNA in healthy controls. The inability to compare circulating CRYM mRNA in 
healthy controls versus diabetic patients makes it unclear whether or not circulating 
CRYM is associated with DN. Moreover, the low levels of CRYM mRNA expression 
in human whole blood samples suggest that it may not be a useful biomarker. 
Therefore, it remains to be established whether alteration in CRYM mRNA levels is a 
cause or a consequence of microvascular disease. Further studies should include the 
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Chapter 5. Are MOSC2 and MOSC1 glucose regulated 
genes both in vivo and in vitro? 
            5.1. Abstract 
We previously identified MOSC2 as one of several hyperglycaemia-induced renal 
genes in the GK rat, and showed that it was regulated by glucose in vitro in HMCs. In 
the current chapter we investigated the expression of MOSC2 and its homolog 
MOSC1 in models of diabetes and patient samples to explore their roles in the 
pathophysiology of DN. 
Kidneys (n= 3) were obtained from an acute STZ-induced mouse, and a β-phb2 KO 
mouse. Additionally, human renal (mesangial, embryonic kidney, tubular) cells grown 
in NG (5mM) and HG (25mM) and blood samples from diabetes patients with and 
without DN (n= 13) were used. mRNA levels were determined using qPCR relative to 
reference genes, and protein location/abundance was determined using 
immunofluorescence. Functional analysis included N-hydroxylation assays. 
MOSC2 mRNAs increased during hyperglycaemia in diabetic kidneys of STZ-induced 
diabetic mice and this increase was attenuated by treatment of diabetes (P<0.05). 
However, we could not find any change of renal MOSC2 expression in β-phb2 KO 
mice. Immunohistochemistry revealed abundant expression of MOSC2 protein in 
HTC, and very low expression in HMCs. We also found that MOSC1 was not 
regulated by glucose both in vivo and in vitro. Surprisingly, in HG, MOSC2 mRNAs 
showed a slight decrease in cultured HTC whereas they showed a significant increase 
in HMCs and HEK293 cells. Upon evaluation of MOSC2/MOSC1 mRNA levels as 
potential biomarkers of DN, we could detect low levels of MOSC1 but there was no 
expression of MOSC2. Biochemical analysis of MOSC protein showed that the N-
reductive activity was increased in diabetic conditions. Our data suggested that 
MOSC2 is a glucose-regulated gene and its glucose induction may be involved in 
glucose-induced pathways. However, we could not find any evidence that MOSC1 is 
regulated or altered. Circulating MOSC1 showed no changes in patients with DN, 
suggesting that MOSC2/MOSC1 are unlikely to be useful biomarkers for DN but may 





Hyperglycaemia contributes to DN and is the hallmark for diabetes mellitus (Christine 
et al., 1995). For the purposes of investigating novel therapeutic targets for DN, 
several novel genes that are regulated in the presence of hyperglycaemia in rodent 
models of DN and in HMCs were identified (Malik et al., 1998). Besides CRYM, 
there are a number of known glucose-regulated genes, such as CTGF (Burns et al., 
2006), serum glucocorticoid-regulated kinase (Feng et al., 2005), beta-defensin-1 
(Page et al., 2003), NSA2 (Shahni et al., 2011) and MOSC2 (CDK7) (Malik et al., 
2007). 
In this chapter, we will investigate the expression and function of MOSC2, a putative 
thiol-related gene; characterised as glucose regulated gene in vivo and in vitro. 
MOSC2 (CDK7) was first identified by the Malik group in 1997. They used 
differential display to determine genes that showed altered expression in the kidneys 
of the GK rat during the development of diabetes. A number of novel genes designated 
as candidate diabetes-associated kidneys (CDK) were recognised by cloning; MOSC2 
was one of several differentially expressed fragments from diabetic kidneys and 
named CDK7 (Table 22; Page et al., 1997). 
A cDNA library of the kidneys from a GK rat was probed and represented the MOSC2 
mRNA (Malik et al., 2007). From 100,000 screening clones, 5 clones which showed a 
strong hybridisation signal were sequenced. Sequencing showed that two clones of 
440 bp and two clones of 770 bp were partial cDNAs of the largest clone (1330 bp), 











Table 22. MOSC2 (CDK7) as one of 26 clones from diabetic rat kidneys. 
Clone Identity 
CDK1 Lactate dehydrogenase 
CDK2 NADH ubiquinone oxidoreductase 42KD subunit precursor 
CDK3 Enach, alpha subunit 
CDK4 Beta-defensin 
CDK5 NADH ubiquinone oxidoreductase 42KD subunit precursor 
CDK6 Megalin 
CDK7 MOSC2 
CDK8 Ubiquitin-like gene BC084728 
CDK9 Phosphatase inhibitor 
CDK10 Ubiquitin like novel 
CDK101 Hepatom a derived growth factor 
CDK102 H-protein 
CDK103 16s Rrna 
CDK104 Chemokine CXC 16 
CDK105 Novel, now called NSA2 
CDK106 Zfn1. Novel zinc finger protein 
CDK107 Schlafen 4 
CDK108 CRYM 
CDK109 RM 16S rRNA 
CDK120 RM cytochrome C oxidase subunit II 
CDK121 RM NAD dehydrogenase subunit 5 
CDK122 RM 16S rRNA 
CDK123 RM cytochrome C oxidase subunit I 
CDK124 RM cytochrome C oxidase subunit I 
CDK125 RM cytochrome C oxidase subunit I 
CDK126 RM cytochrome C oxidase subunit I 
 
MOC2 (CDK7) was one of 26 clones isolated by differential screening which showed 
a strong hybridisation signal in the kidneys of GK rat (Page et al., 1997). 
 
MOSC2 mRNA expression was measured in rat tissues using qPCR (Malik et al., 
2007). They showed that MOSC2 mRNA expression is abundant in the rat brain, 
heart, kidney, liver, lung, spleen, stomach and urinary bladder. They also found that 
MOSC2 mRNA is expressed at higher levels in the liver, kidney and urinary bladder 
and is expressed at lower levels in the heart and spleen. Furthermore, to investigate the 
expression of MOSC2 mRNA in renal diseases, Malik et al. (2007) examined MOSC2 
mRNA expression in the kidneys of GK as hyperglycaemic and Wistar as 
normoglycaemic rat models respectively. qPCR was used to precisely quantify mRNA 
expression of MOSC2 at different ages from the kidneys of both GK and Wistar rats. 
When compared with Wistar rats, GK rats are normoglycaemic at 6 weeks and 
progressively develop hyperglycaemia, being hyperglycaemic by 26 weeks. 




hyperglycaemia lead to elevation in Rat MOSC2 mRNA levels, compared to their 










Figure 20a. Effect of hyperglycaemia on the expression of MOSC2 (CDK7) mRNA in 
the kidneys of a GK rat.  
MOSC2 (CDK7) mRNA levels were quantitated in kidneys of GK rat at different ages 
using qPCR from at least two kidneys at each stage, with quantification being carried out in 
duplicate. The results are expressed as % values relative to those seen in age-matched 
Wistar rats (normoglycaemic controls). Taken from Malik et al., 2007. 
 
 
Using Southern blot, Malik et al. (2007) found that MOSC2 is a highly conserved gene 
in humans and they identified a homologue of human MOSC2 using BLAST. A 
hypothetical protein FLJ20605, was a homologue of MOSC2 as it showed a high 
sequence similarty (84%) to rat MOSC2 when analysed by the IMAGE consortium 
(Accession No.BC011973). Human MOSC2 mRNA expression is abundant in both 
human foetal and adult kidneys as well as HMCs (Malik et al., 2007). MOSC2 mRNA 
is widely expressed in various human tissues such as the foetal brain, foetal lung and 










 Figure 20b. mRNA levels of MOSC2 (CDK7) in some human tissues. 
A) MOSC2 (CDK7) mRNA is widely expressed in various human tissues such as 
lung, brain and kidney. The greatest amount of human CDK7 was found in liver 
tissue and the lowest amount was in spleen tissue. Taken from Malik et al., 2007. 
 
 
Malik et al. (2007) also looked at human MOSC2 mRNA expression in primary 
HMCs and a transformed HMCL which they cultured in NG, HG and NGM 
respectively (Malik et al., 2007). Human MOSC2 was significantly increased in cells 
exposed to HG compared to cells grown in NG; there was no significant difference in 
MOSC2 mRNA levels between human cells cultured in NG and NGM. They also 
reported that human MOSC2 mRNA was expressed in HMCs, confirming that 



















Figure 20c. MOSC2 (CDK7) is induced by glucose in cultured renal 
mesangial cells. 
Primary cultures of  mesangial cells (HMCs) and a transformed mesangial cell line 
(HMCL) were incubated in 5 mM glucose (NG), 25 mM glucose (HG) or 5 mM glucose 
and 20 mM mannitol (NGM). MOSC2 (CDK7) mRNA copy numbers were quantitated 
using qPCR (n = 3). The results are expressed as values relative to 5 mM glucose. Taken 
from Malik et al., 2007. 
 
 
MOSC2 is a highly conserved gene in humans, rats, mice and monkeys and it is a 
highly conserved protein within MOSC and MOSC-N domains which are located at 
residues 35-155 and 169-313. Interestingly, the highly conserved cysteines found at 
position 269 and 272 within the motif CPRC, resembled the catalytic domain found in 
thioredoxin. Thioredoxin is an enzyme which is involved in regulating the redox 
balance of the cells and it provides a highly conserved oxidoreductase system with 
antioxidant and redox regulatory roles (Schulze et al., 2004). Indeed thioredoxin is an 
antioxidant protein which uses the thiol group in oxidation and reduction-based 
signalling (Glyn-Jones et al., 2007).  
Thioredoxin is known to have an important role in hyperglycaemia-induced oxidative 
stress by interacting with protein through the inhibition of thioredoxin function 




within all MOSC2 homologues and its similarity to the thioredoxin protein catalytic 
domain, suggesting a functional link between thioredoxin and MOSC2. Furthermore, 
the thiol group found in cysteines can form disulphide bridges through oxidation. In 
many cellular proteins, the oxidation and reduction of thiol groups have a key role in 
the cellular antioxidant defense system as well as in intracellular signalling (Liang et 
al., 2007). They also showed that cellular thiol plays an important role in 
hyperglycaemia-induced tissue damage (Liang et al., 2007). In addition Ceriello 
(2000) found that the cellular antioxidant responses are defective in patients with DN 
(Ceriello et al., 2000). Morrison et al. (2004) also showed that changes in thiol protein 
levels are linked with DN progression. MOSC2, one of the genes involved in the thiol 
pathway, showed up-regulation in two experimental models of DN (Morrison et al., 
2004). Consistently, there was a presence of highly conserved cysteines in MOSC2 
protein, suggesting that MOSC2 is a novel thiol protein and is postulated to be 
involved in the cell response to oxidative stress (Malik et al., 2007). 
Human MOSC2 is located at chromosome 1q42.11 and the human MOSC2 gene spans 
35,917 and consists of eight exons. MOSC2 protein shows conservation in one 
tyrosine kinase phosphorylation domain and nine protein kinase C phosphorylation 
domains namely four N-myristilation sites and five casein kinase II sites. The MOSC 
domain has been detected in the molybdenum cofactor sulfurase and a number of 
proteins from both prokaryotes and eukaryotes; it is also a superfamily of β-strand-rich 
domains (Anantharaman et al., 2002). In relation, the proteins which have MOSC and 
MOSC-N domains are generated from the promitochondrial endosymbiont and have 
been involved in the synthesis of metal-sulfur clusters in the eukaryotic mitochondrion 
by their function as sulfur carrier proteins (Anantharaman et al., 2002). In the Malik 
laboratory, MOSC2 was used as a fusion protein which is localised to the cytosol and 
nucleus. They also purified the recombinant protein and sent it to Karolinska to be 
tested for thioredoxin-like activity (Shahni, 2011). 
The mitochondrial amidoxime reducing component, mARC, is a newly discovered 
molybdenum enzyme which complexes with two other components in the 
mitochondria; the electron transport proteins NADH-cytochrome b5 reductase 
(CYB5R) and cytochrome b5 (CYB5). mARC was first identified in porcine liver 
mitochondria in 2006 (Hvemeyer et al., 2006). The human genome codes for two 




capable of catalysing the activation of N-hydroxylated prodrugs. Havemeyer (2011) 
found that mARC is the fourth molybdenum containing enzyme and mARC2/MOSC2 
is the same as CDK7, which is located in the outer mitochondrial membrane. They 
also showed that mARC homologues contributed to the reduction of NOHA to L-
arginine (Figure 20d; Kotthaus et al., 2011) 
 
 
Figure 20d. Overview of L-arginine-dependent biosynthesis of Nitric Oxide (NO). 
In the L-arginine-dependent biosynthesis of Nitric Oxide (NO), N-hydroxy-L-arginine 
(NOHA) is the physiological substrate which can be reduced by reconstituted enzyme 




All analysed mammalian genomes include both MOSC1 and MOSC2 genes which 
share high sequence identity (Plitzko et al., 2013). On exploring the function of 
MOSC, they showed that both human MOSC proteins are involved in reduction of N-
hydroxylated substrates in vitro. Plitzko et al. (2013) also showed that MOSC is not 
capable of reducing N-hydroxylated substrates without the electron transport proteins. 
MOSC proteins were reported to work on the same N-hydroxylated substrates and this 
could be one of their physiological activities (Plitzko et al., 2013). 
The full-length transcript of MOSC1 encoded 385 amino acids which are homologue 
to moaA in Escherichia coli. The first cDNA from MOSC1 was homologue to various 
proteins which are involved in the synthesis of MOCO bacteria (Reiss et al., 2010).  
MALDI-TOF (matrix-assisted laser desorption ionisation-time-of-flight) mass 




is more localised at the outer mitochondrial membrane compared to MOSC1 (Katthaus 
et al., 2011). Recently, a genome wide association study (GWAS) found an association 
between MOSC1 with two important risk factors for coronary artery disease and 
accordingly, MOSC might play a role in lipoprotein metabolism (Neve et al., 2011). 
Studying the functional activity of MOSC proteins and testing the hypothesis that 
MOSC acts as an antioxidant in response to ROS could provide a novel therapeutic 
target for DN. The strategies that were undertaken to test this assumption are 
explained below: first we looked at the effect of HG on MOSC2/MOSC1 mRNA 
expression in experimental models of DN and in vitro; secondly we examined 
MOSC2/MOSC1 protein expression to confirm the mRNA study. We also looked at 
MOSC2 protein localisation in the kidneys of control and diabetic mice to determine 
their function using N-reductive assay. Circulating MOSC1 mRNA expression was 
also examined in T2DN patients to test if they were expressed in whole blood. 
Aims and objectives of this chapter 
1) To confirm and extend previous findings that MOSC2 is a glucose-regulated gene 
by using models of diabetes (in vivo and in vitro models). 
2) To determine if MOSC1 is regulated by glucose in vivo and in vitro. 
3) To find out if N-reductive activity (associated to MOSC2 and MOSC1) is increased 
in diabetes. 











5.3.1. Experimental models of diabetes used in this study 
In this study, we used diabetic mouse in vivo models and renal cell in vitro models. 
There were: a) β-Phb2 KO mouse, b) STZ mouse, c) HMCs, d) HEK293 cells and e) 
HTC.   
For in vivo models, kidneys (n= 3) were obtained from a β-Phb2 KO mouse and an 
acute STZ-induced mouse which we previously described (Section 3.3.1.). Human 
cultured renal cells (HMCs, HEK293, HTC) were incubated in different conditions 
until they reached confluence. They were growth arrested for 24 hours and were 
seeded in triplicate at a density of 10,000 in NG (5 mM), HG (25 mM) and NGM ( 
5mM glucose+ 20 mM mannitol) for a 3-day experiment (Section 2.3.1.). Samples 
were then stored in -80°C and used for mRNA and protein studies (Table 23). 
Table 23. In vitro renal cells models used in this study 




































5 mM glucose+20mM mannitol 
Human renal cells (human mesangial cells, human embryonic kidney cells, human 
tubular cells) grown in normal glucose (5mM), high glucose (25mM) and normal 
glucose with mannitol for 3 days. 
5.3.2. Gene expression assay for mouse and human MOSC2/MOSC1 
The aim of this part of the work was to set up a quantification assay for mouse and 
human genes of MOSC1 and MOSC2 to detect the mRNA levels of target genes in the 
in vivo and in vitro models. 
1) Primer design and amplification of mouse MOSC2/MOSC1 in vivo and in vitro 
a) In vivo: Oligonucleotide primers designed for the mouse MOSC2/MOSC1 mRNA 
sequence (Accession numbers NM_133684 and NM_001081361) were used to 
determine the MOSC2/MOSC1 transcript in mouse tissues. The MOSC2 sequence has 




encodes 342 amino acids (Appendix 9). Primers were designed using Roche Applied 
Science software and synthesised at Sigma-Aldrich (Table 24a). Figures 21a and 21b 
show the position of the primers used in this part of the study. 
 
Table 24a. Oligonucleotide primers used in PCR and RT-PCR 





mMOSC2F₁: Forward primer 
 






gga tcc cat ggg tga cag 
 
 
gga aga tgg cca tga gga 
mMOSC1F₁: Forward primer 
 
mMOSC1R₁: Reverse primer 
 
NM_001081361 60 bp 
 
att gtc atc tcg gga tgt gg 
 
 
tcc aat gag aac ctc gtt cc 
hMOSC2F₁: Forward primer 




187bp gac aca tgg tca ctg cc 
 
ttg cca cag tct ctg c 
hMOSC1F₁: Forward primer 
hMOSC1R₁: Reverse primer 
 
NM_022746 78 bp cca cag tgg acc cag aca 
c 
 
ggt cac act ggc gat aac 
tct 
 
The sequences are presented from 5` to 3` with F primers representing the sense 















        1 gtagcccagg cctgcccggg atagtgtaac atgggttcct ccagctctac ggctctggct 
       61 cgcctcggcc tccctgggca gccgcggtcc acctggctcg gcgtcgccgc gctggggctg 
      121 gctgcggtgg cgctggggac cgtagcttgg cgtcgcacgc gtccccggcg gcgccggcag 
      181 ctgcagcagg tgggcacggt gtcgaaggtt tggatctacc cgatcaagtc ctgcaagggg 
      241 gtgtcggtgt gtgagaccga gtgcacggac atggggctgc gctgtggcaa agtgcgcgac 
      301 aggttctgga tggtggtgaa ggaggacgga cacatggtca ctgcccgcca ggagcctcgc 
      361 cttgtgctgg tctccatcac cctggagaac aattacctga cgctggaagc tccaggcatg 
      421 gagcagatag ttctgccaat caagctccct tcttcgaata agatccacaa ctgcaggctg 
      481 tttggtctcg acatcaaagg cagagattgt ggcgatgagg tagctcagtg gttcaccaac 
      541 tacctgaaga cgcaagccta caggttggtt cagtttgata ccagcatgaa aggaagaaca 
      601 acgaagaaac tttacccttc tgaaagttac cttcagaact atgaggtagc ctacccggac 
      661 tgcagccctg tccacctgat ttctgaagcc tccttagtcg atctcaacac caggctgaag 
      721 aagaaagtga agatggaata tttcaggcca aacatcgtgg tgtcaggctg tgaggctttc 
      781 gaggaggata cttgggatga actcctgatt ggtgacgtgg agatgaaaag ggtgttgagc 
      841 tgtcccaggt gcgttctgac tacagtggac ccagacaccg gcatcataga caggaaggag 
      901 ccactggaga ccctgaagag ctatcgcctg tgtgatcctt ctgtgaagag tatataccag 
      961 tcatctccac tttttgggat gtatttctcg gtggagaagc ttgggagcct gagagtgggt 
     1021 gaccctgtgt accggatggt ggattagtgg atcccatggc tgacacgctt ccaggtccga 
     1081 ggagacatat ctgcgagtcc tcatggccat cttcctggaa ccggatctct atttttcttt 
     1141 cggagctgtg tacgccttga cttaattcaa gaaaagtgcc agaggtggtt taggaatgtg 
     1201 aggctgtata aattttagat aatgaggttt ttagaaaaat aaatggaatt tgtctgcaat 
     1261 tattctgaat gctacacccg ctattacgtt tttctcattc ctgcctctac gattgctgaa 
     1321 gtttaaagac acagctcgaa agctgccact tttaaaaaat gtttatactt ttcagtaggt 
     1381 ctgtcgcttg agaaaggtaa gaaaaggagc cctcttgccc tgaatgtgca gggaatgtgc 
     1441 acatatctga tgtgctcgca tgctcacgaa agcctgttgg ccggtcttgg cctggctgtt 
     1501 gagccctgct gagtttggtt tcattattgt ttaccttgct gttatagaag tatgcttaca 
     1561 tacagaaatg acttcagagg tcatggggtt attttgttca tagactgtgg ctttacattt 
     1621 cattctgttc ctatcaagac aggtagaact tatctataat tgtgaattct tccaattcta 
     1681 caagagagtg gaccttaaag gaatggaatc ttccttcgga agaaggaaca aggagaaacc 
     1741 atgaactcag tcttaaaggc tcacggtagc acaggatgat gcactagctt gcagtaacag 
     1801 tacaaacact aagttaacat ggagccgagt tagctctctt acagctgtgt ggttccattg 
     1861 tcattaataa gtgcgagtct ctc 
Figure 21a. Nucleotide sequence of mouse MOSC2 mRNA, accession number 
NM_133684 . 
The forward primer (MOSC2 F₁) is shown in blue and the reverse primer (MOSC2 R ₁) 
 is in green. The putative initiation codon is at position 31 and is in red. The stop codon  is 














        1 ggtgagattc cacagctgag ccaccacctc ccgcccaggc cgaatgaaga tgcacaattt 
       61 ggattggagg ggaagggtca ggagctgctg acctttgggc tcaggcccag gccgctggcc 
      121 acagtagctc ttggtccagt cggcgccgga ggtgtatcaa gcgctcatcc cgccctctcc 
      181 agtcatgggt gcggggtcct gggcgctgac cctcttcggc ttctccgcgt ttcgggtccc 
      241 gggccagccg cggtccacct ggctcggcgt cgccgcgctg ggactggccg cggtggccct 
      301 ggggacagtg gcctggcgtc gtgcgcgtcc ccggcgacgc cggcggctac agcaagtggg 
      361 aacggtggca cagctctgga tctacccaat caagtcctgc aaggggttgt cggtgagcga 
      421 ggcagagtgc actgccatgg ggctgcgcta tggccacctg cgcgacaggt tttggctcgt 
      481 gatcaatgaa gaggggaaca tggtcactgc ccggcaggag cctcgattgg tcctgatttc 
      541 tctgacctgt gaggacgaca ccttgactct cagtgcagct tacacaaagg acctgctgct 
      601 gcctatcacc ccgcctgcca caaacccact cctccagtgc agagtgcatg gcctggagat 
      661 acagggcagg gattgtggag aggatgcagc tcagtgggtc agcagcttct tgaagatgca 
      721 gtcctgtcgc ctggtgcact tcgagccgca catgcgcccc agaagttctc ggcaaatgaa 
      781 ggcttccaaa tcattttctc aaaataatga agtggcctac tcagatgcaa gtccattctt 
      841 ggtcctttct gaggcatcct tggaagatct caactccagg ctggagcgca gagtgaaagc 
      901 gacaaacttc aggcctaaca ttgtcatctc gggatgtggc gtttatgctg aggattcttg 
      961 gaacgaggtt ctcattggag atgtggaact gaaacgggtg atggcttgta cccggtgcct 
     1021 tttaacaaca gtggatccag acactggcat ctcggacagg aaggagcctc tggaaacact 
     1081 gaagagctac cgcctgtgtg acccttccga gcaagcacta tatggaaagt tacccatctt 
     1141 tggacaatac ttcgctctgg aaaatccagg gacaatcaga gtgggagacc ctgtgtacct 
     1201 cctgggccag tgatgggaac tgttcgttct ggaagaacag atggctctta aaaaaaaact 
     1261 tttacaaaca gacatcgctt gaaacagttc ttcagcctgt tctttggatc ggccagttcc 
     1321 aagtttctct tctttcagat ttccgtctgt ttcaatgttt cctggggcca gcccacaaag 
     1381 caggcaaata cagctttgcg aacttagcag gtccctgtta tgtttcttgt agaatgaagg 
     1441 gattatcata ttgccctgtt tataaatacg gagtaatcct tctacgtcgg aattcacttg 
     1501 ccaagacatc atctccctag ccttcttttg ggaaagagaa gaaaaaggga gggacactgt 
     1561 gtaagccaga agaatgttcc agaatgttct gttacccctg gacatggtgc atacaacggg 
     1621 aattaaatac tctcccaagt aaagttggaa tgacggcttt tacttttctc cttgagccca 
     1681 ggctttggaa agagtttaaa gagcaagccc taaagatatt ggatgctgtt gcttactgac 
     1741 agtgtgaagt ttgacagacc ctttagccca agaacacgaa gtgtcagggt caaagccagc 
     1801 tctctacagc atccagacgg gctctcagct ctgtgaaaaa ggtgtttcca ctcttgaagc 
     1861 aaagtgttga tgcgcctcac taaaggattc aagatcgttc ctagcatgtg gggacagata 
     1921 gtgacaccag agagggagat acctccgcct gggtgtctaa gatgagattt gatcttgccc 
     1981 aggaaaatgg tggctctctt aatatgagca aaatgaaatg gtggcgcccc ctagtggtag 
     2041 tgaatggtag gtcggcccac cttgagaaaa atttaaaaag gggaaaaaca aaacaaaaca 
     2101 aaaccaaagc aatcttgtgc ttgttgttta gttttaaatt ttaaaacgtt ttaaaaactg 
     2161 a 
Figure 21b. Nucleotide sequence of mouse MOSC1 mRNA, accession number NM-
001081361.  
The forward primer (MOSC1 F₁) is shown in blue and the reverse primer (MOSC1 R ₁) is in 
green. The putative initiation codon is at position 185 and is in red. The stop codon is also 











Primers for mouse MOSC2/MOSC1 were used to amplify a fragment of mouse 
kidney cDNA. PCR was carried out to confirm the product size of MOSC2 and 
MOSC1 genes using an annealing temperature of 60°C and 3mM concentration of 
MgCl₂. Products with the expected sizes of 60 bp, corresponding to MOSC1, and 
67 bp, corresponding to MOSC2, were observed (Figure 21C). 
 
                                                              1      2         3 
                                                        
       Figure 21c. PCR amplification of mouse MOSC2/MOSC1. 
PCR was carried out to amplify fragments of genes from a mouse kidney cDNA (1µg) 
with mouse MOSC2/MOSC1 primers, using 3mM concentrations of MgCl₂ at 60⁰C. 10 
µl of PCR products were subjected to electrophoresis on an agarose gel along with the 
100 bp DNA ladder. Lane 1 shows the 100 bp DNA ladder and lanes 2 and 3 are the 
PCR products of mouse MOSC1 and mouse MOSC2 respectively. 
 
 
b) In vitro: Oligonucleotide primers were designed for human as well as mouse 
MOSC2/MOSC1. Transcripts were based on the sequence of MOSC2 and MOSC1 
mRNA (Accession number NM_017898 and NM_022746) and they were used to 
determine MOSC2/MOSC1 mRNA transcripts in human renal cells (Table 24a). 
The sequence of human MOSC2 is 1618 bp and it encodes a peptide of 335 amino 
acids. The sequence of human MOSC1 is 2258 bp and it encodes a peptide of 337 
amino acids (Appendix 9). These primers were designed using Roche Applied 
software and synthesised by Sigma-Aldrich. Figure 21d and 21e show the position 
of the primers. 
67 bp mMOSC2 






        1 ggcttggtca ccgcattaag gcattcccgc tctccgcgga actgctctgc cgtctcggcg 
       61 gtgaaagtgt gagagggtcc gtagttgggt caactttgac tcctctcgcc tgcccggatc 
      121 cttaagggcc tcctcgtcct cccggtctcc ggtcgctgcc gggtctgtgc gccggtccgc 
      181 gcccgccctc gctctgccat gggcgcttcc agctcctccg cgctggcccg cctcggcctc 
      241 ccagcccggc cctggcccag gtggctcggg gtcgccgcgc taggactggc cgccgtggcc 
      301 ctggggactg tcgcctggcg ccgcgcatgg cccaggcggc gccggcggct gcagcaggtg 
      361 ggcaccgtgg cgaagctctg gatctacccg gtgaaatcct gcaaaggggt gccggtgagc 
      421 gaggctgagt gcacggccat ggggctgcgc agcggcaacc tgcgggacag gttttggctg 
      481 gtgattaagg aagatggaca catggtcact gcccgacagg agcctcgcct cgtgctcatc 
      541 tccatcattt atgagaataa ctgcctgatc ttcagggctc cagacatgga ccagctggtt 
      601 ttgcctagca agcagccttc ctcaaacaaa ctccacaact gcaggatatt tggccttgac 
      661 attaaaggca gagactgtgg caatgaggca gctaagtggt tcaccaactt cttgaaaact 
      721 gaagcgtata gattggttca atttgagaca aacatgaagg gaagaacatc aagaaaactt 
      781 ctccccactc ttgatcagaa tttccaggtg gcctacccag actactgccc gctcctgatc 
      841 atgacagatg cctccctggt agatttgaat accaggatgg agaagaaaat gaaaatggag 
      901 aatttcaggc caaatattgt ggtgaccggc tgtgatgctt ttgaggagga tacctgggat 
      961 gaactcctaa ttggtagtgt agaagtgaaa aaggtaatgg catgccccag gtgtattttg 
     1021 acaacggtgg acccagacac tggagtcata gacaggaaac agccactgga caccctgaag 
     1081 agctaccgcc tgtgtgatcc ttctgagagg gaattgtaca agttgtctcc actttttggg 
     1141 atctattatt cagtggaaaa aattggaagc ctgagagttg gtgaccctgt gtatcggatg 
     1201 gtgtagtgat gagtgatgga tccactaggg tgatatggct tcagcaacca ggagggattg 
     1261 actgagatct taacaacagc agcaacgata catcagcaaa tccttattat ccagccttca 
     1321 actatcttta ccctggaaaa caatctcgat ttttgacttt tcaaagttgt gtatgctcca 
     1381 ggttaatgca aggaaagtat tagagggggg aatatgaaag tatatatata aattttaggt 
     1441 actgaaggct ttaaaaataa ttaagatcat caaaaatgct attttgaatg ttatcatggc 
     1501 tattacactt ttacttcctg actttaatat tgatgaataa agcaagttta atgaatcaac 
     1561 taaaaagctg caaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaa 
 
Figure 21d. Nucleotide sequence of human MOSC2 mRNA, accession  
number NM_017898. 
The forward primer is shown in blue (MOSC2 F₁) and the reverse primer  
(MOSC2 R₁) is shown in green. The putative initiation codon is at position 















        1 acagcgccct gcagcgcagg cgacggaagg ttgcagaggc agtggggcgc cgaccaagtg 
       61 gaagctgagc caccacctcc cactccccgc gccgcccccc agaaggacgc actgctctga 
      121 ttggcccgga agggttcagg agctgcccag cctttgggct cggggccaaa ggccgcacct 
      181 tcccccagcg gccccgggcg accagcgcgc tccggccttg ccgccgccac ctcgcggaga 
      241 agccagccat gggcgccgcc ggctcctccg cgctggcgcg ctttgtcctc ctcgcgcaat 
      301 cccggcccgg gtggctcggg gttgccgcgc tgggcctgac cgcggtggcg ctgggggctg 
      361 tcgcctggcg ccgcgcatgg cccacgcggc gccggcggct gctgcagcag gtgggcacag 
      421 tggcgcagct ctggatctac cctgtgaaat cctgcaaggg ggtgccggtg agcgaggcgg 
      481 agtgcacggc catggggctg cgcagcggca acctgcggga caggttttgg cttgtgatca 
      541 accaggaggg aaacatggtt actgctcgcc aggaacctcg cctggtcctg atttccctga 
      601 cctgcgatgg tgacaccctg actctcagtg cagcctacac aaaggaccta ctactgccta 
      661 tcaaaacgcc caccacaaat gcagtgcaca agtgcagagt gcacggcctg gagatagagg 
      721 gcagggactg tggcgaggcc accgcccagt ggataaccag cttcctgaag tcacagccct 
      781 accgcctggt gcacttcgag cctcacatgc gaccgagacg tcctcatcaa atagcagact 
      841 tgttccgacc caaggaccag attgcttact cagacaccag cccattcttg atcctttctg 
      901 aggcgtcgct ggcggatctc aactccaggc tagagaagaa agttaaagca accaacttca 
      961 ggcccaatat tgtaatttca ggatgcgatg tctatgcaga ggattcttgg gatgagcttc 
     1021 ttattggtga cgtggaactg aaaagggtga tggcttgttc cagatgcatt ttaaccacag 
     1081 tggacccaga caccggtgtc atgagcagga aggaaccgct ggaaacactg aagagttatc 
     1141 gccagtgtga cccttcagaa cgaaagttat atggaaaatc accactcttt gggcagtatt 
     1201 ttgtgctgga aaacccaggg accatcaaag tgggagaccc tgtgtacctg ctgggccagt 
     1261 aatgggaacc gtatgtcctg gaatattaga tgccttttaa aaatgttctc aaaaatgaca 
     1321 acacttgaag catggtgttt cagaactgag acctctacat tttctttaaa tttgtgattt 
     1381 tcacattttt cgtcttttgg acttctggtg tctcaatgct tcaatgtccc agtgcaaaaa 
     1441 gtaaagaaat atagtctcaa taacttagta ggacttcagt aagtcactta aatgacaaga 
     1501 caggattctg aaaactcccc gtttaactga ttatggaata gttctttctc ctgcttctcc 
     1561 gtttatctac caagagcgca gacttgcatc ctgtcactac cactcgttag agaaagagaa 
     1621 gaagagaaag aggaagagtg ggtgggctgg aagaatatcc tagaatgtgt tattgcccct 
     1681 gttcatgagg tacgcaatga aaattaaatt gcaccccaaa tatggctgga atgccacttc 
     1741 ccttttcttc tcaagccccg ggctagcttt tgaaatggca taaagactga ggtgaccttc 
     1801 aggaagcact gcagatatta attttccata gatctggatc tggccctgct gcttctcaga 
     1861 cagcattgga tttcctaaag gtgctcagga ggatggttgt gtagtcatgg aggacccctg 
     1921 gatccttgcc attcccctca gctaatgacg gagtgctcct tctccagttc cgggtgaaaa 
     1981 agttctgaat tctgtggagg agaagaaaag tgattcagtg atttcagata gactactgaa 
     2041 aacctttaaa gggggaaaag gaaagcatat gtcagttgtt taaaacccaa tatctatttt 
     2101 ttaactgatt gtataactct aagatctgat gaagtatatt ttttattgcc attttgtcct 
     2161 ttgattatat tgggaagttg actaaacttg aaaaatgttt ttaaaactgt gaataaatgg 
     2221 aagctacttt gactagtttc agaaaaaaaa aaaaaaaa 
 
                      Figure 21e. Nucleotide sequence of human MOSC1 mRNA, accession number                  
                       NM_022746. 
The forward primer is shown in blue (MOSC1 F₁) and the reverse primer is shown in 
green (MOSC1 R₁). The putative initiation codon is at position 249 








cDNA from HEK293 cells in NG was used as a template in PCR to optimise 
MOSC2/MOSC1 primers. MOSC2 has previously been used by Malik et al. (2007), 
whereby the optimal conditions for both primers were established to be an 
annealing temperature of 55°C and 3mM concentration of MgCl2. PCR products 
were analysed by agarose gel electrophoresis. Products of the expected sizes of 187 
bp and 78 bp corresponding to MOSC2/MOSC1 were respectivel observed (Figure 
21f). Therefore, the internal primers successfully amplified MOSC2 and MOSC1 
fragments from the human kidney cDNA. 
 
A)     1         2                                    B)            1          2 
                       
               Figure 21f. PCR amplification of human MOSC2/MOSC1. 
 
                PCR was carried out to amplify fragments of MOSC2/MOSC1 genes from HEK293 cells 
               cDNA (1μg) with MOSC1 and MOSC2 primers, using 3 mM concentrations of MgCl2            
                at 55C. The PCR products (10μl) were subjected to electrophoresis along with the 100 bp  
              DNA Ladder. A) Lane 1: 100 bp DNA ladder, lane 2:187 bp of hMOSC2. B) Lane 
              1: 100bp DNA ladder, lane 2: 78 bp of hMOSC1. 
 
 
3) RNA isolation and cDNA synthesis from mouse tissues and human renal 
tubular cells 
To evaluate the regulation of MOSC2/MOSC1 mRNA in mouse tissues and human 
renal cells, RNA was isolated from each sample (Section 2.6.1.). The concentration 
and yield of RNA were determined by measuring the absorbance of RNA at A₂₆₀ using 
Nanodrop (Table 24b and 24c). For each condition, cDNAs were synthesised and 












Table 24b. Concentration of RNA isolated from mouse tissues 




























































RNA was extracted from kidneys of β-Phb2 KO and STZ-induced diabetic mice in 
vivo. RNA concentration in each condition was detected by measuring the absorbance 



























Table 24c. Concentration of RNA from cultured human renal cells 
 



































































































RNA was extracted from cultured human renal cells (human mesangial cells, human 
embryonic kidney cells and human tubular cells). RNA concentration in each 
condition was detected by measuring the absorbance at A₂₆₀ using Nanodrop. 
 
4)  Purification and generation of standard curves  
To test the hypothesis that MOSC2/MOSC1 may be regulated by glucose in the 
experimental mouse models in vivo and in vitro, we performed a qPCR using 
LightCycler and QuantiFast DNA SYBR Green Kit (Qiagene, UK) to accurately 




of MOSC2 and MOSC1 genes were purified to prepare standards for the generation of 
standard curves.  
A standard curve was created for mouse and human MOSC2/MOSC1 and the 
quantification of each sample was done in triplicate. To examine specificity, melting-
curve analysis was performed. Samples were normalised with respect to mRNA 
expression of reference genes. The concentration of the nucleic acids used as standards 
for target genes and reference genes (Appendix 10 and 11) were known. 
5.3.3. Glucose regulation of mouse and human MOSC2 in vivo and in vitro 
In this part, we first tested the hypothesis that mouse MOSC2 is a glucose regulated 
gene in kidneys from experimental models of β-Phb2 KO and STZ mice; their cDNA 
was used to test the effect of HG on their mRNA expression. To confirm the mRNA 
expression, we examined the protein expression in the kidneys of STZ mice by using 
western blot and we determined the location of the MOSC2 protein in control and 
diabetic kidneys of STZ mice by using immunofluresence. Following these findings, 
we observed the mRNA and protein expression of MOSC2 in human cultured renal 
cells (HMCs, HEK293 and HTC). 
1)  Quantification of renal CRYM copy numbers in βeta-Prohibitin2 knockout 
and streptozotocin-induced diabetic mice in vivo 
qPCR was performed with gene-specific primers to determine the expression of renal 
MOSC2 mRNA in control and diabetic kidneys of ß-Phb2 KO mice and also in 
control, diabetic and treated kidneys from STZ mice. qPCR experiments were 
performed in triplicate; cDNAs from each condition were used. Statistical analysis of 
the data using student‟s t test provided the mean, standard deviation and the p values 
for all conditions. 
 
● Renal mRNA levels of MOSC2 in the ß-Phb2 KO, a spontaneous model of 
diabetes 
Renal MOSC2 values were measured in control and diabetic kidneys of ß-Phb2 KO 
mice (Table 25a). The results showed no significant difference in renal MOSC2 
mRNA copy numbers in diabetic kidneys compared to control kidneys (1.02 ± 0.61 vs. 
0.59 ± 0.13, P>0.05; Table 25b). The data was log-transformed as the actual MOSC2 




Table 25a. Relative renal MOSC2 and GAPDH mRNA expression values of β-
Phb2 KO mouse kidney 


















































































Renal MOSC2 copy numbers relative to GAPDH mRNA copy numbers were detected 
using qPCR in control and KO mouse kidneys. For control, 4 separate kidneys and for 
the diabetic condition, 6 separate kidneys were used to prepare cDNA. Renal MOSC2 
was quantified from each sample in triplicate. Data are shown as relative expression 
values. 
 
Table 25b. Relative renal copy numbers of MOSC2 mRNA in kidneys of ß-Phb2 
KO mice 
Condition N Mean values ± SD of 
MOSC2 copy numbers 
Mean values ± SD of 
MOSC2 log 
Control 4 0.59  ± 0.13 -0.04 ± 0.23 
KO 6 1.02 ± 0.61 -0.23 ± 0.09 
Renal MOSC2 mRNA copy numbers relative to GAPDH copy numbers were detected 










Figure 22. Renal MOSC2 mRNA levels were elevated in diabetic ß-Phb2 KO mice 
kidneys.  
Mouse kidneys were collected from diabetic and control KO mice. Renal MOSC2 copy 
numbers were detected using qPCR (n= 3). The mean values and standard deviation of 
different experiments are shown. A) Values shown are copy numbers of renal MOSC2 mRNA 
relative to GAPDH. B) The data were log-transformed. P>0.05 
 
 
● Renal mRNA levels of MOSC2 in kidneys of streptozotocin-induced diabetic mice 
In the previous experiment, renal MOSC2 mRNA was found not to change in the 
presence of hyperglycaemia in ß-Phb2 KO mice. To determine whether MOSC2 
mRNA is regulated in the presence of hyperglycaemia in other diabetic mouse models, 
we investigated MOSC2 mRNA levels in control, diabetic and treated kidneys from 
STZ mice (Table 26a). The data showed a large increase in diabetic mice compared to 
control kidneys.  
The data were log-transformed, and the log data showed a significant difference 
between control and diabetic (0.53  0.25 vs. -0.2 ± 0.07, P<0.05; Table 26b) in the 
kidneys of STZ mice. The renal MOSC2 levels were higher in diabetic mice compared 
to control mice. This significant increase supports the association between renal 
MOSC2 mRNA expressions with hyperglycaemia. There was not a significant 
difference between renal MOSC2 levels of control and mice treated with STZ (-0.2  
0.07 vs. -0.07 ± 0.19, P>0.05). This data showed that hyperglycaemia can result in an 




Table 26a. Relative renal MOSC2 and GAPDH mRNA expression in kidneys of 
STZ mice 










































































Renal MOSC2 copy numbers relative to GAPDH mRNA copy numbers were detected 
using qPCR in control, diabetic and treated mouse kidneys. For each condition, 3 
separate samples were used to prepare cDNA and renal MOSC2 was quantified from 
each sample in triplicate. Data are shown as relative expression values. 
 
Table 26b. Relative copy numbers of MOSC2 mRNA in kidneys of STZ mice 
Condition N Mean values ± SD of 
MOSC2 copy numbers 
Mean values ± SD of 
MOSC2 log 
Control 3 0.63 ± 0.11 -0.2 ± 0.07 
Diabetic 3 3.82 ± 2.22  0.53 ± 0.25* 
Treated 3 0.89 ± 0.43 -0.07 ± 0.19 
Renal MOSC2 mRNA copy numbers relative to GAPDH copy numbers were detected 









             
 Figure 23.  Renal MOSC2 mRNA levels were elevated in diabetic STZ mouse kidneys. 
Mouse kidneys were collected from control, diabetic and cured mice. Renal MOSC2 copy   
numbers were detected using qPCR (n= 3). The mean values and standard deviation of 
different experiments are shown. A) Values shown are copy numbers of renal MOSC2  
mRNA relative to GAPDH. B) The data were log-transformed and showed an increase in 
renal MOSC2 mRNA expressions in diabeic kidneys. *P>0.05 
 
 
2) Renal levels of MOSC2 proteins in streptozotocin-induced diabetic mice 
The aim of this part of the study was to investigate the mouse MOSC2 protein 
expression in order to see whether hyperglycaemia enhanced protein expression of 
MOSC2. This part of the work was carried out in collaboration with Havemeyer group 
in Germany. Therefore, the same samples from the mouse MOSC2 mRNA expression 
experiments in a variety of kidneys from STZ mice were sent to Germany for protein 
analysis. Proteins from control, diabetic and treated kidneys (n= 3) of STZ mice were 
purified and assayed for total protein using a BCA protein assay kit (Pierce, UK). A 
dilution series of known concentrations of BSA protein was prepared (Section 2.11) 
and evaluated alongside protein samples from mice kidneys by measuring the 
absorbance at 450 nm using a plate reader (Table 27a). The concentration of protein 
samples was then determined according to the standard curve (Table 27b), which was 
produced by plotting A540 measurement for each BSA standard versus its concentration 
in mg/ml. The standard curve was used to detect the protein concentration of each 





Table 27a. Concentration, Mean and SD absorbance of BSA  
BSA concentration  
(mg/ ml) 




2 1.14 0.01 
1 0.72 0.05 
               0.5 0.35 0.08 
    0.25 0.28 0.00 
      0.125 0.13 0.01 
               0 0.08 0.03 
A dilution series of known concentrations of BSA protein was prepared and evaluated 




Table 27b. Concentration of protein from STZ mouse kidneys 




Control 16.2 0.1 
Control2 12.9 0.1 
Control3 17.8 0.4 
Diabetic1              6 0.8 
Diabetic2 13.3 0.1 
Diabetic3 15.3 0.7 
Treated1 16.8 0.4 
Treated2  22.5 0.2 
Treated3              17.1 2.1 
   
The concentrations of protein samples from kidneys of STZ mice were determined 
using the standard curve shown in Figure 24a. 
                         
 Figure 24a. Determination of protein concentration in STZ mice. 
 Dilution series of BSA protein was prepared and the concentration of each dilution 
 was assayed by measuring the absorbance at 540 nm.  
 





























Immunoblot analysis was carried out by blotting extracted proteins (12µl) separated by 
12.5% SDS-PAGE. The blot was incubated with anti-MOSC2 (MOCO sulfurase C-
terminal-domain-containing) antibody raised against mouse MOSC2 (1:2500 dilution; 
Sigma-Aldrich), followed by horseradish peroxidise-conjugated anti-rabbit IgG 
secondary antibody (1:10000 dilution; Jackson Immuno Research, UK). 
Immunoreactive bands were detected by ECL (Enhanced chemiluminescence) system 
(ECL plus Western blotting detection system; GE Healthcare). 
Figure 24b shows a representative immunoblot of the MOSC2 protein in control, 
diabetic and treated kidneys of STZ mice. The anti-MOSC2 antibody recognised an 
expected band of 34 kDa in STZ mouse kidneys. Induced expression of MOSC2 
protein was observed in all types of STZ mouse kidneys, as detected by the strong 
intensity of the protein band. These results confirmed the increase of MOSC2 mRNA 
expression in diabetic mouse kidneys compared to control and showed that 
hyperglycaemia increased mouse MOSC2 protein expression as well as mRNA 
expression, shown previously in this chapter. 
 
                                            Control              Diabetic           Treated        kDa 
                                   
                                   
             Figure 24b.Western blot analysis of mouse MOSC2 protein in kidneys of STZ mice. 
 
 Kidneys from control, diabetic and treated streptozotocin-induced diabetic mice 
 were used to show the mouse MOSC2 protein expression. Equal amounts of proteins (12 µg) 
 were subjected to SDS-PAGE and the expression of MOSC2 protein was detected by 
 immunoblot analysis using a primary antibody anti-MOSC2  raised against MOSC2. The blot 
 was re-probed with ß-actin antibody to demonstrate equal loading of protein in all lanes 
 (This part of work was carried out in the Havemeyer lab, Kiel, Germany, by Heyka  











3) Determination of MOSC2 protein in diabetic and control kidneys of 
streptozotocin-induced diabetic mice 
In this part of the study MOSC2 protein localisation was determined in control and 
diabetic mouse kidney sections using immunofluorescence. Mouse kidney sections 
were incubated with MOSC2 antibody overnight and anti-rabbit FITC conjugated 
secondary antibodies for 1 hour; nuclei were stained blue with DAPI (Section 2.14.2.). 
Sections were viewed under a fluorescent microscope (Eclipse TE 2000-U, Nikon). 
The fluorescent probe detected by the green emission indicated that the MOSC2 
protein was located predominantly in the tubules and not in glomerulus of the mouse 
kidney. The MOSC2 protein was expressed at relatively higher levels in the tubules, 
suggesting MOSC2 protein expressed in tubular cells but not in mesangial cells. The 
data also showed that MOSC2 is more abundant in diabetic kidneys compared to 
control kidneys, which confirmed findings from the immunoblot analysis in kidneys of 
STZ mice. In addition to higher expression of MOSC2 protein, the tubules were bigger 
(hypertrophy) and distorted in comparison to the control kidney (Figure 25). 
 
                            Control                                                           Diabetic 
      
      
Figure 25.  MOSC2 protein is highly abundant in tubular and less in glomerular cells 
from control and diabetic kidneys of STZ mice. 
 Sections of kidneys from control mice (blood glucose<11mmol/L) and diabetic mice (blood 
 glucose level >20mmol/L) were labelled with mMOSC2 primary antibody and FITC  
 conjugated secondary antibody and nuclei were stained with DAPI. White boxes are showing 
 no green staining in glomeruli, which indicated renal expression of MOSC2 in tubules but not 





4)  Is renal MOSC2 mRNA regulated by glucose in human cultured renal cells? 
Previously, Malik (2007) showed that renal MOSC2 is increased in HMCs and HMCL 
when cells were exposed to HG. We subsequently tested the hypothesis that mRNA 
expression levels of renal MOSC2 were up-regulated in human renal cells (HMCs, 
HEK293, HTC). In order to measure copy numbers of renal MOSC2 mRNA under 
different conditions, human cultured renal cells were incubated in different conditions 
as previously described (Section 5.3.1.) and total RNA was isolated from each sample 
(Table 24c, Section 5.3.2.). cDNA was then synthesized, MOSC2 values relative to the 
reference gene (PGK) were determined and the data was normalised. All qPCR 
experiments were performed in triplicate for each particular sample in all conditions 
and a blank control was included in all runs. 
● Effect of high glucose on renal MOSC2 mRNA expression in human cultured 
mesangial cells 
Copy numbers of renal MOSC2 mRNA relative to reference gene (PGK) were 
measured by qPCR (Table 28a). The data showed a significant elevation in renal 
MOSC2 copy numbers when the cells were exposed to HG compared to NG. This 
result was similar to the previous findings by Malik (2007). Statistical analysis of the 
data using student‟s t test showed that this elevation was significant (3.87 ± 1.07 vs. 
0.85 ± 0.58, P<0.05; Table 28b). There was no significant difference between cells 
which were exposed to NG and NGM (0.09 ± 0.07 vs. 0.85 ± 0.58, P>0.05). This 
demonstrated that there was no osmalarity effect in play (Figure 26). This finding 
supports our previous results and demonstrates that the expression of renal MOSC2 is 










Table  28a. Renal MOSC2 mRNA expression values relative to PGK in human 
mesangial cells cultured under different conditions 



















































































Renal MOSC2 mRNA copy numbers relative to PGK mRNA copy numbers were 
detected using real time PCR in human renal mesangial cells cultured in normal 
glucose (NG), high glucose (HG) and normal glucose with mannitol (NGM). For 
individual conditions, 3 separate samples were applied to prepare cDNA and MOSC2 
was quantified for each sample in triplicate. Data are shown as relative expression 
values. 
 
Table 28b. Relative copy numbers of renal MOSC2 mRNA in human mesangial 
cells 
Condition N Mean values ± SD of MOSC2 
copy numbers 
Mean values ± SD 
of MOSC2 log 
NG 3 0.85 ± 0.58 -0.13 ± 0.27 
HG 3 3.87 ± 1.07*  0.57 ± 0.12* 
NGM 3 0.09 ± 0.07 -1.2 ± 0.64 
Renal MOSC2 mRNA copy numbers relative to PGK mRNA copy numbers were 
detected in human mesangial cell line grown in normal glucose (NG) and high glucose 
(HG) and in normal glucose with mannitol (NGM). Copy numbers are shown as 









                                                                       
Figure 26. The effect of high glucose on renal expression of MOSC2 mRNA in mesangial 
cells. 
After being synchronised, human mesangial cells were grown in 5mM glucose (NG), 25mM 
glucose (HG) and normal glucose with mannitol (5mM glucose + 20mM mannitol) for 3 days. 
Renal MOSC2 copy numbers were measured using real-time PCR (n = 3). The mean values of 
3 different experiments are shown. A) Values shown are copy numbers of renal MOSC2 
mRNA relative to PGK. B) The data showed an increase of renal MOSC2 levels in human 
mesangial cells exposed to HG. *P<0.05 
 
 
● Effect of high glucose on renal MOSC2 mRNA expression in human cultured 
embryonic kidney 293 cells 
In the previous experimental study, we showed that renal MOSC2 was up-regulated in 
HMCs upon exposure of cells to HG. To test the hypothesis that renal MOSC2 also 
regulated in HEK293 cells, copy numbers of renal MOSC2 mRNA relative to PGK 
were measured by qPCR (Table 29a). Using student‟s t test for statistical analysis of  
the data, we found a significant increase in HG compared to NG (0.36 ± 0.03 vs. 0.04 
± 0.02, P<0.05; Table 29b). There was a non-significant difference between cells 
grown in NG with cells grown in NGM (0.15 ± 0.04 vs. 0.04 ± 0.02). The data were 
log-transformed as the actual copy values of MOSC2 were skewed. These results 










Table 29a. Renal MOSC2 mRNA expression values relative to PGK in human 
embryonic kidney 293 cells cultured in different conditions 
 
Renal MOSC2 mRNA copy numbers relative to PGK mRNA copy numbers were 
detected using real time PCR in human embryonic kidney 293 cells cultured in normal 
glucose (NG), high glucose (HG) and normal glucose with mannitol (NGM). For 
individual conditions, 3 separate samples were applied to prepare cDNA and renal 
MOSC2 was quantified for each sample in triplicate. Data are shown as relative 
expression values. 
 
Table 29b. Relative copy numbers of renal MOSC2 mRNA in human embryonic 
kidney 293 cells 
Condition N Mean values ± SD 
of hMOSC2 copy 
numbers 
Mean values ± SD 
of hMOSC2 log 
NG 2 0.04 ± 0.02 -1.32 ± 0.19 
HG 3 0.36 ± 0.03* -0.44 ± 0.04 
NGM 3 0.15 ± 0.04 -0.83 ± 0.12 
Renal MOSC2 mRNA copy numbers relative to PGK mRNA copy numbers were 
detected in human embryonic kidney 293 cells grown in normal glucose (NG), high 
glucose (HG) and in normal glucose with mannitol (NGM). Copy numbers are shown 







































































































Figure 27. The effect of high glucose on renal expression of MOSC2 mRNA in human 
embryonic kidney 293 cells. 
After being synchronised, human embryonic kidney 293 cells were incubated in 5mM (NG), 
25 mM glucose (HG) and normal glucose with mannitol (5mM glucose + 20mM mannitol) 
for 3 days. Renal MOSC2 copy numbers were detected applying qPCR. The mean values of 
different experiments are shown. A) Values shown are copy numbers of renal MOSC2 
mRNA relative to PGK. B) The data showed an increase of renal MOSC2 levels in cells 
exposed to HG.*P<0.05 
 
 
● The effect of high glucose on MOSC2 mRNA expression in human cultured 
tubular cells 
 As we found an up-regulation of renal MOSC2 by glucose in HMCs and HEK293, we 
examined the renal MOSC2 mRNA relative to reference gene (PGK) by qPCR (Table 
30a). Surprisingly, we found a 2.15-fold decrease in renal MOSC2 copy numbers 
when cells were grown in HG compared to NG. Statistical analysis using student‟s t 
test showed a significant reduction of renal MOSC2 in cells grown in HG compared to 
NG (P<0.05; Table30b). However, the difference between NG and NGM was not 
significant, confirming no effect of osmolarity. HTC cultured in HG contained 0.2 ± 
0.1 copies of renal MOSC2, whereas when cultured in NG, HTC contained 0.43 ± 0.05 
copies of renal MOSC2 (Figure 28). These data showed that renal MOSC2 is 







Table 30a. Renal MOSC2 mRNA expression values relative to PGK in human 
tubular cells cultured in different conditions 



















































































Renal MOSC2 mRNA copy numbers relative to PGK mRNA copy numbers were 
detected using qPCR in human tubular cells cultured in normal glucose (NG), high 
glucose (HG) and normal glucose with mannitol (NGM). For individual conditions, 3 
separate samples were used for preparation of cDNA and renal MOSC2 was quantified 
for each sample in triplicate. Data shown are relative expression values. 
 Table 30b. Relative copy numbers of renal MOSC2 mRNA in human tubular 
cells 
Condition N Mean values ± SD of 
MOSC2 copy numbers 
Mean values ± SD of  
MOSC2 log 
NG 3 0.43 ± 0.05 -0.36 ± 0.07 
HG 3 0.2 ± 0.1* -0.7 3± 0.28 
Mannitol 3 0.9 ± 1.3 -0.47 ± 0.75 
Renal MOSC2 mRNA copy numbers relative to PGK mRNA copy numbers were 
detected in human tubular cells grown in normal glucose (NG) and high glucose (HG) 















Figure 28. Effect of high glucose on renal expression of MOSC2 mRNA in human 
tubular cells. 
After being synchronised, human tubular cells were incubated in 5mM (NG), 25mM glucose 
(HG) and normal glucose with mannitol (5 mM glucose + 20mM mannitol) for 3 days. 
MOSC2 copy numbers were detected by real-time PCR (n= 3). The mean values of 3 
different experiments are shown. a) Values shown are copy numbers of renal MOSC2 mRNA 
relative to PGK. b) The data showed a decrease in human tubular cells exposed to HG. 
*P<0.05 
 
5) Does hyperglycaemia result in increased renal MOSC2 protein levels in human 
cultured renal cells? 
We have previously found that the human MOSC2 gene is directly up-regulated by 
glucose in HMCs and HEK293 cells. However, we found a down-regulation of 
MOSC2 mRNA expression in HTC. The aim of this part of the study was to determine 
the human MOSC2 protein levels to see the effect of HG on its protein expression. For 
the protein analysis, cell pellets from human cultured renal cells (HMCs, HEK293, 
HTC) grown in different conditions were saved from mRNA expression (Table 24c, 
Section 5.3.2.). For human MOSC2 protein, cell pellets were centrifuged and lysed in 
an appropriate lysis buffer and then cell lysate including the protein was recovered and 
examined. 
A dilution series of  known concentrations of BSA protein was prepared (Section 
2.11.) and measured alongside protein samples from human renal cell lysates (HMCs, 
HEK293, HTC) by measuring the absorbance at 540 nm using a plate reader (Table 
31a). The concentrations of the protein samples were then determined according to 
their respective standard curves (Table 31b). The standard curve was produced by 




mg/ml. The standard curve was then used to assay the protein concentration of each 
particular sample (Figure 29a). 
Table 31a. Concentration, mean and SD absorbance of BSA in human cultured 
renal cells 
Cells BSA concentration  
in cells (mg/ml) 
Mean Absorbance  
(540 nm) 












































A dilution series of known concentrations of BSA protein was prepared and evaluated 
alongside protein samples from human cultured renal cells (human mesangial cells, 
human embryonic kidney 293 cells, human tubular cells) by measuring the 














Table 31b. Concentration of protein from human renal cells 




HMCsl NG  0.7 0.03 









HMCs5 HG  1.7 0.25 









HMCs9 NGM  0.6 0.19 
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 Figure 29a. Determination of protein concentration in human renal cells. 
 
 Dilution series of BSA protein was prepared and the concentration of each dilution was  
              assayed by measuring the absorbance at 540 nm. A) Determination of BSA protein  
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Immunoblot analysis was carried out by blotting extracted proteins (25 µg) separated 
by 12.5% SDS-PAGE. The blot was incubated with anti-MOSC2 antibody raised 
against human MOSC2 (diluted 1:500; Abgent, USA; Sigma-Aldrich), followed by 
horseradish peroxidise-conjugated anti-rabbit IgG secondary antibody (1:10000 
dilution; Jackson Immuno Research, UK). Immunoreactive bands were detected by 
ECL (Enhanced chemiluminescence) system (ECL plus Western blotting detection 
system; GE Healthcare). 
● MOSC2 protein levels in human renal cells grown under different conditions 
Figure 29b shows a representative immunoblot of MOSC2 proteins in human renal 
cells grown under NG, HG and NGM conditions. The anti-MOSC2 antibody did not 
detect any band of the expected size of 34 kDa for all conditions of HMCs. In 
HEK293 cells, induced expression of MOSC2 protein was observed in cells exposed 
to HG compared to NG but the bands were faint (Figure 29b). For the HTC samples, 
the concentrations of protein samples from HTC (Table 31b) were determined using 
the standard curve shown in Figure 29a. The concentration of protein samples was too 
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            Figure 29b. Western blot analysis of MOSC2 protein in human mesangial and  
            human embryonic kidney 293 cells. 
Human cultured renal cells were serum-starved and exposed to normal glucose (5mM), high 
glucose (25mM) and normal glucose with mannitol (20+5 mM) for 3 days. Equal amounts of 
cell lysate proteins (25µg) were subjected to SDS-PAGE and the MOSC2 protein expression 
was determined by immunoblot analysis using rabbit polyclonal IgG primary antibody raised 
against MOSC2. The blot was re-probed with anti-calnexin antibody to determine the equal 
loading of protein in all lanes (This part of work was carried out in the Havemeyer lab, Kiel, 
Germany, by Heyka Jacob in collaboration with our group). 
 
 
5.3.4. Is MOSC1 a glucose regulated gene in vivo and in vitro models? 
In this section, we looked at the effect of hyperglycaemia on MOSC1 mRNA 
expression in STZ-induced diabetic mice in vivo. We also examined mRNA and 
protein regulation of MOSC1 in human renal cells (HMCs, HEK293, HTC) in the 
presence of hyperglycaemia. 
● Renal mRNA levels of MOSC1 in kidneys of streptozotocin-induced diabetic mice 
First, we examined renal MOSC1 mRNA expression in control (n= 3), diabetic (n= 3) 
and treated (n= 3) kidneys of STZ-induced diabetic mice which were the same samples 
used previously for MOSC2 mRNA expression (Table 24b; Section 5.3.2). Copy 
hMOSC2 in 
HMCs 




anti-calnexin   
 
hMOSC2 in     








numbers were automatically measured from their concentration and samples were 
normalised with respect to expression of GAPDH mRNA. All qPCR experiments were 
performed in triplicate (Table 32a). Statistical analysis of the data using student‟s t test 
provided the p values for all conditions. 
 
Table 32a. Relative Renal MOSC1 and GAPDH mRNA expression values in the 
kidneys of STZ mice 









































































Renal MOSC1 copy numbers relative to GAPDH mRNA copy numbers were detected 
using real-time qPCR in control, diabetic and treated mice kidneys. For each 
condition, 3 separate samples were used to prepare cDNA and renal MOSC1 was 
quantified from each sample in triplicate. Data are shown as relative expression 
values. 
Renal MOSC1 mRNA copy numbers were elevated compared to control kidneys and 
they were corrected by treatment. However, statistical analysis of the data using 
student‟s t test showed that this increase was not significant (39.33 ± 50 vs. 4.33 ± 
7.50, P>0.05; Table 32b). The standard deviation was very large in diabetic kidneys 
compared to control and treated kidneys (Figure 30). We also could not determine the 
MOSC1 protein levels in control, diabetic and treated kidneys as no antibody against 
mouse MOSC1 exists. With this in mind, we did not examine further models of 









Table 32b. Relative copy numbers of renal MOSC1 mRNA in kidneys of STZ 
mice 
Condition N Mean values ± SD of  
MOSC1 copy numbers 
Mean values ± SD 
of MOSC1 log 
Control 3 4.33 ± 7.50 -1.33 ± 2.08 
Diabetic 3 39.33 ± 50.65  1 ± 1 
Treated 3 1.33 ± 2.30 -1 ± 2 
Renal MOSC1 mRNA copy numbers relative to mGAPDH copy numbers were 




Figure 30. Effect of high glucose on renal MOSC1 mRNA levels in the kidneys of STZ 
mice. 
Mouse kidneys were collected from control, diabetic and treated kidneys of STZ mice. Renal 
MOSC1 copy numbers were detected using real-time qPCR (n= 3). The mean values and 
standard deviation of different experiments are shown. A) Values shown are copy numbers of 
renal MOSC1 mRNA relative to GAPDH. B) The data were log-transformed and results were 




● Effect of high glucose on renal MOSC1 mRNA expression in human cultured 
mesangial cells 
To determine if MOSC1 is a glucose-regulated gene, we examined renal MOSC1 
mRNA expression in human cultured renal cells (HMCs, HEK293, HTC) from the 
samples previously used for renal MOSC2 mRNA expression (Table 24c; Section 
5.3.2). As renal MOSC2 was regulated by glucose in HMCs and HEK293 cells, we 





Renal copy numbers of MOSC1 mRNA relative to control gene (PGK) were measured 
by qPCR in HMCs (Table 33a). Statistical analysis of the data using student‟s t test 
showed that these results are non-significant (Table 33b) and there is no significant 
difference between each condition. The data were log-transformed, as the actual 
MOSC1 copy number values were not normally distributed (Figure 31).  
Table 33a. Renal MOSC1 mRNA expression values relative to PGK in human 
mesangial cells cultured in different conditions 



















































































Renal MOSC1 mRNA copy numbers relative to PGK mRNA copy numbers were 
detected using real time PCR in human renal mesangial cells, cultured in normal 
glucose (NG), high glucose (HG) and normal glucose with mannitol (NGM). For 
individual conditions, 3 separate samples were applied to prepare cDNA and renal 
MOSC1 was quantified for each sample in triplicate. Data are shown as relative 
expression values. 
Table  33b. Relative copy numbers of MOSC1 mRNA in human mesangial cells 
Condition N Mean values ± SD 
of MOSC1 copy 
numbers 
Mean values ± SD of 
MOSC1 log 
NG 3 0.44 ± 0.12 -.036 ± -0.13 
HG 3 0.66 ± 0.58 -0.28 ± 0.36 
NGM 3 0.24 ± 0.09 -0.36 ± 0.16 
Renal MOSC1 mRNA copy numbers relative to PGK mRNA copy numbers were 
detected in human mesangial cell lines grown in normal glucose (NG), high glucose 
(HG) and in normal glucose with mannitol (NGM). Copy numbers are shown as 











Figure 31. The effect of high glucose on renal expression of MOSC1 mRNA in 
human mesangial cell. 
After being synchronised, human mesangial cells were grown in 5 mM glucose (NG), 25 mM 
glucose (HG) and normal glucose with mannitol (5 mM glucose + 20 mM mannitol) for 3 
days. Renal MOSC1 copy numbers were measured using qPCR (n= 3). The mean values of 3 
different experiments are shown. A) Values shown are copy numbers of renal MOSC1 mRNA 
relative to PGK. The results were not significant. B) After log-transformation of data, results 
were still not significant. P>0.05 
 
 
● Effect of high glucose on Renal MOSC1 mRNA expression in human cultured 
embryonic kidney 293 cells 
Renal copy numbers of MOSC1 mRNA relative to reference gene (PGK) were 
measured by qPCR in HEK293 cells grown in NG, HG and NGM respectively (Table 
34a). The data showed the same trend that we found in HMCs and it showed a non-
significant difference between HEK293 cells cultured in HG compared to NG (0.87 
±0.24 vs. 1.62 ± 0.98, P>0.05; Table 34b). Statistical analysis of the data using 









Table 34a.  Renal MOSC1 mRNA expression values relative to PGK in human 
embryonic kidney 293 cells cultured in different conditions 
Renal MOSC1 mRNA copy numbers relative to PGK mRNA copy numbers were 
detected using real time PCR in human renal embryonic kidney 293 cells cultured in 
normal glucose (NG), high glucose (HG) and normal glucose with mannitol (NGM). 
For individual conditions, 3 separate samples were applied to prepare cDNA and renal 
MOSC1 was quantified for each sample in triplicate. Data are shown as relative 
expression values. 
 
Table 34b. Relative copy numbers of renal MOSC1 mRNA in human embryonic 
kidney 293 cells 
Condition N Mean values ± SD of 
MOSC1 copy 
numbers 
Mean values ± SD 
of MOSC1 log 
NG 4 1.62 ± 0.98 0.11 ± 0.37 
HG 4 0.87 ± 0.24 -0.06 ± 0.11 
NGM 4 1.76 ± 0.98 0.20 ± 0.20 
Renal MOSC1 mRNA copy numbers relative to PGK mRNA copy numbers were 
detected in human renal human embryonic kidney 293 cells grown in normal glucose 
(NG), high glucose (HG) and in normal glucose with mannitol (NGM). Copy numbers 






















































































































Figure 32. The effect of high glucose on renal expression of MOSC1 mRNA in human 
embryonic kidney 293 cells. 
After being synchronised, human embryonic kidney 293 cells were grown in 5 mM glucose 
(NG), 25 mM glucose (HG) and normal glucose with mannitol (5 mM glucose+20mM 
mannitol) for 3 days. Renal MOSC1 copy numbers were measured using qPCR (n = 4). The 
mean values of 3 different experiments are shown. A) Values shown are copy numbers of 




● The effect of high glucose on renal MOSC1 mRNA expression in cultured human 
tubular cells. 
We could not demonstrate any change in renal MOSC1 mRNA expression in HTC. 
Renal copy numbers of MOSC1 mRNA relative to reference gene (PGK) in NG, HG 
and NGM of HTCs were measured by qPCR (Table 35a). Student‟s t test revealed no 
significant difference between NG and NGM (0.33 ± 0.15 vs. 0.61 ± 0.4, P>0.05; 
Table 35b), thereby suggesting the absence of osmolarity effect. Cells cultured in HG 
showed a non-significant difference in renal MOSC1 copy numbers when compared to 
those cultured in NG (P>0.05). HTC cultured in HG contained 0.27 ± 0.16 copies of 
renal MOSC1, whereas those cultured in NG contained 0.33 ± 0.15 copies of MOSC1 
relative to PGK. The changes between MOSC1 mRNA levels were not significant 









Table 35a. Renal MOSC1 mRNA expression values relative to PGK in human 
tubular cells cultured in different conditions 



















































































Renal MOSC1 mRNA copy numbers relative to PGK mRNA copy numbers were 
detected using qPCR in human tubular cell lines cultured in normal glucose (NG), 
high glucose (HG) and normal glucose with mannitol (NGM). For individual 
conditions, 3 separate samples were applied to prepare cDNA and renal MOSC1 was 
quantified for each sample in triplicate. Data are shown as relative expression values. 
Table 35b. Relative copy numbers of Renal MOSC1 mRNA in human tubular 
cells 
Condition N Mean values ± SD of MOSC1 
copy numbers 
Mean values ± SD of  
MOSC1 log 
NG 3 0.33 ± 0.15 -0.50 ± 0.21 
HG 3 0.27 ± 0.16 -0.65 ± 0.38 
Manitol 3 0.61 ± 0.40 -0.27 ± 0.30 
Renal MOSC1 mRNA copy numbers relative to PGK mRNA copy numbers were 
detected in human tubular cell lines grown in normal glucose (NG), high glucose (HG) 













Figure 33. The effect of high glucose on renal expression of MOSC1 mRNA in human 
tubular cells. 
After being synchronised, the tubular cells were incubated in 5 mM (NG), 25 mM glucose 
(HG) and normal glucose with mannitol (5 mM glucose + 20 mM mannitol) for 3 days.  
Renal MOSC1 copy numbers were detected by qPCR (n= 3). The mean values of 3 different 
experiments are shown. A) Values shown are copy numbers of renal MOSC1 mRNA relative 
to PGK. B) The data were log-transformed and results were not significant. P>0.05 
 
 
To conclude our observations, renal MOSC1 expression was found to remain 
unchanged in human renal cells (HMCs, HEK293, HTC) in HG. 
3) Does hyperglycaemia result in increased MOSC1 protein levels in human 
cultured renal cells? 
We have previously shown a non-significant difference in MOSC1 mRNA expression 
in human cultured renal cells. The aim of this part of the study was to determine 
MOSC1 protein levels in vitro in order to see the effect of HG on protein expression as 
well as mRNA expression. For the protein analysis, we used the same samples which 
were used for determining the expression of MOSC2 proteins in human cultured renal 
cells (Table 31b; Section 5.3.3). 
Immunoblot analysis was carried out by blotting extracted proteins (25 µg) separated 
by 12.5% SDS-PAGE. The blot was incubated with anti-MOSC1 antibody raised 
against MOSC1 (diluted 1:1000; Abgent, USA) followed by horseradish peroxidise-
conjugated anti-rabbit IgG secondary antibody (1:10000 dilution; Jackson Immuno 
Research, UK). Immunoreactive bands were detected by ECL (Enhanced 




Healthcare). Figure 34 shows the representative immunoblot of MOSC1 protein in 
NG, HG and NGM of HMCs. The anti-MOSC1 recognised an expected band of 35 
kDa which was very faint. In HEK293 cells, the anti-MOSC1 gave a band of 35 kDa 
corresponding to the expected molecular size of positive control (Figure 34). There 
was no major difference in MOSC1 protein expression in all conditions as the bands 
were almost identical. In HTC, MOSC1 was not determined as its concentration was 
too low in these cells (Table 31b; section 5.3.3). 
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Figure 34. Western blot analysis of MOSC1 proteins in human mesangial and human 
embryonic kidney 293 cells. 
Human mesangial cells and human embryonic kidney 293 cells were serum-starved and 
exposed to normal glucose (5 mM), high glucose (25 mM) and normal glucose plus mannitol 
(20+5 mM) for 3 days. Equal amounts of cell lysate proteins (25µg) were subjected to SDS-
PAGE and MOSC1 protein expression was determined by immunoblot analysis using rabbit 
polyclonal IgG primary antibody raised against MOSC1.The blot was re-probed with anti-
calnexin antibody to determine the equal loading of protein in all lanes (This part of work was 


















5.3.5. Investigation of N-reductive activity of MOSC in vivo and in vitro 
In this part, we examined the N-reductive activity for both MOSC2 and MOSC1 in 
vivo and in vitro. The same samples saved from mRNA and protein studies were sent 
to Germany for N-reductive assay performed by the Havemeyer group. Previous 
studies by Havemeyer (2011) showed that MOSC2 is involved in the N-reductive 
pathway and it reduces N-hydroxylated compounds (Havemeyer et al., 2011). We 
previously showed that MOSC2 mRNA and protein were up-regulated in diabetic 
mice and HMCs, HEK293 cells under HG condition. Thus, it was interesting to 
determine whether N-reductive activity was also affected by glucose. 
The endogenous function and substrates of the MOSC enzyme system are unknown. 
However, there is some evidence that MOSC is capable of reducing N-hydroxylated 
structures such as our model compound benzamidoxime (Havemeyer et al., 2011). 
Therefore, our hypothesis was to investigate whether N-reductive activity was 
increased in the presence of HG. 
1) The effect of high glucose on N-reductive activity of MOSC in vivo 
To test the hypothesis that N-reductive activity may be increased by glucose, we sent 
kidneys from control, diabetic and treated of STZ mice to Germany. The Havemayer 
group measured N-reductive activity for MOSC2 and MOSC1 in control, diabetic and 
treated kidneys of STZ mice. Samples were incubated with an incubation buffer and 
substrate buffer and their N-reductive activity were respectively calculated (Section 
2.16). The protein activity for each sample was also measured for MOSC-activity as it 
reflects the complete reduction for both MOSC2 and MOSC1. Statistical analysis was 
performed for N-reductive activity and the results were shown as mean ± standard 
deviation (Sigma plot 11). 
The results showed a 2.4-fold increase in the diabetic kidneys of mice when compared 
to control kidneys (Table 36). Statistical analysis of data using Tukey test showed a 







Table 36. The mean and SD of protein activity of MOSC in STZ mice kidneys  
Condition N Mean values ± SD of 
protein activity (nmol 
Benzamide/ min × mg) 
Control  3 1.8 ± 0.5 
Diabetic  3 4.4 ± 0.6* 
Treated  3 4.6 ± 0.03 
The protein activity of MOSC was detected in kidneys of streptozotocin-induced 
diabetic mice. Values are shown as mean±SD. *P<0.05 
 
 
Figure  35. The increase of N-reductive activity in diabetic kidneys of mice. 
The N-reductive activity for MOSC protein was measured in control (n= 3), diabetic (n= 3)  
and treated (n= 3) kidneys of streptozotocin-induced diabetic mice. The N-reductive activity 
showed a significant increase.* P<0.05 (This part of work was carried out in the Havemeyer 
lab, Kiel, Germany, by Heyka Jacob in collaboration with our group). 
 
2) Effect of high glucose on N-reductive activity of MOSC in vitro 
Human renal cells (HMCs, HEK293, and HTC) were cultured in NG, HG and NGM 
for 3 days. The culture media were then removed and divided for mRNA, protein 
expression and N-reductive assays. To determine N-reductive activity, the human 
renal cells were incubated with an incubation and substrate buffer. The incubation time 
and protein content were subsequently calculated (Section 2.16). The protein activity 





































complete reduction for both MOSC2 and MOSC1. To determine the N-reductive 
activity, statistical analysis was used and results were shown as mean and standard 
deviation (Sigma plot 11). 
Statistical analysis of data was performed using the Tukey test for analysis of variance 
and a significant increase between HG and NG of HMCs was found (P<0.05, Table 
37). HMCs cultured in HG (0.59 ± 0.08) showed a 2-fold increase compared to NG 
(0.29 ± 0.03). Similar results were obtained with HEK293 cells: HEK293 cells 
cultured in HG showed 1.3-fold increase compared with those cultured in NG (P<0.05; 
Table 37). There was a significant difference between cells grown in HG and NG 
(0.58 ± 0.03 vs. 0.44 ± 0.02, P<0.05; Figure 36a). 
Table 37. The mean and SD of MOSC protein activity in human renal cells  
Cells Condition N Mean values ± SD of protein 







0.29 ± 0.03 
0.59 ± 0.08* 







0.44 ± 0.02 
0.58 ± 0.03* 







0.7 ± 0.02 
0.7 ± 0.04 
0.8 ± 0.5 
The protein activity of MOSC was detected in human cultured renal cells (human 
mesangial cells, human embryonic kidney 293 cells, human tubular cells) separately. 









                   
Figure 36a. The increase of N-reductive activity in human mesangial and human 
embryonic kidney 293 cells in the presence of high glucose. 
The N-reductive activity for MOSC protein was measured in 5 mM (NG) or 25 mM glucose 
(HG) or 5 mM glucose + 20 mM mannitol (NGM) of both human mesangial cells (n= 3 for 
each condition) and human embryonic kidney 293 cells (n= 4 for each condition). The N-
reductive activity showed a significant increase. (Red: HMCs, Blue: HEK293), *P<0.05 (This 
part of work was carried out in the Havemeyer lab, Kiel, Germany, by Heyka Jacob in 




We found an increase of N-reductive activity in cells exposed to HG in both HMCs 
and HEK293 cells. In order to examine the N-reductive activity in HTC, MOSC2 and 
MOSC1 activity were measured. Statistical analysis of data using a Tukey test for 
analysis of variance showed a non-significant difference between all conditions as the 
protein concentration of HTC was low (Table 37). In these samples, the differences in 
the mean values among all groups were not great enough to exclude the possibility that 
the difference is due to random sampling variability; there was no statistically 













































Figure 36b.The N-reductive activity in human renal tubular cells. 
The N-reductive activity for MOSC protein was measured in 5 mM (NG) , 25  mM glucose 
(HG) and normal glucose with mannitol (5 mM glucose +20  mM mannitol) of human tubular 
cells (n=3 for each condition). The N-reductive activity did not show any change in HG.  
P>0.05 (This part of work was carried out in the Havemeyer lab, Kiel, Germany, by Heyka 
Jacob in collaboration with our group). 
 
          5.3.6. MOSC1 mRNA expression in peripheral blood of patients with DN 
Previously, the Malik group showed that MOSC2 mRNA could not be determined in 
the circulating blood of patients with DN, suggesting that MOSC2 mRNA was not 
expressed in human blood (Shahni, Thesis 2011). Su (2004) established that human 
MOSC1 mRNA is expressed in white blood cells. Therefore, we tested MOSC1 
mRNA expression in patients with T2DN to see if MOSC1 was expressed in 
circulating blood. 
In this part of study and for the first time, MOSC1 mRNA levels in the circulating 
blood of patients with Type 2 diabetes and with no DN were compared. To determine 
MOSC1 mRNA expression, 0.2 ml of whole blood stored in RNAlater was used to 
measure MOSC1 mRNA copy numbers relative to the reference gene. mRNA was 






































out using hMOSC1 F₁ and hMOSC1 R₁ primers (shown in table 24a; section 5.3.2.) 
and the data were normalised to PGK.  
1) Grouping for analysis purposes 
The data consisted of 13 patients with only T2D, of which 5 patients had no DN and 8 
patients had T2DN with onset after the age of 35 and controlled by diet or established 
oral hypoglycaemic treatment and/or insulin. These samples were collected from 
SEEDA/JJ study (Section 2.5) and were previously used for CRYM study. 
● Are circulating MOSC1 mRNA levels altered in patients with type 2 diabetic 
nephropathy? 
To confirm whether MOSC1 could be a potential predictive or diagnostic marker, 
circulating MOSC1 mRNA levels in the blood of patients with type 2 DN were 
compared with patients with no DN. All samples were analysed in triplicate. No 
change in MOSC1 mRNA levels was found upon comparing patients with no DN 
(30.27 ± 59.27) against patients with T2DN (21.62 ± 47.47; Table 38a). As the patient 
data were not normally distributed and were skewed, the data were log-transformed to 
achieve a symmetric distribution (Figure 37a). 
 
Table 38a. Relative copy numbers and log copy numbers of circulating MOSC1 






MOSC1 copy number 








30.27 ± 59.27 
21.62 ± 47.47 
0.69 ± 0.98 
0.51 ± 1.03 
Circulating MOSC1 mRNA copy numbers relative to PGK copy numbers were 











Figure  37a. MOSC1 mRNA copy in the circulating blood of patients with and without 
diabetic nephropathy.  
A)  Comparison of diabetic patients without nephropathy (control no neph, n= 5) to those with 
nephropathy (neph, n= 8; 30.27 ± 59.27 vs. 21.62 ± 47.47 and P>0.05) is illustrated as a 
boxplot (SPSSS 20). B) The data were log-transformed and showed a non-significant 
difference in circulating MOSC1 levels of patients with diabetic nephropathy. P>0.05 
 
 
For further analysis, the patients in this study with a history of albuminuria were 
divided into groups: (1) Control: Patients with type 2 diabetes of > 10 years duration, 
with no history of albuminuria, with normal renal function, normal blood pressure 
(<130/80 mmHg) and taking no antihypertensive agents. (2) Normoalbuminuria; ACR 
< 2.5 mg/mmol for men (albumin extraction rate AER <25 mg/day) and ACR < 3.5 
mg/mmol for women (AER < 35 mg/day). (3) Albuminuria; ACR > 2.5 mg/mmol for 
men (AER >25 mg/day) and > 3.5 mg/mmol for women (AER > 35 mg/day). GFR 
was evaluated using the Modification of Diet in Renal Disease (MDRD) formula. As 











Table 38b. Relative copy numbers and log copy numbers of circulating MOSC1 






















30.27 ± 59.27 
5.7 ± 4.13 
69.4 ± 98.01 
 
0.69 ± 0.98 
0.5 ± 0.71 
0.55 ± 2.24 
 
MOSC1 mRNA copy numbers relative to PGK mRNA copy numbers were determined 
in patients with nephropathy and log values were calculated. NA: nephropathy patients 





Figure 37b. MOSC1 mRNA copy number in circulating blood from diabetic patients 
with and without nephropathy according to their blood function. 
A) Comparison of nephropathy patients with microalbuminuria or proteinuria (DN-A, n= 2)  
and nephropathy patients who had reverted to normallbuminuria (DN-NA, n= 6) with diabetic 
controls (n= 5). The data are illustrated as a boxplot (SPSS 20). B) The data were log-
transformed and showed a non-significant result. P>0.05 
 
 
● Association of clinical parameters 
The data was composed of controls (n= 5) and DN (n= 8). For the control group, there 
were 3 women and 2 men with an average age of 65 ± 10.51 years and who were 




their blood glucose was controlled and they had good blood pressure control (119.4 ± 
14.08 mmHg). They also had normal renal function as their ACR, eGFR and 
albuminuria were all within normal range. In the patient group with DN, there were 2 
women and 6 men with an average age of 62.5 ± 11.01 (an average of 10 years older 
than the controls). Their blood glucose was high as their HbA1c was higher than the 
normal average (7.83 ± 2.31%). Their ACR was higher compared to the normal group 
(13.31 ± 28.06 vs. 52 ± 0.25, P>0.05) and they suffered from kidney disease as their 
ACR and albuminuria were higher than the normal range and eGFR was lower than 
controls (Table 38c). 
 













65 ± 10.51 62.5 ± 11.01 62.5 ± 10.82 62.5 ± 16.26 
Gender (F:M) 
 
3:2 2:6 2:4 0:2 
Diabetes duration (years) 
 
25 ± 10.72 15.25 ± 6.38 17 ± 6.22 10 ± 4.24 
BMI (kg/m2) 
 
25.28 ± 2.63 30.61 ± 8.39 32.08 ± 9.28 26.2 ± 3.11 
HbA1c (%) 
 
7.76 ±  1.6 7.83 ± 2.31 7.76 ± 2.25 8.05 ± 3.46 
ACR (mg/mmol) 
 
0.5 2± 0.25 13.31 ± 28.06 2.38 ± 1.4 
 
46.1 ± 51.33* 
eGFR (ml min–1 1.73 m–2) 
 
89.4 ± 8.64 65.37 ± 36.5 60.66 ± 24.78 79.5 ± 75.66 
Systolic Bp (mmHg) 
 
119.4 ± 14.08 
 
122.88 ± 14.99 117.67 ± 11.05 138.5 ± 17.67 
Diastolic Bp (mmHg) 
 
63.6 ±  6.65  66.88 ± 13.07 68.17 ± 6.16 78 ± 25.45 
     
BMI: body mass index, HbA1c: Glycated haemoglobin, ACR: albumin/creatinine 




Patients with T2DN were further subdivided into two groups as previously described. 
Patients with T2DN-NA (n= 6) and T2DN-A (n= 2) were older than controls (n= 5). 
The T2DN-A group had higher blood pressure compared with the T2DN-NA group 
and their BMI and HbA1c were nearly identical. Both groups had nephropathy as they 
had higher ACR and lower eGFR compared to the control group. However, the most 
important difference between T2DN-NA and T2DN-A was in ACR; they had 19% 
more ACR compared to the DN-NA group which was a sizeable figure (Table 38c) 
This implies that the T2DN-A group is progressing more rapidly towards end stage 
renal disease compared to the T2DN-NA group, despite both groups taking 
medication. 
● Overall trend in circulating MOSC1 mRNA regulation 
Circulating MOSC1 mRNA expression was detected in blood of patients with DN. We 
could not determine a significant association between hyperglycaemia and MOSC1 
mRNA expression in patients with DN. After adjustment for test variables such as age, 
gender, BMI, HbA1c, SBP, DBP and diabetes duration, a standardised increase of 
ACR was observed in patients with DN-A. This pilot study needs to be scaled up to 
understand the function of MOSC1 in the circulating blood of patients with kidney 
failure. 
A student‟s t test analysis was performed with DN as the grouping variable and 
MOSC1 copy numbers, log MOSC1 copies, age, gender, BMI, HbA1c, SBP, DBP and 
diabetes duration as test variables using SPSS 20. Compared with diabetic controls and 
patients with DN-NA, only those patients with DN-A groups showed a significant 
increase with ACR (P<0.05). There was no significant difference between groups in 










In this chapter, we looked at renal MOSC2 and MOSC1 expression in vivo and in 
vitro. In the first part of the study renal MOSC2 and MOSC1 mRNA and protein 
expression were measured in diabetic models of STZ-induced diabetic mice. During 
the second part, we investigated MOSC2 and MOSC1 mRNA and protein expression 
in human renal cells. Finally, we tested MOSC1 mRNA expression through 
measurement of MOSC1 copy numbers in the circulating blood of patients with DN 
compared to patients with no DN. 
For the first time we were able to show that MOSC2 is increased during 
hyperglycaemia in the diabetic kidneys of STZ-induced diabetic mice and this increase 
was attenuated by the treatment of diabetes (P<0.05).  However, we found no change 
in MOSC1 in the kidneys of diabetic mice. These results were consistent with the 
Malik studies, as MOSC2 (also known as CDK7) was found to increase in the GK rat. 
In addition, they showed that renal MOSC2 mRNA is not up-regulated in the 
normoglycaemic Wistar rat, suggesting that elevation of MOSC2 is a glucose-induced 
effect (Malik et al., 2007). 
Western blot analysis showed that MOSC2 was highly expressed in the diabetic 
kidneys of STZ mice, whereas MOSC2 levels showed a decline in control samples. 
These findings confirmed the mRNA studies in the diabetic kidneys of STZ mice, 
suggesting that MOSC2 is a glucose-regulated gene in mice. However, we could not 
detect the MOSC1 protein expression in the mouse as there exists no commercial 
antibody against mouse mARC1. The immunofluorescent staining was performed to 
determine the location of MOSC2 protein in control and diabetic mouse kidneys. 
MOSC2 was abundantly expressed in the tubules of both control and diabetic kidneys 
and suprisingly not expressed in the glomerulus. 
Previously, Malik et al. (2007) found that MOSC2 mRNA levels were up-regulated in 
cells exposed to HG compared to NG in HMCs and HMCL. Shahni (2011) showed 
that MOSC2 expression was 10-fold increased in HMCs grown in HG compared to 
those grown in NG. In this chapter, we looked at both renal MOSC2 and MOSC1 
mRNA expression in NG, HG and NGM of three different types of human cultured 
renal cells (HMCs, HEK293, HTC). Renal MOSC2 showed a significant increase in 




confirmed our previous findings in vivo, and also confirmed the previous results by 
Malik et al. (2007). The hyperglycaemia-induced increase in renal MOSC2 was 
specific as we could not demonstrate any change in MOSC1. 
Surprisingly, in HG, MOSC2 mRNA levels showed a slight decrease in HTC whereas 
they showed a significant increase in HMCs and HEK293 cells. This was the first time 
that renal MOSC2 and MOSC1 mRNA expression was measured in HTC. To confirm 
the mRNA studies, we used Western blot analysis for both MOSC2 and MOSC1 in 
human cultured renal cells (HMCs, HEK293, HTC). However, our Western blot 
experiments for both MOSC1 and MOSC2 were not successful and we could not 
detect any difference in the expression of both MOSC2 and MOSC1. 
In this chapter, we showed the up-regulation of MOSC2 in vivo and in vitro in 
association with hyperglycaemia. As described previously, hyperglycaemia is a key 
factor in the progression of DN and it induces renal injury through chemical pathways 
(Sheets et al., 2002). This process involved several main molecules such as protein 
kinase C, TGF-β1 and glycation end products (Brownlee et al., 2001). There is a 
possible explanation for MOSC2, as its up-regulation in hyperglycaemia could be 
linked to its contribution in different aspects of regulating intracellular redox balance 
in the cell.  
ROS is a key mediator in the progression of microvascular diseases by affecting the 
redox balance in the cell which can lead to abnormal activation of different pathways 
in the cell (Lee et al., 2003). For instance, hyperglycaemia can promote oxidative 
stress by inhibiting the thioredoxin function (Schulze et al., 2004). Thioredoxin is a 
small protein (12 kDa) which is involved in the redox regulation of the cell (Nordberg, 
2001). Malik et al. (2007) showed that there is a notable conservation of cys-pro-arg-
cys domain within the MOSC and MOSC-N domains of MOSC2 protein which is 
similar to the catalytic domain of thioredoxin. This similarity suggests a functional 
link between thioredoxin-like proteins and MOSC2. Hence, protein structures of 
MOSC2 contain the CPRC region, which could lead to a redox function of MOSC2. 
This could explain why MOSC2 is up-regulated in HG as it could protect cells from 
ROS-induced damage. 
Malik et al. (2007) showed that MOSC2 mRNA expression appeared to be increased 




hyperglycaemia. Because of these findings, they named the molybdenum enzyme 
“CDK7” (Candidate Diabetes-associated Kidney) in their studies (Page et al., 1997; 
Malik et al., 2007). 
It was shown by Havemeyer (2006) that MOSC protein purified from pig liver 
mitochondria was homologous to the C-terminal domain of Moco-Sulfurases 
(MOCO). They named this recently discovered protein “mitochondrial amidoxime-
reducing component” (mARC), because initially the N-reductive activity of 
amidoxime was studied with this isolated mitochondrial enzyme. MOSC is identical to 
mARC, which is an N-reductive protein and part of a three component enzyme, 
consisting of mARC, cyt (cytochrome) b5 and NADH cyt b5 reductase. This 
molybdenum enzyme is capable of reducing nitrogen–containing groups (Havemeyer 
et al., 2011). mARC has been identified in the outer mitochondrial membrane of pig 
liver, which harboured the N-reductive system. They also showed that the human 
genome holds two mARC genes: mARC1/MOSC1 and mARC2/MOSC2. Both 
mARC1 and mARC2 genes were cloned and expressed in Esherichia coli (Havemeyer 
et al., 2006). 
Havemeyer and co-workers identified MOSC2 and MOSC1 as outer mitochondria 
membrane proteins in pigs (Havemeyer et al., 2006). However, contrary to this result, 
other authors have purified MOSC2 and MOSC1 from the inner mitochondrial 
membrane of a mouse (Cruz et al., 2003). Shahni (2011) have shown subcellular 
localisation of MOSC2 using its specific antibody in HMCLs and determined that 
MOSC2 is localised to the mitochondria. 
 As the involvement of three enzymes in this reduction pathway was demonstrated, we 
therefore assessed the N-reductive activity for this molybdenum enzyme in vivo and in 
vitro. Biochemical analysis of MOSC protein showed that hyperglycaemia increased 
the N-reductive activity of MOSC protein in the kidneys of STZ mice in vivo. We also 
showed that the N-reductive activity is elevated in cells grown in HG compared to NG 
of both HMCs and HEK293 cells. However, we could not find any significant 
difference in HTC. This was the first occasion in which the function of MOSC in N-
reductive activity with hyperglycaemia has been demonstrated. This result was 
consistent with our previous findings of MOSC2 being up-regulated in the presence of 




MOSC and its N-reductive enzyme system are involved in drug metabolism, and they 
also play a role in the activation of amidoxime prodrugs. This recent discovery is a 
main target for drug research and the development of prodrugs (Clement et al., 2005). 
The Havemayer group demonstrated that MOSC2 is located in the outer mitochondrial 
membrane which harboured an N-reductive system and proposed that it was involved 
in the N-reductive system; MOSC2 was also postulated to protect cell from cytotoxic 
NO formation (Kotthaus et al., 2011).  
To evaluate MOSC1 and MOSC2 mRNA levels as potential biomarkers of DN, we 
examined their expression in the peripheral blood of diabetic patients. There was no 
expression of MOSC2 (Shahni, 2011); however, the closely related homolog MOSC1 
was expressed in the peripheral blood. Circulating MOSC1 mRNA did not change in 
association with complications. Therefore it is currently unclear if circulating MOSC1 
is associated with DN. 
We can conclude that up-regulation of MOSC2 in the presence of hyperglycaemia 
occurs in both mouse models and human cultured renal cells (HMCs, HEK293). This 
increase of MOSC2 and also its identity with cysteine domain suggests that MOSC2 is 
a novel thiol gene and it may play a role in response to oxidative stress. Despite not 
finding any significant results for MOSC1 in vivo or in vitro, its similarity with 
MOSC2 supports the assumption that it may be involved in hyperglycaemia-induced 
pathways. Also, its expression in circulating blood increases its chance of being a 








































Chapter 6. General Discussion 
 
DN is a frequent complication in patients with diabetes mellitus and it is the major 
cause of end stage renal disease (ESRD), which has been linked to cardiovascular 
morbidity and mortality. Previously, the Malik group (1997) used differential 
screening and differential display to isolate genes based on their differential 
expression from GK rat kidneys in vivo (Page et al., 1997; Page and Malik, 2003). 
CRYM and MOSC2 were identified as two of several hyperglycaemia-induced renal 
genes in the GK rat, and both were found to be regulated by glucose in vitro (Page 
and Malik, 2003).   
In this thesis, we showed that the expression of CRYM and MOSC2 are altered in 
conditions of diabetes and may play a role in hyperglycaemia-induced pathways in the 
kidney that lead to renal failure. However, MOSC1 expression was found not to 
change in diabetic conditions in vivo and in vitro. Furthermore, circulating CRYM 
mRNA levels showed some change in patients with DR and DN but MOSC1 mRNA 
levels remained unchanged, suggesting that CRYM and MOSC2 are regulated but that 
MOSC1 is not. Unfortunately, it is unlikely that CRYM and MOSC2 could be useful 
biomarkers for DN or DR because of their low and variable levels of expression in 
circulating cells. However, our data supports the view that both genes may be 
involved in glucose-induced pathways. 
CRYM 
In the first part of this thesis, we demonstrated for the first time that renal CRYM 
mRNA expression is regulated during the development of hyperglycaemia in the 
kidneys of STZ-induced diabetic mice. In addition, when STZ-induced diabetic mice 
were treated by islet transplantation, renal CRYM mRNAs were normalised, 
providing direct evidence that hyperglycaemia-induced CRYM mRNA. The increase 
in renal CRYM mRNA levels in the STZ-induced model was specific as we could not 
show any change in cardiac CRYM, suggesting that up-regulation in CRYM in 
response to hyperglycaemia might be tissue specific. 
Parallel to these findings, we also examined renal and cardiac CRYM mRNA levels 




type 1 diabetes. Surprisingly, we could not demonstrate any change in renal and 
cardiac CRYM mRNA levels in the diabetic kidneys of ß-Phb2 KO mice when 
compared to control kidneys. Earlier studies with the GK rat have shown increased 
renal and cardiac CRYM in conditions of hyperglycemia (Al-Kafaji and Malik, 2010). 
 
Differential expression of CRYM in ß-Phb2 KO and STZ-induced diabetic mice 
might result from difference between these biological models;  ß-Phb2 KO mice are a 
unique model of spontaneous development of diabetes, through a series of molecular 
events and do not require the usage of chemicals such as STZ (Supale et al., 2013). 
Therefore, it is possible that the biological difference of these two models could affect 
renal and cardiac CRYM expression in both models. Furthermore, the difference 
between the duration of diabetes, blood glucose levels, and gender may have an 
effect. We used only kidneys from male mice in STZ-induced diabetic mice, whereas 
in the KO mice both genders were used. Therefore differences between these two 
models might cause the differential renal and cardiac CRYM mRNA regulation. 
Despite these issues, our data show that CRYM mRNA can be regulated in response 
to hyperglycaemia in vivo.  
Previous studies have not managed to localise CRYM protein in vivo. We carried out 
immunofluorescence and found high levels of renal CRYM protein in the STZ mouse 
model, with particular abundance being noted in HTC, and less expression in the 
HMCs. Hyperglycaemia is known to affect different renal cells, affecting various 
renal cell types including glomerular mesangial cells, tubular epithelial cells as well 
as others (Kanwar et al., 2011). Therefore one question from our finding of high 
CRYM protein levels in HTC was whether hyperglycaemia can induce an increase in 
CRYM in these cells. However, we were not able to detect increased CRYM staining 
in the diabetic tubular cells compared to controls using immunofluorescence. It would 
be useful to carry out a Western blot for the confirmation of CRYM mRNA results 
and to complement the immunofluorescence findings. Unfortunately, we were unable 
to confirm the mRNA results by Western blot due to lack of tissues and time.  
As the expression of CRYM was more abundant in renal tubular cells throughout the 
kidneys of STZ-induced diabetic mice, we examined renal CRYM mRNA levels in 
HTCs for the first time to see if it could be induced by HG. However, we found a 




CRYM mRNA levels were reduced following the exposure of cells to HG compared 
to NG. The Malik group previously found an increase of renal CRYM mRNA levels 
by hyperglycaemia in cultured HMCs (Al-Kafaji and Malik, 2010). Cellular 
localisation of CRYM within HMCs showed cytoplasmic localisation of CRYM 
protein in both NG and HG conditions. We also found CRYM protein staining in the 
cytoplasm of HTC as expected but we did not see any increase in the protein levels in 
HTC grown in HG.  
The expression of CRYM mRNA in human peripheral blood mononuclear cells 
(PBMCs) has been previously reported (Suzuki et al., 2009). For the first time, we 
detected mRNA levels of CRYM in whole blood samples. We compared the levels of 
circulating CRYM mRNA in diabetic patients with and without DN and found that 
circulating CRYM mRNA levels were 7.4-fold increased in patients with T2DN. This 
effect was strongest in patients with a well controlled nephropathy compared to those 
with proteinuria. There was a significant correlation between some risk factors such 
as age, ACR, diabetic duration in patients with and without DN. In contrast, when we 
measured circulating CRYM in patients with DR, we found that levels were reduced 
compared to patients with no DR. This could suggest that DN and DR have different 
mechanisms; however, it may also be due to the way blood samples for the two 
studies were stored. The DN samples had been stored in RNAlater and the DR 
samples had been stored in Paxgene tubes, with the latter being more likely to be 
reliable. This part of the work showed potential but needs to be repeated.  
Our results with CRYM from the in vitro, in vivo and patient studies support the view 
that CRYM is a regulated gene and could be induced by hyperglycaemia. With 
hyperglycaemia being widely accepted as a major cause of diabetic complications 
(Weiss and Sumpio, 2006; Brownlee, 2001), the up-regulation of CRYM in HG is 
interesting. In STZ-induced diabetic mice, we showed up-regulation of renal CRYM 
in diabetic kidneys. These findings and previous studies, which revealed increased 
renal CRYM mRNA in GK rat and HMCs (Al-kafaji and Malik, 2010; Ziadi, 1997), 
suggest a role for CRYM in hyperglycaemia-induced biochemical pathways that lead 
to the development of DN. However, the exact mechanism by which HG can result in 
increased renal CRYM mRNA remains to be determined. CRYM is likely to be of 
fundamental importance in the cell because 1) it is highly conversed in human, 




tissues showing the highest levels of expression in the kidney, heart and retina and 
lower levels in the lung, liver and other tissues (Osima et al., 2006, Abe et al., 2003, 
Aoki et al., 2000; Witsow and Kim, 1991). The exact cellular function of CRYM in 
the context of diabetes remains to be determined.  
Several studies have described different functions for CRYM. For example, CRYM 
was shown to be a major structural lens protein in marsupial species (Chen et al., 
1992) and proposed to have an enzymatic role (Witsow et al., 1993). In kangaroos and 
other species, CRYM acts as the major lens protein in the retina, brain and other 
tissues (Chen et al., 1992). In humans, another function for CRYM as a NADP-
regulated thyroid hormone-binding protein has been shown (Kim et al., 1992, Vie et 
al., 1997). In fact, most of the lens proteins that act as crystallins are not specialised 
structural proteins and their synthesis is not limited to the lens (Wistow and 
Piatigorsky, 1988). Many of these crystallins are NADPH-binding proteins. Thus, 
they can protect against oxidation in the lens or help to filter UV radiation (Vie et al., 
1996; Beslin et al., 1995).  
When acting as an NADP-regulated thyroid hormone-binding protein, CRYM binds 
thyroid hormone T3 in the presence of NADPH (Hashizume et al., 1989; Vie et al., 
1997). CRYM was also related to non-syndromic deafness in humans and it was 
suggested that CRYM dysfunction may be involved in potassium ion recycling, and 
could also abrogate the thyroid hormone affinity as a vital factor for the progression 
of the auditory system (Abe et al., 2003). Interestingly, patients with DN exhibit an 
increased occurrence of thyroid dysfunction (Bando et al., 2002; Bando et al., 1999). 
Chen et al. (2007) proposed subclinical hypothyroidism as an independent risk marker 
for diabetic kidney and cardiovascular disease. It has been well documented that there 
is an association between thyroid and kidney function. Recently, Lin (2011) revealed 
that the use of T₃ prevented the development of kidney damage in a mouse with T2D 
(Hoeck and Daminet, 2009). Therefore, it is possible for regulation of CRYM to be 
involved in molecular events which have been linked to the pathogenesis of thyroid 
disease and diabetic kidneys.  
 
We suggested that CRYM might be involved in a hyperglycaemia-induced polyol 
pathway as CRYM has NADPH binding activity and it is a NADP-regulated thyroid 




pathway is one of the metabolic factors which are involved in the genesis of DN. In 
this pathway, aldose reductase reduces glucose to sorbitol in the presence of 
hyperglycaemia, which is later oxidised to fructose (Brownlee, 2005). In this process, 
a high rate of glucose elevates the turnover of cofactors including NADPH and 
NAD+. Therefore, NADPH is an essential co-factor for the reduction and 
regeneration of glutathione. By depleting glutathione, the polyol pathway increases its 
resistance to oxidative stress (Oates, 2002). Indeed, consumption of NADPH cofactor 
by aldose reductase may cause an impaired antioxidant defence system.  
We have previously discovered that CRYM over-expression reduces glucose-induced 
intracellular ROS in cultured renal cells (Al-Kafaji and Malik, 2010). As CRYM 
binds to NADPH and its level is increased in the presence of hyperglycaemia where 
oxidative stress plays a role, we are lead to hypothesise that CRYM may play a role in 
the cellular response to oxidative stress caused by hyperglycaemia-induced ROS 
accumulation. Furthermore, various studies reported that hyperglycaemia resulted in 
ROS generation in HMCs (Xia et al., 2006; Frecker et al., 2005, Hua et al., 2003). 
ROS-induced oxidative stress has been proposed as a strong pathogenic co-factor in 
the progression of diabetic complications including DN and DR.  
In HG, ROS produces and increases glucose signalling in renal cells and it is also 
involved in excessive ECM deposition in DN (Ha and Lee, 2005; Lee et al., 2003). 
CRYM and ROS increase simultaneously in HMCs in response to HG; suggesting 
that CRYM might be involved in protecting renal cells from the result of high 
glucose-induced ROS formation and increases the hypothesis that CRYM may serve 
as an endogenous antioxidant.  
The demonstration that CRYM may act as an antioxidant suggests how important it is 
to investigate this area for the prevention or treatment of DN. Identifying the CRYM 
mechanism in inhibition of hyperglycaemia-induced intracellular ROS in HMCs may 
provide insight into its valuable role in protecting against oxidative stress, resulting in 
kidney damage in DN. It may provide a new direction for the treatment of DN. Future 
studies must investigate the in vivo consequences of the biochemical events by which 




Diabetic patients have been reported to have high levels of oxidative stress because of 
lowered antioxidant function (Sindhu et al., 2005). In the current study we 
demonstrated that CRYM mRNA is present in the whole blood of patients with 
diabetes. However, its low levels of expression suggest it may not be a useful 
biomarker. Furthermore, our data showed that circulating CRYM mRNA levels were 
reduced in patients with severe DR and in patients with DN. Therefore, the regulation 
of CRYM can raise the theory that CRYM is involved in an antioxidant defence 
system.  
MOSC 
In this thesis, we also found that the expression of MOSC2 mRNA and protein was 
up-regulated in response to hyperglycaemia in the kidneys of STZ-induced diabetic 
mice. These findings support previous studies, which described MOSC2 to be a 
glucose-regulated gene in the diabetic kidneys of a GK rat and suggested that an 
increase in MOSC2 was a glucose-induced effect (Malik et al., 2007). The 
immunofluorescent staining was performed to demonstrate the location of MOSC2 
protein in the kidneys of the control and diabetic mice. We found that MOSC2 was 
abundantly expressed in tubules of both control and diabetic kidneys and it was not 
expressed in the glomerulus. Parallel with MOSC2 studies, we have also looked at its 
homologue MOSC1. Unlike MOSC2, we found no changes in MOSC1 mRNA levels 
in any of our models or patient groups. As no antibody against mouse MOSC1 exists, 
we could not detect MOSC1 protein expression.  
In keeping with our in vivo studies, we looked at renal regulation of human MOSC2 
and MOSC1 in vitro. Previously, Malik et al. (2007) showed that human MOSC2 
mRNA levels were up-regulated in cells exposed to HG compared to NG in HMCL. 
Shahni (2011) also reported that the expression of human MOSC2 was 10-fold 
increased in HMCs grown in HG compared to those grown in NG. 
 In the current study, we also found that the expression of human MOSC2 
significantly increased in cells grown in HG compared to NG in both HMCs and 
HEK293 cells. These results confirmed our in vivo findings, and also confirmed the 
previous results by the Malik group (Malik et al., 2007). However, we found a 
decrease of MOSC2 mRNA levels in HTC grown in HG compared to HTC grown in 
NG, which was contrary to our previous findings. This was the first time that we had 




are required to confirm this data. We also could not find any difference between all 
conditions of human MOSC1 expression in human cultured renal cells (HMCs, 
HEK293, HTC). To confirm the mRNA studies, we used Western blot analysis for 
both MOSC2 and MOSC1 protein in human renal cells (HMCs, HEK293, HTC). 
However, our western blot for both human MOSC1 and MOSC2 was inconclusive. 
It was previously suggested by our group that MOSC2 may be acting as an 
antioxidant because of the presence of the CPRC domain and that it could be a thiol 
protein (Liang et al., 2007). The oxidation and reduction of thiol groups play a main 
role in the cellular antioxidant defence system as well as intracellular signalling which 
is found in various cellular proteins. This cellular antioxidant response has been 
identified to be defective in DN (Ceriello et al., 2000; Hodgkinson et al., 2003). Other 
studies have previously shown the up-regulation of certain genes involved in the thiol 
pathway (Liang et al., 2007; Morrison et al., 2004). We have also demonstrated that 
MOSC2 expression is up-regulated in both in vivo and in vitro models. One possible 
clarification for the up-regulation of MOSC2 in the presence of hyperglycaemia and 
the presence of highly conserved cysteine in the protein could be consistent with the 
theory that MOSC2 is a novel thiol protein playing a role in the cellular response to 
oxidative stress (Malik et al., 2007). Thus, our observations suggest a possible 
function for MOSC2 in DN, either as a regulator of intracellular ROS or as being 
involved in protecting the cells from ROS-induced damage. 
Some groups have reported MOSC2 cellular localisation by using an antibody 
specific to MOSC2. Havemeyer and co-workers purified native MOSC2 from the 
outer membrane of a pig liver mitochondria (Havemeyer et al., 2006). However, Da 
Cruz et al. (2003) showed that MOSC1 and MOSC2 proteins were located in the inner 
membrane of the liver mitochondria using a proteomic approach (referred to 
as Q9CW42 and Q922Q1). Although these two findings were in contrast to the 
specific sub-compartment of MOSC, they both suggested mitochondrial membrane 
localisation. Interestingly, another study reported a dual subcellular localisation 
of MOSC2 (referred to as O88994) in both peroxisomes and mitochondria. In keeping 
with the current observation, the Malik group has shown that the full length 





Havemeyer (2006) reported that human MOSC2 is exclusively localised in 
mitochondria and it is expressed at higher levels in the kidney, liver and thyroid 
(Clement et al., 2005). Malik et al. (2007) also revealed that MOSC2 mRNA was 
expressed in most tissues and they also showed that MOSC2 mRNA levels were 
highly expressed in the kidney, liver and thyroid. 
Havemeyer et al. (2011) mentioned that MOSC and its N-reductive enzyme system 
are involved in drug metabolism and play a role in the activation of amidoxime 
prodrugs. This recent discovery is a main target for drug research and development of 
prodrugs (Clement et al., 2005, Havemeyer et al., 2011). Human MOSC2 is proposed 
to be involved in the N-reductive system and also, it has been postulated to protect 
cells from cytotoxic NO formation (Kotthaus et al., 2011).  
As the involvement of three enzymes in this reduction pathway was demonstrated, we 
sent our samples to the Havmeyer group to assess the N-reductive activity for this 
molybdenum enzyme in vivo and in vitro. We found that N-reductive activity 
increased in the diabetic kidneys of STZ-induced diabetic mice. We also showed that 
N-reductive activity is elevated in cells grown in HG, compared to NG of both HMCs 
and HEK293 cells. However, we could not find any significant difference in HTC as 
their protein concentration was very low. This was the first time the function of 
MOSC in N-reductive with hyperglycaemia was demonstrated. This result was 
consistent with our previous findings of MOSC being up-regulated in the presence of 
hyperglycaemia in vivo and in vitro, suggesting that MOSC played a role in N-
reductive activity in the presence of hyperglycaemia.  
In this thesis, we also examined circulating MOSC1 mRNA levels in patients with 
DN. This was the first study which detected MOSC1 mRNA expression in whole 
blood of patients with DN. Previously, Shahni (2011) reported a lack of MOSC2 
mRNA expression in human peripheral blood and suggested that it was not a good 
candidate as predictive marker of DN. In this experimental study, we looked at only a 
few samples in diabetic patients with and without DN. Circulating MOSC1 mRNA 
was not changed in association with complications, suggesting that it is unlikely to be 
a useful biomarker for DN but may be involved in the pathways that lead to DN. 





Our previous hypothesis was that levels of MOSC2 mRNA increased in 
hyperglycaemia in GK rat and in HMCs. In this thesis, we showed that N-reductive 
activity was up-regulated in the diabetic kidneys of STZ diabetic mice, in HMCs and 
in HEK293 cells, suggesting that MOSC could play a role in N-reductive activity in 
the presence of hyperglycaemia. 
Overall conclusion 
In conclusion, we have shown that renal CRYM and MOSC2 can be regulated by 
glucose in the diabetic kidneys of STZ-induced diabetic mice, suggesting that diabetes 
leads to increased expression of renal CRYM and MOSC2 mRNAs which can be 
corrected in the kidneys by treatment of diabetes. Further studies are needed for both 
CRYM and MOSC2 to determine their exact function in the progression of DN. 
 
Taken together, it appears likely that both CRYM and MOSC2 genes play a role in 
hyperglycaemia-induced signalling pathways in DN, and their glucose regulation 
raises the hypothesis that both CRYM and MOSC2 levels are up-regulated to correct 
for oxidative stress caused by increased hyperglycaemia-induced ROS. Our findings 
suggested that both CRYM and MOSC2 are involved in a cellular response to 
oxidative stress and it might be an association between CRYM and MOSC2 as they 
followed the same pattern of expression in response to hyperglycaemia. It would be 
interesting to investigate the role of both genes in oxidative stress, whether regulation 
of CRYM and MOSC2 is specific to hyperglycaemia-induced ROS production, or if it 
is as a result of activation of other hyperglycaemia-induced biochemical pathways. 
Further consideration to discover the antioxidant effect of CRYM and MOSC2 are of 
great interest and additional investigation might provide more insight into their 
function. 
One aspect of DN is the abnormal activation of hyperglycaemia–induced metabolic 
and haemodynamic pathways (Brownlee, 2001). As described previously, 
hyperglycaemia can be the cause of increased intracellular ROS, both through 
NADPH oxidase and via electron leakage from mitochondrial electron transport 
chains. NADPH is known as a main mediator for different fundamental biological 
processes, such as mitochondrial function, energy metabolism and oxidative stress 




expression of CRYM and MOSC2 can affect the NADPH/NADP+ ratio in the cell, as 
this ratio plays a role in the control of redox environment inside cells. 
 
As circulating CRYM mRNA levels showed changes in patients with DN and DR, 
MOSC1/2 remained unchanged. These data suggest that CRYM or MOSC1 are 
unlikely to be useful biomarkers for DN but may be involved in the pathways that 
lead to DN. Further studies should examine the mRNA levels of CRYM and MOSC1 
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Appendix 1: List of chemicals, reagents and their suppliers 
Cell culture flask (25; 75; 162 cm2), 6-well cell culture cluster, 
Polypropylene conical Falcon tube (15; 50 ml), sterile pipette (5; 10; 25 
Beckton Dickinson Ltd 
(UK) 
Materials and kits Supplier 
Bacto-agar, Mannitol   Difco   
Dulbecco‟s Modified Eagle‟s Medium (DMEM)-low glucose,  
DMEM-high glucose, Penicillin-Streptomycin, Ampicillin, Trypsin-
EDT, Phenol: Chloroform, transfer ribonucleic acid (tRNA), 
Bromophenol blue, Ethidium bromide, Glycerol, Trypan blue, Sodium 
dodecyl lsulfate (SDS), Acrylamide, Tris base (Tris-HCl), Ammonium 
persulphate, TEMED, Glycine, Nonfat milk, Tween 20, ox-LDL, n-
LDL, TGF-β1,TNF-α, Formaldehyde,  Acetone, Bovine serum 
albumine (BSA) 
Sigma-Aldrich Ltd (UK) 
RPMI 1640 media, Insulin-transferrin-selenium (ITS), HEPES buffer, 
Foetal bovine serum (FBS), Phosphate buffer saline (PBS), L-
glutamine, Sodium bicarbonate (NaHCO3), Sodium acetate, Sodium 
hydroxide (NaOH) 
GIBCO® Life 
 Technologies (UK) 
Goat polyclonal IgG antibody, Rabbit polyclonal IgG antibody, FITC-
conjugated donkey anti-goat IgG, Rat kidney extract 
Sant Cruz  Biotechnology 
Inc (USA)  
Vectashield mounting medium with propidium iodide Vector Laboratories   
Peterborough (UK) 
Hybond nitrocellulose filter, Horseradish peroxidase (HRP)-conjugated 
donkey anti-goat IgG antibody  
Amersham  
Biosciences Ltd (UK) 
3MM Chromatography papers Whatman Ltd (UK) 
Bio-Rad Protein Assay Dye Reagents Concentrate  BioRad Laboratories Ltd 
(UK) 
S.N.A.P.™ MidiPrep kit, β-Gal assay kit, Lipofectamine™ LTX, anti-
V5-FITC conjugated antibody, anti-His-FITC conjugated antibody, 
SeeBlue® Plus2 Pre-Stained Standard marker, Image-iT™ LIVE 
Green ROS detection kit,  Luria Bertani broth, Agarose  
Invitrogen (UK) 
Wizard miniprep kit, UV quartz cuvettes, Taq DNA polymerase, 
Restriction endonucleases, DNA Ladders, dNTPs    
Promega Ltd (UK) 
GFX PCR DNA and Gel Purification Kit, Enhanced chemiluminensce 
(ECL) detection system 
Amersham Biosciences Ltd 
(UK) 
Totaly RNA isolation kit, RNAqueousTM- 4PCR kit, DNase-1 
treatment and DNase inactivation kit, ENDOFREE RT TM kit, 
Nuclease-freetubes, Oligo-dT primer, AMV reverse transcriptase, 
Nuclease-free water, DEPCE-treated water, RnaseZap 




ml), 0.22 ml sterile filters, 1 ml Cryo-vials 
4-glass chamber slides Electron Microscopy 
Sciences, Lab-Tek (UK) 
Sterile non pyrogenic DNase and RNase free freezing tube Greiner BIO-one Ltd 
(UK) 
FastStart DNA Master  SYBR Green 1; LC-capillaries Roche Diagnostics Ltd 
(Germany) 
Filter tips  STar Lab (UK) 
Molecular Biology Grade Solutions, Ethanol, Methanol, Glacial acetic 
acid, Isopropanol, Boric acid 
































Figure 2a.Protein sequence of mCRYM. 









Figure 2b. Protein sequence of hCRYM . 




















Appendix 3: Average expression stability values of 






            
                
              




















1.85E+01 2.33E+01 1.57E+01 1.74E+01 2.38E+01 9.09E+00 0.9368 
2613 2.06E+01 2.41E+01 1.70E+01 1.87E+01 2.77E+01 1.01E+01 1.0258 
2615 2.04E+01 2.33E+01 1.61E+01 1.85E+01 2.52E+01 9.69E+00 0.9803 
2458 2.18E+01 2.31E+01 1.71E+01 2.01E+01 2.76E+01 9.97E+00 1.0366 
2589 2.12E+01 2.35E+01 1.64E+01 1.80E+01 2.73E+01 1.08E+01 1.0187 
2609 2.08E+01 2.41E+01 1.67E+01 1.78E+01 2.75E+01 9.72E+00 1.0052 



















Appendix 4: Standard Curve of mouse CRYM and GAPDH 
produced by real-time qPCR 
 
  A)                                                         B) 
 
                                              C) 
 
 
Figure 4a. Amplification of mCRYM in 10-fold dilutions and standardcurve generation. 




 copies of the mCRYM PCR product were prepared and 
amplified by real time PCR. A) Amplification of mCRYM PCR product plotted versus cycle 
number. B) Melting curve derived from the amplification of mCRYM PCR product and after 
the last cycle, melting point analysis of mCRYM was obtained at 83°C. Also, the single 
melting peak for each amplified product is shown. C) Crossing point plotted against the 
known concentration of mCRYM standard (number of cycles needed to determine the PCR 
















A)                                                                B) 
 
 
                                                                 C) 
                
 
Figure 4b. Amplification of mGAPDH in 10-fold dilutions and standard curve 
generation. 
Dilution series from 10⁸ to 10³ copies of the mGAPDH PCR product were prepared and 
amplified by real time PCR. A) Amplification of mGAPDH PCR product plotted versus cycle 
number. B) Melting curve derived from the amplification of mGAPDH PCR product and after 
the last cycle, melting point analysis of mGAPDH was obtained at 83°C. Also, the single 
melting peak for each amplified product is shown. C) Crossing point plotted against the 
known concentration of mGAPDH standard (number of cycles needed to determine the PCR 
product plotted versus log concentration) to give the linear standard curve over 5 logs (10⁸ to 















Appendix 5: Standard Curve of human CRYM and PGK 
produced by real-time qPCR 
A)                                                                  B) 
 
                                                      C)    
                   
Figure 5a.Amplification of hCRYM in 10-fold dilutions and standard curve generation. 




 copies of the hCRYM PCR product were prepared and 
amplified by real time PCR. A) Amplification of hCRYM PCR product plotted versus cycle 
number. B) Melting curve derived from the amplification of hCRYM PCR product and after 
the last cycle, melting point analysis of hCRYM was obtained at 83°C. Also, the single 
melting peak for each amplified product is shown. C) Crossing point plotted against the 
known concentration of hCRYM standard (number of cycles needed to determine the PCR 
















      A)                                                                B) 
 
                                                                   C) 
                              
Figure 5b. Amplification of hPGK in 10-fold dilutions and standard curve generation. 




 copies of the hPGK PCR product were prepared and amplified by 
real time PCR. A) Amplification of hPGK PCR product plotted versus cycle number. B) Melting 
curve derived from the amplification of hPGK PCR product and after the last cycle, melting point 
analysis of hPGK was obtained at 83°C. Also, the single melting peak for each amplified product is 
show. n) Crossing point plotted against the known concentration of hPGK standard (number of 
cycles needed to determine the PCR product plotted versus log concentration) to give the linear 















Appendeix 6. Quantification of CRYM mRNA copy 
numbers in the circulating blood of patients with type 2 





































T2DR CRYM(1) CRYM(2)  CRYM(3) GAPDH(1) GAPDH(2)  GAPDH(3) 
158 1970 371 91 173000 211000 227000 
177 237 17 14 57800 59300 109000 
186 41300 NA 146000 249000 388000 495000 
79 111 299 1490 244000 232000 637000 
39 34 984 22 169000 183000 200000 
107 NA 33600 NA 438000 468000 635000 
132 503 486 537 92400 110000 117000 
100 663 261 234 198000 211000 221000 
66 NA 5100  NA 583000 785000 873000 
151 421 NA  NA 596000 964000 1610000 
67 NA NA 45400 184000 195000 514000 
114 NA NA 328 622000 711000 729000 
20 0.79 2.36 4.53 184000 200000 229000 
40 NA 20.60 0.30 170000 191000 207000 
33 0.12  NA 18.70 536000 597000 502000 
46  NA  NA 0.51 128000 129000 176000 
68  NA 38.90 19.40 112000 113000 166000 
39 1.33 58.70 14.30 24700 30300 35800 
28  NA   NA 6.35 358000 366000 574000 
56  NA   NA 8.90 410000 426000 628000 
233 2.37 0.05 NA 274000 305000 354000 
244  NA 0.36 NA 107000 46200 89700 
42  NA 11.80 NA 198000 130000 209000 
246  NA  7.4 NA 53200 75800 117000 
176 2.91   NA 1.70 102000 102000 132000 
Control      
39 70 96 78 284 374 503 
139 49 193 220 2780 3250 3430 
346 35 54 62 6360 6600 7650 
356 75 331 103 1140 1620 1880 




Appendix 7. Quantification of CRYM CT values in the 
circulating blood of patients with type 2 diabetes, with and 
without retinopathy. 
T2DR  CRYM-CT  GAPDH-CT delta CT  delta delta CT fold difference  
174 19.54 16.13 3.41 4.91 0.06 
179 12.99 14.43 -1.44 0.05 0.52 
158 25.50 16.36 9.14 10.64 0.0013 
177 28.61 17.89 10.72 12.22 0.0004 
186 18.61 15.50 3.11 4.61 0.0819 
79 25.63 15.63 9.99 11.49 0.0007 
39 27.48 16.50 10.97 12.47 0.0004 
86 18.81 15.08 3.72 5.22 0.0534 
130 12.70 14.55 -1.85 -0.35 2.5521 
84 18.87 13.77 5.10 6.60 0.0206 
107 19.71 15.21 4.50 6 0.0313 
123 21.54 15 6.54 8.04 0.0076 
132 25.21 16.86 8.34 9.84 0.0022 
100 25.72 17.48 8.23 9.73 0.0023 
66 22.18 16.47 5.71 7.21 0.0135 
150 17.56 16.15 1.41 2.91 0.2661 
151 25.45 14.17 11.27 12.77 0.0003 
156 16.20 15.22 0.97 2.47 0.3601 
67 19.31 16.12 3.18 4.68 0.0777 
115a 15.49 14.61 0.87 2.37 0.3851 
141 14.86 14.08 0.78 2.28 0.4113 
114 25.78 14.70 11.07 12.57 0.0003 
146 19.83 16.68 3.15 4.65 0.0797 
20 34.42 16.81 17.61 19.11 0.0000 
40 34.17 16.92 17.25 18.75 0.0000 
33 34.80 15.31 19.49 20.99 0.0000 
46 36.18 17.34 18.83 20.33 0.0000 
68 31.12 17.51 13.60 15.10 0.0001 
39 32.35 19.72 12.63 14.13 0.0001 
28 32.98 15.70 17.28 18.78 0.0000 
56 32.55 15.50 17.04 18.54 0.0000 
32 24.40 16.07 8.33 9.83 0.0022 
233 36.64 16.17 20.46 21.96 0.0000 
187 32.18 19.22 12.96 14.46 0.0001 
244 36.63 19.75 16.87 18.37 0.0000 
57 37.62  19.46 18.16 19.66 0.0000 
42 32.19  18.51 13.67 15.17 0.0001 
215 32.09  20 12.09 13.59 0.0002 
197 30.12 18.49 11.62 13.12 0.0002 
157 31.04 18.18 12.85 14.35 0.0001 
27 32.78 20.53 12.25 13.75 0.0001 
176 34.31 19.19 15.11 16.61 0.0000 










Control T2D     
71  26.8 24.20 2.6 2.6 0.3399 





















































Appendix 8. Quantification of CRYM mRNA in the 
circulating blood of patients with type 2 diabetes, with and 
without nephropathy 
T2DN-A CRYM(1) CRYM(2) CRYM(3) PGK(1) PGK(2) PGK(3) 
18 2.03 1.24 7.10 34.10 0.55 0.48 
82 2.49 1.29 5.05 0.07 0.11 0.07 
68 NA 6.95 3.30 0.73 0.62 0.00 
25 7.35 3.49 1.30 0.25 NA 0.25 
60 NA 1.14 21.30 1.02 0.38 0.11 
16 5.68 1.43 1.61 0.05 0.13 0.18 
56 NA 3.02 7.77 0.33 0.22 0.16 
51 NA 1.26 NA 4.32 0.31 0.14 
21 19.90 3.86 20.80 6.55 0.43 0.52 
26 5.28 5.86 3.31 0.03 0.07 0.12 
64 13.00 5.00 7.79 0.04 0.17 0.36 
11 41.20 17.20 6.59 0.12 0.08 0.17 
66 9.63 10.20 11.00 8.92 0.19 0.47 
40 4.31 7.05 2.85 0.17 0.28 0.25 
77 NA 6.62 22.00 0.15 0.10 0.12 
36 5.83 2.44 6.23 0.49 0.05 0.00 
59 3.13 4.19 1.30 6.00 0.07 0.24 
67 3.19 3.54 3.42 0.16 0.20 0.18 
75 5.82 2.57 1.70 0.39 0.40 0.17 
83 57.50 4.13 18.60 1.07 0.59 0.24 
110 123.00 46.00 97.10 0.38 0.62 0.72 
111 2.05 3.93 7.43 2.07 0.40 0.82 
210 NA 4.60 6.16 0.26 0.05 0.08 
20 6.79 7.26 4.17 0.16 14.20 0.15 
376 0.11 8.56 25.10 0.17 0.24 0.18 
4 49.20 1.21 0.53 0.17 0.11 0.02 
267 1.34 3.25 0.19 0.00 0.14 0.07 
325 NA 3.42 2.83 0.25 0.86 0.45 
305 4.33 2.22 0.40 0.84 0.39 0.25 
278 2.44 2.67 7.02 0.09 0.13 0.35 
183 NA 0                0.93 0.39 0.10 0.02 
208 3.97 0.66 2.56 0.01 0.78 0.17 
390 NA 4.43 4.25 0.04 0.25 0.85 
117 NA 1.24 NA 0.19 0.09 0.19 
212 1.65 2.67 NA 0.22 1.28 0.56 
376 NA 4.25 NA 0.38 0.71 2.98 
121 2.85 0 NA 0.15 0.16 0.08 
271 8.65 0 3.13 0.23 0.17 0.19 
T2DN-NA      
102 1.36 1.16 0.87 3.59 0.16 0.18 
122 NA 4.31 2.23 0.26 0.17 0.28 
141 2.47 1.96 3.43 0.05 0.41 0.31 
133 4.11 6.21 3.74 0.04 0.03 0.08 
113 3.88 2.77 3.18 1.70 2.48 1.38 
19 2.32 0.79 0.08 0.26 0.25 0.21 
15 2.17 2.84 1.59 0.15 0.16 0.13 
3 NA 6.38 2.91 0.19 0.16 0.37 
31 1.30 2.61 8.50 0.09 0.12 0.01 
155 NA 26.30 22.40 0.28 0.21 0.10 
159 11.50 30.40 2.75 0.11 0.33 0.13 




191 17.40 1.87 4.92 0.11 0.14 0.52 
174 NA 38.40 NA 0.22 0.14 0.17 
204 6.01 2.86 2.39 0.09 1.32 0.18 
207 0.16 1.40 1.07 0.08 0.34 0.18 
211 211.00 NA 1.07 0.14 0.13 0.25 
262 1.45 4.81 23.20 0.11 0.07 0.11 
232 196.00 NA 0.95 0.20 0.38 0.17 
221 2.00 3.52 3.52 0.13 0.15 0.30 
243 31.70 NA NA 0.39 0.48 205.0 
217 39.00 29.90 47.00 0.21 0.14 0.25 
322 NA 8.66 NA 0.14 0.53 0.57 
283 NA 20.30 18.90 0.32 0.43 0.13 
292 24.20 8.35 29.30 0.30 0.41 0.21 
297 1.27 314.00 2.75 0.54 0.21 0.88 
342 38.90 35.80 61.40 0.21 0.13 0.54 
326 27.50 13.20 1.27 0.49 0.61 0.26 
339 5.58 10.90 9.04 0.37 0.12 0.16 
350 11.20 8.99 2.21 24.90 16.10 24.90 
120 10.90 236.00 12.40 26.80 17.10 23.00 
Control 
T2D 
      
123 11.70 11.30 14.60 21.80 19.80 23.30 
127 22.20 2.71 7.18 16.00 16.30 10.50 
131 10.30 31.80 4.84 52.70 37.80 43.80 
138 55.50 8.62 9.25 34.10 29.10 16.30 
140 10.40 7.88 4.26 38.70 27.00 41.20 
154 11.50 32.10 11.90 31.60 33.00 20.40 
157 11.00 80.70 2.39 11.40 10.30 14.70 
187 9.81 21.80 4.87 19.70 13.10 13.70 
185 11.50  NA NA 17.10 18.10 22.50 
229 19.10 30.40 19.20 18.70 23.60 21.70 
235 1.38 1.54 1.87 33.00 15.30 13.30 
284 5.83 2.13 1.40 12.70 10.70 12.80 
252 10.00 1.24 1.32 28.90 11.00 11.20 
182 0.08 0.05 0.73 81.60 4.75 23.60 
152 NA 3.24 0.22 26.10 25.90 15.90 
368 3.34 0.40 1.03 16.80 16.10 12.00 
142 0.04 0.63 0.41 19.20 21.30 31.10 
143 0.02 0.85 1.44 23.00 31.20 26.70 
101 0.71 1.55 1.52 30.80 22.00 28.10 
100 0.50 0.09 28.70 18.10 18.50 23.80 
312 NA 1.37 1.49 9.22 8.78 15.90 
330 4.93 1.17 7.01 10.00 13.80 12.60 
379 7.91 2.56 11.00 0.51 1.08 0.50 
317 NA 4.44 1.53 0.38 0.18 0.40 
47 NA 2.93 3.64 0.34 0.37 0.41 
23 NA 4.06 17.70 0.05 0.12 0.07 
48 NA 5.84 1.74 0.30 0.18 0.05 
302 NA 16.80 2.97 0.13 0.35 0.35 
2 NA 10.70 0.07 3.31 0.12 0.08 
















             Figure 9a. Protein sequence of mMOSC2. 










Figure 9b. Protein sequence of mMOSC1. 

























Figure 9c. Protein sequence of hMOSC2. 









Figure 9d. Protein sequence of hMOSC1. 























Appendix 10: Standard Curve of mouse and human MOSC2 
produced by real-time qPCR  
 
   A)                                                               B) 
 
                                                                  C) 
              
 
Figure 10a. Amplification of mMOSC2 in 10-fold dilutions and standard curve 
generation. 




 copies of the mMOSC2 PCR product were prepared and 
amplified by real time PCR. A) Amplification of mMOSC2 PCR product plotted versus cycle 
number. B) Melting curve derived from the amplification of mMOSC2 PCR product and after 
the last cycle, melting point analysis of mMOSC2 was obtained at 83°C. Also, the single 
melting peak for each amplified product is shown. C) Crossing point plotted against the 
known concentration of mMOSC2 standard (number of cycles needed to determine the PCR 
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Figure 10b.Amplification of hMOSC2 in 10-fold dilutions and standard curve 
generation. 




 copies of the hMOSC2 PCR product were prepared and 
amplified by real time PCR. A) Amplification of hMOSC2 PCR product plotted versus cycle 
number. B) Melting curve derived from the amplification of hMOSC2 PCR product and after 
the last cycle, melting point analysis of hMOSC2 was obtained at 83°C. Also, the single 
melting peak for each amplified product is shown. C) Crossing point plotted against the 
known concentration of hMOSC2 standard (number of cycles needed to determine the PCR 















Appendix 11: Standard Curve of mouse and human MOSC1 
produced by real-time qPCR  
 
A)                                                          B) 
 
                                                               C) 
          
Figure 11a. Amplification of mMOSC1 in 10-fold dilutions and standard curve 
generation. 




 copies of the mMOSC1 PCR product were prepared and 
amplified by real time PCR. A) Amplification of mMOSC1 PCR product plotted versus cycle 
number. B) Melting curve derived from the amplification of mMOSC1 PCR product and after 
the last cycle, melting point analysis of mMOSC1 was obtained at 83°C. Also, the single 
melting peak for each amplified product is shown. C) Crossing point plotted against the 
known concentration of mMOSC1 standard (number of cycles needed to determine the PCR 
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Figure 11b.Amplification of hMOSC1 in 10-fold dilutions and standard curve 
generation. 




 copies of the hMOSC1 PCR product were prepared and 
amplified by real time PCR. A) Amplification of hMOSC1 PCR product plotted versus cycle 
number. B) Melting curve derived from the amplification of hMOSC1 PCR product and after 
the last cycle, melting point analysis of hMOSC1 was obtained at 83°C. Also, the single 
melting peak for each amplified product is shown. C) Crossing point plotted against the 
known concentration of hMOSC1 standard (number of cycles needed to determine the PCR 




















1,25(OH)2D3                1,25-DihydroxyvitaminD3 
ACE    Angiotensin-converting enzyme  
AD    Aldose reductase  
ADA   American Diabetes Association  
AGEs   Advanced glycation end products 
Ang    Angiotensinogen 
 
BSA    Bovine serum albumin  
Phb2 KO                     βeta-Prohibitin2 knockout  
CT   Threshold cycle  
CDKs    Candidate diabetes associated kidney clones  
CKD    Chronic kidney disease 
CRYM                         µ-crystalline 
CTGF              Connective tissue growth factor  
CVD   Cardiovascular disease 
DAG    Diacylglycerol   
DCCT                            Dibetes Control and Complications Trial  
DMEM   Dulbecco‟s Modified Eagle‟s Medium  
DMSO              Dimethyl Sulfoxide  
DN     Diabetic nephropathy 
DR                               Diabetic retinopathy 
ds DNA  Double stranded DNA 
ECM    Extracellular matrix  
EDIC Epidemiology of Diabetes Interventions and Complications Study Research 
Group 




ERK1/2  Extracellular-signal regulated kinase 1 and 2  
ESRD    End stage renal disease  
FITC    Fluorescein isothiocyanate 
FN   Fibronectin  
GAPDH   Glyceraldehyde-3 phosphate dehydrogenase  
GBM    Glomerular basement membrane  
GFAT              Glutamine:fructose-6 phosphate amidotransferase  
GFR                            Growth filtration rate  
GH               Growth hormone  
GK    Goto Kakizaki   
G-6-P   Glucose 6-phosphate 
 
GLUT   Glucose transporter  
HDL                            High density lipoprotein 
HEK                            Human embryonic kidney  
HG      High glucose  
HMCs                Human mesangial cells  
HMCLs                        Human mesangial cell line 
HRP                Horseradish peroxidase 
HSP               Heat shock proteins  
HTC                             Human tubular cells 
IDDM               Insulin dependent diabetes mellitus  
IGF     Insulin-like growth factor  
ITS    Insulin-transferrin-selenium  
LC    Light cycler  
LDL     Low-density lipoprotein 




            MnSOD             Manganese superoxide dismutase  
            MOPS                        3-(N-morpholino) propanesulfonic acid 
            MOSC                        Molybdenum Cofactor Sulfurase C-Terminal 
            NADP   Nicotinamide adenine dinucleotide phosphate 
            NOHA                        N-hydroxyl-L-arginine 
NG    Normal glucose 
NGF    Nerve growth factor  
NGM    Normal glucose plus mannitol  
NF-KB              Nuclear factor kappa B 
NIDDM  Non insulin dependent diabetes mellitus  
n-LDL                         Native low density lipoprotein 
nNOS   Neuronal nitric oxide synthase  
NO   Nitric oxide  
OD   Optical density  
PAGE   Polyacrylamide gel electrophoresis  
PBS   Phosphate buffer saline  
PBMCs                       Peripheral Blood Mononuclear Cells 
PGK                           Phosphoglycerate kinase 
PKC   Protein kinase C  
PPIB                            Peptidylprolyl isomerase B  
qPCR   Quantitative real time PCR  
RAS    Renin-angiotensin system  
RAGE               Receptor for advanced glycation end products  
ROS    Reactive oxygen species 
RT-PCR   Reverse transcriptase polymerase chain reaction  




SDS    Sodium dodecyl sulphate  
SNP    Single nucleotide polymorphism  
SOD    Superoxide dismutase  
TBP                             TATA box binding protein 
T1D               Type 1 diabetes  
T2D               Type 2 diabetes  
TGF-β1  Transforming growth factor beta 1 
             tRNA   Transfer ribonuclease  
UKPDS                          UK Prospective Diabetes study    
USRDS                        US Renal Data System Annual Data Report  
 
 
 
 
